EP0975573A1 - Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity - Google Patents

Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity

Info

Publication number
EP0975573A1
EP0975573A1 EP98918157A EP98918157A EP0975573A1 EP 0975573 A1 EP0975573 A1 EP 0975573A1 EP 98918157 A EP98918157 A EP 98918157A EP 98918157 A EP98918157 A EP 98918157A EP 0975573 A1 EP0975573 A1 EP 0975573A1
Authority
EP
European Patent Office
Prior art keywords
compound
carbons
alkyl
phenyl
accordance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP98918157A
Other languages
German (de)
French (fr)
Other versions
EP0975573B1 (en
Inventor
Tae K. Song
Min Teng
Roshantha A. Chandraratna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Sales LLC
Original Assignee
Allergan Sales LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales LLC filed Critical Allergan Sales LLC
Publication of EP0975573A1 publication Critical patent/EP0975573A1/en
Application granted granted Critical
Publication of EP0975573B1 publication Critical patent/EP0975573B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/51—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition
    • C07C45/54—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition of compounds containing doubly bound oxygen atoms, e.g. esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/66—Polycyclic acids with unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/19—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups having unsaturation outside the aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/28—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
    • C07C65/40—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring

Definitions

  • the present invention relates to novel compounds having retinoid-like, retinoid antagonist and/or retinoid inverse-agonist-like biological activity. More specifically, the present invention relates to trisubstituted phenyl derivatives which have retinoid-like, retinoid antagonist or retinoid inverse agonist-like biological activity.
  • Background Art Compounds which have retinoid-like activity are well known in the art, and are described in numerous United States and other patents and in scientific publications. It is generally known and accepted in the art that retinoid-like activity is useful for treating animals of the mammalian species, including humans, for curing or alleviating the symptoms and conditions of numerous diseases and conditions.
  • compositions having a retinoid-like compound or compounds as the active ingredient are useful as regulators of cell proliferation and differentiation, and particularly as agents for treating skin-related diseases, including, actinic keratoses, arsenic keratoses, inflammatory and non-inflammatory acne, psoriasis, ichthyoses and other keratinization and hyperproliferative disorders of the skin, eczema, atopic dermatitis, Darriers disease, lichen planus, prevention and reversal of glucocorticoid damage (steroid atrophy), as a topical anti-microbial, as skin anti-pigmentation agents and to treat and reverse the effects of age and photo damage to the skin.
  • skin-related diseases including, actinic keratoses, arsenic keratoses, inflammatory and non-inflammatory acne, psoriasis, ichthyoses and other keratinization and hyperproliferative disorders of the skin, eczem
  • Retinoid compounds are also useful for the prevention and treatment of cancerous and precancerous conditions, including, premalignant and malignant hyperproliferative diseases such as cancers of the breast, skin, prostate, cervix, uterus, colon, bladder, esophagus, stomach, lung, larynx, oral cavity, blood and lymphatic system, metaplasias, dysplasias, neoplasias, leukoplakias and papillomas of the mucous membranes and in the treatment of Kaposi's sarcoma.
  • premalignant and malignant hyperproliferative diseases such as cancers of the breast, skin, prostate, cervix, uterus, colon, bladder, esophagus, stomach, lung, larynx, oral cavity, blood and lymphatic system, metaplasias, dysplasias, neoplasias, leukoplakias and papillomas of the mucous membranes and in the treatment of
  • retinoid compounds can be used as agents to treat diseases of the eye, including, without limitation, proliferative vitreoretinopathy (PVR), retinal detachment, dry eye and other corneopathies, as well as in the treatment and prevention of various cardiovascular diseases, including, without limitation, diseases associated with lipid metabolism such as dyslipidemias, prevention of post-angioplasty restenosis and as an agent to increase the level of circulating tissue plasminogen activator (TPA).
  • PVR proliferative vitreoretinopathy
  • TPA tissue plasminogen activator
  • retinoid compounds include the prevention and treatment of conditions and diseases associated with human papilloma virus (HPV), including warts and genital warts, various inflammatory diseases such as pulmonary fibrosis, ileitis, colitis and Krohn's disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and stroke, improper pituitary function, including insufficient production of growth hormone, modulation of apoptosis, including both the induction of apoptosis and inhibition of T-Cell activated apoptosis, restoration of hair growth, including combination therapies with the present compounds and other agents such as Minoxidil R , diseases associated with the immune system, including use of the present compounds as immunosuppressants and immunostimulants, modulation of organ transplant rejection and facilitation of wound healing, including modulation of chelosis.
  • HPV human papilloma virus
  • various inflammatory diseases such as pulmonary fibrosis, ileitis, colitis and Krohn's disease
  • retinoids also cause a number of undesired side effects at therapeutic dose levels, including headache, teratogenesis, mucocutaneous toxicity, musculoskeletal toxicity, dyslipidemias, skin irritation, headache and hepatotoxicity. These side effects limit the acceptability and utility of retinoids for treating disease. It is now general knowledge in the art that two main types of retinoid receptors exist in mammals (and other organisms).
  • the two main types or families of receptors are respectively designated the RARs and RXRs. Within each type there are subtypes; in the RAR family the subtypes are designated RAR tt , RAR ⁇ and RAR ⁇ , in RXR the subtypes are: RXR punishment, RXB ⁇ and RXR ⁇ . It has also been established in the art that the distribution of the two main retinoid receptor types, and of the several sub-types is not uniform in the various tissues and organs of mammalian organisms. Moreover, it is generally accepted in the art that many unwanted side effects of retinoids are mediated by one or more of the RAR receptor subtypes.
  • the "effect" of compounds on retinoid receptors may fall in the range of having no effect at all, (inactive compound, neither agonist nor antagonist), the compound may elicit an agonist-like response on all receptor subtypes (pan-agonist), or a compound may be a partial agonist and/or partial antagonist of certain receptor subtypes if the compound binds to but does not activate certain receptor subtype or subtypes but elicits an agonist-like response in other receptor subtype or subtypes.
  • a pan-antagonist is a compound that binds to all known retinoid receptors but does not elicit an agonist-like response in any of the receptors.
  • retinoid antagonist and/or inverse agonist- like activity of a compound is also a useful property, in that such antagonist or inverse agonist-like compounds can be utilized to block certain undesired side effects of retinoids, to serve as antidotes to retinoid overdose or poisoning, and may lend themselves to other pharmaceutical applications as well.
  • R r is H, lower alkyl of 1 to 10 carbons, F, Cl, Br, I, CF 3 , OR 2 SR 2 , OCH ⁇ OC ⁇ alkyl or CF 2 CF 3 ;
  • R 2 is independently H, lower alkyl of 1 to 10 carbons, R 3 Si, or COR 3 where R 3 is independently H, lower alkyl of 1 to 6 carbons or phenyl;
  • R 4 is lower alkyl of 1 to 6 carbons, F, Cl, Br, I, CF 3 , CF 2 CF 3 , N0 2 , N(R 6 ) 2 , CN, COR 3 , or N(R 6 )-COR 3 ;
  • m is an integer between 0 and 3;
  • Y x is phenyl, naphthyl or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl,
  • N CR 6 -
  • n is an integer having the value 0 - 5
  • R 7 is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbons
  • R 8 is an alkyl group of 1 to 10 carbons or (trimethylsilyl)alkyl where the alkyl group has 1 to 10 carbons, or a cycloalkyl group of 5 to 10 carbons, or R 8 is phenyl or lower alkylphenyl
  • R, and R 10 independently are hydrogen, an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5-10 carbons, or phenyl, hydroxyphenyl or lower alkylphenyl
  • R n is lower alkyl, phenyl or lower alkylphenyl, R n * s lower alkyl
  • R 13 is divalent alkyl radical of 2-5 carbons.
  • this invention relates to the use of the compounds of Formula 1 for the treatment of skin-related diseases, including, without limitation, actinic keratoses, arsenic keratoses, inflammatory and non-inflammatory acne, psoriasis, ichthyoses and other keratinization and hyperproliferative disorders of the skin, eczema, atopic dermatitis, Darriers disease, lichen planus, prevention and reversal of glucocorticoid damage (steroid atrophy), as a topical anti-microbial, as skin anti-pigmentation agents and to treat and reverse the effects of age and photo damage to the skin.
  • skin-related diseases including, without limitation, actinic keratoses, arsenic keratoses, inflammatory and non-inflammatory acne, psoriasis, ichthyoses and other keratinization and hyperproliferative disorders of the skin, eczema, atopic dermatitis, Darrier
  • the compounds are also useful for the prevention and treatment of cancerous and precancerous conditions, including, premalignant and malignant hyperproliferative diseases such as cancers of the breast, skin, prostate, cervix, uterus, colon, bladder, esophagus, stomach, lung, larynx, oral cavity, blood and lymphatic system, metaplasias, dysplasias, neoplasias, leukoplakias and papillomas of the mucous membranes and in the treatment of Kaposi's sarcoma.
  • premalignant and malignant hyperproliferative diseases such as cancers of the breast, skin, prostate, cervix, uterus, colon, bladder, esophagus, stomach, lung, larynx, oral cavity, blood and lymphatic system, metaplasias, dysplasias, neoplasias, leukoplakias and papillomas of the mucous membranes and in the treatment of Kaposi's
  • the present compounds can be used as agents to treat diseases of the eye, including, without limitation, proliferative vitreoretinopathy (PVR), retinal detachment, dry eye and other corneopathies, as well as in the treatment and prevention of various cardiovascular diseases, including, without limitation, diseases associated with lipid metabolism such as dyslipidemias, prevention of post-angioplasty restenosis and as an agent to increase the level of circulating tissue plasminogen activator (TPA).
  • PVR proliferative vitreoretinopathy
  • TPA tissue plasminogen activator
  • Other uses for the compounds of the present invention include the prevention and treatment of conditions and diseases associated with Human papilloma virus (HPV), including warts and genital warts, various inflammatory diseases such as pulmonary fibrosis, ileitis, colitis and Krohn's disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and stroke, improper pituitary function, including insufficient production of growth hormone, modulation of apoptosis, including both the induction of apoptosis and inhibition of T-Cell activated apoptosis, restoration of hair growth, including combination therapies with the present compounds and other agents such as Minoxidil R , diseases associated with the immune system, including use of the present compounds as immunosuppressants and immunostimulants, modulation of organ transplant rejection and facilitation of wound healing, including modulation of chelosis.
  • HPV Human papilloma virus
  • various inflammatory diseases such as pulmonary fibrosis, ileitis, colitis and Krohn's disease
  • those compounds of the invention which act as antagonists or inverse agonists of one or more retinoid receptor subtypes are useful to prevent certain undesired side effects of retinoids which are administered for the treatment or prevention of certain diseases or conditions.
  • the retinoid antagonist and/or inverse agonist compounds of the invention may be co-administered with retinoids.
  • the retinoid antagonist and inverse agonist compounds of the present invention are also useful in the treatment of acute or chronic toxicity resulting from overdose or poisoning by retinoid drugs or Vitamin A.
  • This invention also relates to a pharmaceutical formulation
  • a pharmaceutical formulation comprising a compound of Formula 1 in admixture with a pharmaceutically acceptable excipient, said formulation being adapted for administration to a mammal , including a human being, to treat or alleviate the conditions which were described above as treatable by retinoids, to be co-administered with retinoids to eliminate or reduce side effects of retinoids, or to treat retinoid or Vitamin A overdose or poisoning.
  • BIOLOGICAL ACTIVITY MODES OF ADMINISTRATION Assays of Retinoid-like or Retinoid Antagonist and Inverse A ⁇ onist- like Biological Activity
  • a classic measure of retinoic acid activity involves measuring the effects of retinoic acid on ornithine decarboxylase. The original work on the correlation between retinoic acid and decrease in cell proliferation was done by Verma & Boutwell, Cancer Research, 1977, 37, 2196-2201. That reference discloses that ornithine decarboxylase (ODC) activity increased precedent to polyamine biosynthesis. It has been established elsewhere that increases in polyamine synthesis can be correlated or associated with cellular proliferation.
  • ODC ornithine decarboxylase
  • TPA 12-0-tetradecanoyl ⁇ horbol-13-acetate
  • Retinoic acid inhibits this induction of ODC activity by TPA.
  • An assay essentially following the procedure set out in Cancer Research: 1662-1670,1975 may be used to demonstrate inhibition of TPA induction of ODC by compounds of this invention.
  • I o is that concentration of the test compound which causes 60% inhibition in the ODC assay.
  • IC 80 is that concentration of the test compound which causes 80% inhibition in the ODC assay.
  • retinoid receptor subtypes measure the ability of the compounds of the present invention to bind to, and/or activate various retinoid receptor subtypes.
  • a compound binds to a given receptor subtype and activates the transcription of a reporter gene through that subtype, then the compound is considered an agonist of that receptor subtype.
  • a compound is considered an antagonist of a given receptor subtype if in the below described co-tranfection assays the compound does not cause significant transcriptional activation of the receptor regulated reporter gene, but nevertheless binds to the receptor with a K,, value of less than approximately 1 micromolar.
  • a holoreceptor transactivation assay and a ligand binding assay which measure the antagonist/agonist like activity of the compounds of the invention, or their ability to bind to the several retinoid receptor subtypes, respectively, are described in published PCT Application No. WO W093/11755 (particularly on pages 30 - 33 and 37 - 41) published on June 24, 1993, the specification of which is also incorporated herein by reference.
  • a detailed experimental procedure for holoreceptor transactivations has been described by Heyman et al. Cell 68, 397 - 406, (1992); Allegretto et al. J. Biol. Chem. 268, 26625 - 26633, and Mangelsdorf et al.
  • RAR-P-GR holoreceptor Transactivation Assay CV-1 cells (4 x 10 5 cells/well) were transiently transfected with the luciferase reporter plasmid MTV-4(R5G)-Luc (0.7 ⁇ g/well) containing four copies of the R5G retinoid DNA response element along with the RXR ⁇ expression plasmid pRS-hRXR ⁇ (0.1 ⁇ g/well) and one of the RAR-P-GR expression plasmids (0.05 ⁇ g/well) in 12 well plates via calcium phosphate precipitation Chen et al. (1987) Mol. Cell. Biol.
  • the three different RAR-P-GR expression plasmids express RAR ⁇ , RAR/3 and RAR ⁇ receptors, respectively, which contain modified DNA binding domains such that their "P-boxes" have been altered to that of the glucocorticoid receptor.
  • RAR-P-GR receptors bind to DNA as heterodimeric complexes with RXR.
  • the RAR-P-GR receptors bind retinoic acid response elements designated R5G, comprised of two RAR half sites (nucleotide sequence 5'-GGTTCA-3') separated by 5 base pairs in which the 3'-half site has been modified to that of a glucocorticoid receptor half site, 5'- AGAACA-3'.
  • R5G retinoic acid response elements
  • a ⁇ - galactosidase expression plasmid (0.01 ug/well) was used as an internal control.
  • the assay was performed in a 96-well microtiter plate format (5000 cells/well) in a manner which was identical to that described above except 1/5 of the amount of the DNA-calcium phosphate precipitant (20 ⁇ l instead of 100 ⁇ l) was applied to each well. Eighteen hours after introduction of the DNA precipitants, cells were rinsed with phosphate buffered saline (PBS) and fed with D-MEM (Gibco-BRL) containing 10% activated charcoal extracted fetal bovine serum (Gemini Bio-Products). Cells were treated for 18 hours with the compounds indicated in the figures.
  • PBS phosphate buffered saline
  • D-MEM activated charcoal extracted fetal bovine serum
  • % Efficiency is percentage of efficiency of the test compounds in this assay relative to all-tr ⁇ ns-retinoic acid.
  • Inverse agonists are ligands that are capable of inhibiting the basal receptor activity of unliganded receptors.
  • RARs retinoic acid receptors
  • the biological effects associated with retinoid inverse agonists are distinct from those of retinoid agonists or antagonists.
  • RAR inverse agonists, but not RAR neutral antagonists cause a dose- dependent inhibition of the protein MRP-8 in cultured human keratinocytes differentiated with serum.
  • MRP-8 is a specific marker of cell differentiation, which is also highly expressed in psoriatic epidermis, but is not detectable in normal human skin.
  • retinoid inverse agonists may offer a unique way of treating diseases such as psoriasis.
  • the activity of retinoid inverse agonists can be tested by the procedure of Klein et al. J. Biol. Chem. 271, 22692 - 22696 (1996) which is expressly incorporated herein by reference.
  • retinoid inverse agonists are able to repress the basal activity of a RAR ⁇ -VP- 16 chimeric receptor where the constituitively active domain of the herpes simplex virus (HSV) VP-16 is fused to the N-terminus of RAR ⁇ .
  • HSV herpes simplex virus
  • CV-1 cells are cotransfected with RAR ⁇ -VP-16, an ER-RXR ⁇ chimeric receptor and an ERE-tk-Luc chimeric reporter gene to produce a basal level of luciferase activity, as shown by Nagpal et al. EMBO J. 12, 2349 -2360 (1993) expressly incorporated herein by reference.
  • Retinoid inverse agonists are able to inhibit the basal luciferase activity in these cells in a dose dependent manner and IC 50 s measured.
  • Modes of Administration The compounds of this invention may be administered systemically or topically, depending on such considerations as the condition to be treated, need for site-specific treatment, quantity of drug to be administered, and numerous other considerations.
  • any common topical formulation such as a solution, suspension, gel, ointment, or salve and the like may be used. Preparation of such topical formulations are well described in the art of pharmaceutical formulations as exemplified, for example, by Remington's Pharmaceutical Science, Edition 17, Mack Publishing Company, Easton, Pennsylvania. For topical application, these compounds could also be administered as a powder or spray, particularly in aerosol form.
  • the drug may be confected as a powder, pill, tablet or the like or as a syrup or elixir suitable for oral administration.
  • the compound will be prepared as a solution or suspension capable of being administered by injection.
  • it may be useful to formulate these compounds by injection.
  • it may be useful to formulate these compounds in suppository form or as extended release formulation for deposit under the skin or intramuscular injection.
  • Other medicaments can be added to such topical formulation for such secondary purposes as treating skin dryness; providing protection against light; other medications for treating dermatoses; medicaments for preventing infection, reducing irritation, inflammation and the like.
  • the partial or pan retinoid antagonist and/or retinoid inverse agonist compounds of the invention when used to take advantage of their antagonist and/or inverse agonist property, can be co-administered to mammals, including humans, with retinoid agonists and, by means of pharmacological selectivity or site-specific delivery, preferentially prevent the undesired effects of certain retinoid agonists.
  • the antagonist and/or inverse agonist compounds of the invention can also be used to treat Vitamin A overdose, acute or chronic, resulting either from the excessive intake of vitamin A supplements or from the ingestion of liver of certain fish and animals that contain high levels of Vitamin A.
  • the antagonist and/or inverse agonist compounds of the invention can also be used to treat acute or chronic toxicity caused by retinoid drugs. It has been known in the art that the toxicities observed with hypervitaminosis A syndrome (headache, skin peeling, bone toxicity, dyslipidemias) are similar or identical with toxicities observed with other retinoids, suggesting a common biological cause, that is RAR activation. Because the antagonist or inverse agonist compounds of the present invention block or diminish RAR activation, they are suitable for treating the foregoing toxicities.
  • the antagonist and/or inverse agonist compounds of the invention can be admistered enterally or topically as an antidote to vitamin A, or antidote to retinoid toxicity resulting from overdose or prolonged exposure, after intake of the causative factor (vitamin A, vitamin A precursor, or other retinoid) has been discontinued.
  • the antagonist and/or inverse agonist compounds of the invention are co-administered with retinoid drugs, in situations where the retinoid provides a therapeutic benefit, and where the co-administered antagonist and/or inverse agonist compound alleviates or eliminates one or more undesired side effects of the retinoid.
  • the antagonist and/or inverse agonist compound may be administered in a site-specific manner, for example as a topically applied cream or lotion while the co-administered retinoid may be given enterally.
  • the antagonist compounds of the invention like the retinoid agonists compounds, are incorporated into pharmaceutical compositions, such as tablets, pills, capsules, solutions, suspensions, creams, ointments, gels, salves, lotions and the like, using such pharmaceutically acceptable excipients and vehicles which per se are well known in the art.
  • the antagonist and/or inverse agonist compounds of the invention could also be administered as a powder or spray, particularly in aerosol form.
  • the drug may be confected as a powder, pill, tablet or the like or as a syrup or elixir suitable for oral administration.
  • the compound will be prepared as a solution or suspension capable of being administered by injection. In certain cases, it may be useful to formulate these compounds by injection. In certain cases, it may be useful to formulate these compounds in suppository form or as extended release formulation for deposit under the skin or intramuscular injection.
  • the antagonist and/or inverse agonist compounds also, like the retinoid agonists of the invention, will be administered in a therapeutically effective dose.
  • a therapeutic concentration will be that concentration which effects reduction of the particular condition, or retards its expansion.
  • the antagonist and/or inverse agonist compounds of the invention are used in a prophylactic manner to prevent onset of a particular condition, such as skin irritation.
  • a useful therapeutic or prophylactic concentration will vary from condition to condition and in certain instances may vary with the severity of the condition being treated and the patient's susceptibility to treatment. Accordingly, no single concentration will be uniformly useful, but will require modification depending on the particularities of the chronic or acute retinoid toxicity or related condition being treated. Such concentrations can be arrived at through routine experimentation.
  • alkyl refers to and covers any and all groups which are known as normal alkyl, branched-chain alkyl and cycloalkyl.
  • alkenyl refers to and covers normal alkenyl, branch chain alkenyl and cycloalkenyl groups having one or more sites of unsaturation.
  • alkynyl refers to and covers normal alkynyl, and branch chain alkynyl groups having one or more triple bonds.
  • Lower alkyl means the above-defined broad definition of alkyl groups having 1 to 6 carbons in case of normal lower alkyl, and as applicable 3 to 6 carbons for lower branch chained and cycloalkyl groups.
  • Lower alkenyl is defined similarly having 2 to 6 carbons for normal lower alkenyl groups, and 3 to 6 carbons for branch chained and cyclo- lower alkenyl groups.
  • Lower alkynyl is also defined similarly, having 2 to 6 carbons for normal lower alkynyl groups, and 4 to 6 carbons for branch chained lower alkynyl groups.
  • esters refers to and covers any compound falling within the definition of that term as classically used in organic chemistry. It includes organic and inorganic esters. Where B of Formula 1 is -COOH, this term covers the products derived from treatment of this function with alcohols or thiols preferably with aliphatic alcohols having 1-6 carbons.
  • ester is derived from compounds where B is -CH 2 OH
  • this term covers compounds derived from organic acids capable of forming esters including phosphorous based and sulfur based acids, or compounds of the formula -CH 2 OCOR u where R n is any substituted or unsubstituted aliphatic, aromatic, heteroaromatic or aliphatic aromatic group, preferably with 1-6 carbons in the aliphatic portions.
  • preferred esters are derived from the saturated aliphatic alcohols or acids of ten or fewer carbon atoms or the cyclic or saturated aliphatic cyclic alcohols and acids of 5 to 10 carbon atoms.
  • Particularly preferred aliphatic esters are those derived from lower alkyl acids and alcohols. Also preferred are the phenyl or lower alkyl phenyl esters. Amides has the meaning classically accorded that term in organic chemistry. In this instance it includes the unsubstituted amides and all aliphatic and aromatic mono- and di- substituted amides. Unless stated otherwise in this application, preferred amides are the mono- and di-substituted amides derived from the saturated aliphatic radicals of ten or fewer carbon atoms or the cyclic or saturated aliphatic-cyclic radicals of 5 to 10 carbon atoms.
  • amides are those derived from substituted and unsubstituted lower alkyl amines. Also preferred are mono- and disubstituted amides derived from the substituted and unsubstituted phenyl or lower alkylphenyl amines. Unsubstituted amides are also preferred.
  • Acetals and ketals include the radicals of the formula-CK where K is (-OR) 2 . Here, R is lower alkyl. Also, K may be -OR 7 0- where R 7 is lower alkyl of 2-5 carbon atoms, straight chain or branched.
  • a pharmaceutically acceptable salt may be prepared for any compounds in this invention having a functionality capable of forming a salt, for example an acid functionality.
  • a pharmaceutically acceptable salt is any salt which retains the activity of the parent compound and does not impart any deleterious or untoward effect on the subject to which it is administered and in the context in which it is administered.
  • Pharmaceutically acceptable salts may be derived from organic or inorganic bases.
  • the salt may be a mono or polyvalent ion. Of particular interest are the inorganic ions, sodium, potassium, calcium, and magnesium.
  • Organic salts may be made with amines, particularly ammonium salts such as mono-, di- and trialkyl amines or ethanol amines. Salts may also be formed with caffeine, tromethamine and similar molecules.
  • salts are those formed with inorganic acids such as hydrochloric acid, sulfuric acid or phosphoric acid. Any of a number of simple organic acids such as mono-, di- or tri- acid may also be used.
  • Some of the compounds of the present invention may have trans and cis (E and Z) isomers.
  • the compounds of the present invention may contain one or more chiral centers and therefore may exist in enantiomeric and diastereomeric forms.
  • the bromo compound is reacted with (trimethylsilyl)acetylene to provide a [l-(2- trimethylsilyl)ethynyl]phenyl derivative, from which the trimethylsilyl group is removed by treatment with base.
  • the Y(R 5 )-CO ketone function may be subjected to a Grignard reaction, followed by dehydration of the resulting tertiary alcohol to provide compouds of the invention where X is CH 2 .
  • the ethyne compounds are coupled with a reagent of the formula X 2 -Y 2 (R 4 )-A-B where X 2 is a halogen and the remaining symbols are defined in connection with Formula 1.
  • Z represents an ester, amide, thioester, thioamide, or azo linkage
  • OH or SH function in the para position of the phenyl ring may be protected by appropriate acid or base labile protecting groups, such as methoxymethyl (MOM), acetyl or trialkylsilyl.
  • MOM methoxymethyl
  • the Z-Y 2 (R 4 )-A-B moiety can be formed in multiple steps starting with the introduction of a two-carbon moiety (such as the CH 3 CO group) in place of the reactive bromo group of the substituted phenyl nucleus.
  • n is 3, 4 or 5
  • Carboxylic acids are typically esterified by refluxing the acid in a solution of the appropriate alcohol in the presence of an acid catalyst such as hydrogen chloride or thionyl chloride.
  • an acid catalyst such as hydrogen chloride or thionyl chloride.
  • the carboxylic acid can be condensed with the appropriate alcohol in the presence of dicyclohexylcarbodiimide (DCC) and 4- (dimethylamino)pyridine (DMAP).
  • DCC dicyclohexylcarbodiimide
  • DMAP 4- (dimethylamino)pyridine
  • Alcohols, aldehydes and ketones all may be protected by forming respectively, ethers and esters, acetals or ketals by known methods such as those described in McOmie, Plenum Publishing Press, 1973 and Protecting Groups. Ed. Greene, John Wiley & Sons, 1981.
  • aromatic or heteroaromatic carboxylic acids are subjected to homologation by successive treatment under Arndt-Eistert conditions or other homologation procedures.
  • derivatives which are not carboxylic acids may also be homologated by appropriate procedures.
  • the homologated acids can then be esterified by the general procedure outlined in the preceding paragraph.
  • Compounds of the invention as set forth in Formula 1 (or precursors thereof) where A is an alkenyl group having one or more double bonds can be made for example, by synthetic schemes well known to the practicing organic chemist; for example by Wittig and like reactions, or by introduction of a double bond by elimination of halogen from an alpha-halo-arylalkyl-carboxylic acid, ester or like carbox- aldehyde.
  • Compounds of the invention or precursors thereof, where the A group has a triple (acetylenic) bond can be made by reaction of a corresponding aromatic methyl ketone with strong base, such as lithium diisopropylamide, reaction with diethyl chlorophosphate and subsequent addition of lithium diisopropylamide.
  • strong base such as lithium diisopropylamide
  • the acids and salts derived from compounds of the invention are readily obtainable from the corresponding esters.
  • Basic saponification with an alkali metal base will provide the acid.
  • an ester of the invention may be dissolved in a polar solvent such as an alkanol, preferably under an inert atmosphere at room temperature, with about a three molar excess of base, for example, lithium hydroxide or potassium hydroxide.
  • the solution is stirred for an extended period of time, between 15 and 20 hours, cooled, acidified and the hydrolysate recovered by conventional means.
  • the amide may be formed by any appropriate amidation means known in the art from the corresponding esters or carboxylic acids.
  • One way to prepare such compounds is to convert an acid to an acid chloride and then treat that compound with ammonium hydroxide or an appropriate amine.
  • the ester is treated with an alcoholic base solution such as ethanolic KOH (in approximately a 10% molar excess) at room temperature for about 30 minutes.
  • the solvent is removed and the residue taken up in an organic solvent such as diethyl ether, treated with a dialkyl formamide and then a 10-fold excess of oxalyl chloride.
  • esters may be reduced with lithium aluminum hydride at reduced temperatures. Alkylating these alcohols with appropriate alkyl halides under Williamson reaction conditions (March, Ibid, pg. 357) gives the corresponding ethers. These alcohols can be converted to esters by reacting them with appropriate acids in the presence of acid catalysts or dicyclohexylcarbodiimide and dimethylaminopyridine. Aldehydes can be prepared from the corresponding primary alcohols using mild oxidizing agents such as pyridinium dichromate in methylene chloride (Corey, E. J., Schmidt, G., Tet. Lett..
  • Ketones can be prepared from an appropriate aldehyde by treating the aldehyde with an alkyl Grignard reagent or similar reagent followed by oxidation. Acetals or ketals can be prepared from the corresponding aldehyde or ketone by the method described in March, Ibid, p 810.
  • Compounds of the invention, or precursors thereof, where B is H can be prepared from the corresponding halogenated aromatic or heteroaromatic compounds, preferably where the halogen is I.
  • the preferred compounds of the invention are those where Y t is phenyl, pyridyl, thienyl, furyl and thiazolyl. Among these the phenyl group and particularly methyl substituted phenyl are more preferred. Furthermore, substitution of the Yi phenyl group with the carbonyl group and the methyl group is preferred in the 1,4 (para) and 1,3 (meta) positions.
  • the Y 2 group is preferably phenyl, naphthyl, pyridyl, thienyl or furyl. Even more preferred are compounds where Y 2 is phenyl.
  • the Y 3 phenyl group is preferably substituted in the 1,3 (meta) positions by the Y 1 (R 5 )CX and Z groups.
  • the Rj group is preferably in the 4 (para) position relative ot the Z, and in the 2 (ortho) position relative to the YJR 5 )CX group.
  • the A-B group of the preferred compounds is (CH 2 ) q COOH or (CH 2 ) q -COOR 8 , where R 8 is defined as above. Even more preferably q is zero and R 8 is lower alkyl.
  • m is 0, that is, there is no R 4 substituent on the phenyl ring.
  • R x group of the preferred compounds of the invention is OH, or OR 2 where R 2 is preferably H, lower alkyl of 1 to 10 carbons, methoxymethyl or dimethyl-t-butylsilyl. Among the R 2 alkyl groups methyl and isopropyl are especially preferred.
  • R 2 alkyl groups methyl and isopropyl are especially preferred.
  • the most preferred compounds in accordance with Formula 1 are listed below in Table 3 for Formula 2 and with reference to that formula.
  • the compounds of this invention can be made by the general procedures outlined above under the title ""GENERAL EMBODIMENTS AND SYNTHETIC METHODOLOGY".
  • the following chemical pathways represent the presently preferred synthetic routes to certain classes of the compounds of the invention and to certain specific exemplary compounds.
  • the synthetic chemist will readily appreciate that the conditions set out here for these specific embodiments can be generalized to any and all of the compounds represented by Formula 1.
  • Reaction Scheme 1 a synthetic process is disclosed whereby exemplary compounds of the invention are obtained in which, with reference to Formula 1, the Z group is ethynyl (-C ⁇ C-) and the X group is CH 2 .
  • the compounds shown in this reaction scheme and in the other reactions schemes of this specification, include an OR 2 * substituent where the R 2 * group represents the moieties defined as R 2 in connection with Formula 1.
  • the R 2 * moiety is distinguished from the R 2 group of the "final" biologically active compounds of the invention, because the synthetic steps involved in the synthesis of the compounds of the invention may require the R 2 * to act as protecting group, and not all of the R 2 groups are necessarily suitable for this purpose.
  • 5-bromo-2-methoxyacetophenone which can be obtained through a Friedel Crafts reaction from 4-bromoanisol, as is described in detail in the Specific Examples.
  • 5- bromo-2-methoxymethoxyacetophenone which can be obtained from 5- bromo-2-hydroxyacetophenone by treatment with chloromethyl methyl ether in the presence of base.
  • the ethynyl substituted acetophenone derivatives of Formula 5 are then coupled with the reagent of the formula X 2 -Y 2 (R 4 )-A-B (Formula 6), where X 2 is halogen and the remaining symbols are defined in connection with Formula 1.
  • the coupling reaction is conducted in the presence of copper(I)iodide, diethylamine and bis(triphenylphosphine)palladium(II) chloride to provide the disubstituted acetylene compounds of Formula 7.
  • Examples for the reagent X 2 -Y 2 (R 4 )-A-B (Formula 6) are ethyl 4-iodobenzoate, ethyl 6- bromo-2-naphthoate, ethyl 6-iodonicotinate, ethyl 2-iodofuran-5- carboxylate, and ethyl 2-iodothiophen-5-carboxylate.
  • Precise conditions of the reactions leading from compounds of Formula 3 to the compounds of Formula 7 are described in connection with the specific examples. These reactions are analogous to the reaction described in several United States Letters Patent, such as United States Patent Nos.
  • Y r MgBr reagent is the Grignard reagent obtained from /r ⁇ r ⁇ -tolylbromide
  • other examples are Grignard or organometal reagents obtained from halogenated heteroaryl compounds.
  • the product of the Grignard (or like) reaction is a tertiary alcohol of Formula 8, which is dehydrated by treatment with acid, to provide compounds of Formula 9.
  • a frequently used reaction in this regard is saponification whereby an ester function (represented in Formula 9 by the symbol B) is converted into a carboxylic acid function.
  • the R 2 * group may represent an acyl function that can be removed by saponification, or R 2 * may represent an acid labile group (such as methoxymethyl) that can be removed to yield compounds of the invention where R 2 is H.
  • Reaction Scheme 2 discloses another process for synthesizing exemplary compounds of the invention where, with reference to Formula 1, X represents CH 2 .
  • the reactions in this scheme differ from the reactions illustrated in Scheme 1 primarily in the sequence in which they are conducted.
  • the brominated acetophenone derivative of Formula 3 is reacted with the Grignard (or similar organometal) reagent having the formula Y r MgBr, to provide a tertiary alcohol that is dehydrated by treatment with acid, to yield the brominated vinylphenyl compounds of Formula 10.
  • the brominated vinylphenyl compounds of Formula 10 are then coupled with (trimethylsilyl)acetylene, the resulting the (trimethylsilyl)ethynylphenyl compounds (Formula 11) are reacted with base to give ethynylphenyl compounds (Formula 12) which are then coupled with the reagent X 2 -Y 2 (R 4 )-A-B (Formula 6), in a series of reactions of the type described above in connection with Reaction Scheme 1.
  • the compounds of Formula 9 can be converted to further homologs and derivatives, as described above and indicated in the reaction scheme.
  • Reaction Scheme 3 discloses a process for synthesis of exemplary compounds of the invention where X of Formula 1 is O.
  • Starting material for this synthesis is a halogen, preferably bromo-substituted phenol derivative of Formula 14 that is protected in the phenolic hydroxyl group.
  • An example is 4-bromoanisole.
  • the compound of Formula 14 is subjected to a Friedel Crafts (or like) reaction with a reagent of the formula Y r COCl.
  • a reagent of the formula Y r COCl An example for this reagent, used for the preparation of several preferred compounds of the invention, is / ⁇ zr ⁇ -toluoyl chloride.
  • the ketone compound of Formula 15 is subjected to the sequence of reactions described above, namely coupling with (trimethylsilyl)acetylene, followed by treatment with base, and followed by coupling with the reagent X 2 -Y 2 (R 4 )-A-B (Formula 6), to provide, through the intermediates of Formulas 16 and 17, the ketone compounds within the scope of the invention (Formula 18).
  • the compounds of Formula 18 can be converted into further homologs and derivatives, as described above.
  • suitable vinylaryl compounds are ethyl 4-vinylbenzoate, ethyl 6-vinyl nicotinate, ethyl 5-vinylfuran-2- carboxylate and ethyl 5-vinylthiophen-2-carboxylate.
  • the Heck reaction is typically conducted in the presence of triethylamine, copper(I)iodide, palladium(II)acetate and tri-( ⁇ -tolyl)phosphine.
  • the Heck reaction provides compounds of Formula 19 which are within the scope of the present invention.
  • its ketone function may need to be protected before the Heck coupling reaction is performed, and the protective group is then removed after the Heck reaction.
  • Suitable protective groups for this purpose are ketal groups, such as the ketal formed under acidic condition with ethyleneglycol. Protection and deprotection of the ketone group of Formula 3 is not shown in the scheme, but will become readily apparent to those skilled in the art in light of the nature of the compound of Formula 3 and the present disclosure.
  • the need for protection and deprotection of the ketone group in the form of a ketal may also arise in connection with other reactions described in this specification.
  • the compounds of Formula 19 are reacted in a Grignard (or like organometal) reaction with the reagent Y MgBr (or other suitable organometal reagent, Y r Me where Me is metal such as lithium) to provide after dehydration of the intermediary tertiary alcohol the aryl vinylphenyl compounds of Formula 20 which are within the scope of the invention.
  • the compounds of Formula 20 can be converted to further homologs and derivatives still within the scope of the present invention, as described above.
  • Reaction Scheme 5 discloses synthetic routes to compounds of the invention where, with reference to Formula 1, Z is -CONH- (amides), -COO- (esters) -COS- (thioesters) and -CSNH- (thioamides).
  • Z is -CONH- (amides), -COO- (esters) -COS- (thioesters) and -CSNH- (thioamides).
  • the brominated aryl vinylphenyl compounds of Formula 10 are reacted with rc-butyl lithium and carbon dioxide to "capture" the carbon dioxide and to provide the aryl vinylbenzoic acid derivatives of Formula 22.
  • Examples for the reagents of formula H 2 N-Y 2 (R 4 )-A-B are ethyl 4-aminobenzoate and ethyl 6- aminonicotinate, for the reagents of the formula HO-Y 2 (R 4 )-A-B ethyl 4-hydroxybenzoate and ethyl 6-hydroxynicotinate, and for the reagents of the formula HS-Y 2 (R 4 )-A-B ethyl 4-mercaptobenzoate and ethyl 6- mercaptonicotinate.
  • the reactions between the carboxylic acids of Formula 22 and the reagents of the formulas H 2 N-Y 2 (R 4 )-A-B, HO- Y 2 (R 4 )-A-B and HS-Y 2 (R 4 )-A-B, can be performed in several ways in which amides, esters and thioesters are normally prepared.
  • the carboxylic acids of Formula 22 can be activated to form an acid chloride or an activated ester which is thereafter reacted with the amines, alcohols or thioalcohols of the above formulas.
  • the formation of the amides, esters or thioesters is performed by condensation of the carboxylic acid of Formula 22 with the amines, alcohols or thiols in a suitable aprotic solvent, such as pyridine, in the presence of a condensing agent such as dicyclohexylcarbodiimide (DCC) or more preferably l-(3- dimethylaminopropyl)-3-ethylcarbodiimidehydrochloride (EDCI).
  • DCC dicyclohexylcarbodiimide
  • EDCI l-(3- dimethylaminopropyl)-3-ethylcarbodiimidehydrochloride
  • the amide derivatives of Formula 23 can be readily converted to the thioamides of Formula 24 by reaction with [2,4-bis(4-methoxyphenyl)- l,3-dithia-2,4-diphos ⁇ hetane-2,4-disulfide] (Lawesson's reagent).
  • the amide derivatives of Formula 23 where the symbol B represents an ester function (such as COOEt) can be readily saponified by treatment with aqueous base, for example LiOH, to yield the corresponding amide derivatives where B represents a free carboxylic acid or its salt.
  • this is a reaction scheme for obtaining compounds of the invention where the -Y 2 (R 4 )-A-B moiety is directly linked to the position of the phenyl ring which is meta to the Y r C(CH 2 )- moiety.
  • the brominated aryl vinylphenyl compounds of Formula 10 are reacted with t-butyl lithium and subsequently with triisopropylborate to provide the boronic acid derivative intermediates of Formula 27.
  • the boronic acid derivatives of Formula 27 react with compounds of the formula X 2 - Y 2 (R 4 )-A-B (where the symbols are defined as above and X 2 is preferably bromine) in the presence of tetrakis[triphenylphosphine]palladium [Pd(PPh 3 ) 4 ] and a base, such as sodium carbonate, to yield compounds of Formula 28.
  • Examples of preferred reagents of formula X 2 -Y 2 (R 4 )-A-B are ethyl 6-bromo-2- naphthoate, ethyl 4-iodobenzoate, ethyl 6-iodonicotinate, ethyl 2- iodofuran-5-carboxylate, and ethyl 2-iodothiophen-5-carboxylate.
  • the compounds of Formula 28 can be converted into further compounds of the invention by the reactions described above, such as saponification, amide formation, homologation and the like.
  • n is 3
  • the B group is directly attached to the Z group.
  • the brominated aryl vinylphenyl compounds of Formula 10 are reacted with (l-ethoxyvinyl)tributyltin in the presence of bis(triphenylphosphine)palladium(II) chloride to introduce the acetyl group into the position of the phenyl ring which is meta to the Y r C(CH 2 )- moiety, and yield the acetophenone derivatives of Formula 29.
  • the latter reaction is known in the art as a Stille coupling.
  • the acetophenone derivatives of Formula 29 are then reacted in a Homer Emmons reaction, in the presence of strong base such as lithium diisopropylamide (LDA), with diethylcyanomethyl phosphonate.
  • LDA lithium diisopropylamide
  • the latter reagent is commercially available.
  • the product of the Homer Emmons reaction is an arylvinylphenyl compound of Formula 30 that is substituted in the meta position with a l-methyl-2- cyanoethenyl group.
  • the compounds of Formula 30 can also be obtained as a result of an analogous Wittig reaction.
  • the cyano function of the compounds of Formula 30 is reduced with a mild reducing agent, such as diisobutylaluminum hydride (Dibal-H) to provide the aldehyde compounds of Formula 31.
  • a mild reducing agent such as diisobutylaluminum hydride (Dibal-H)
  • Dibal-H diisobutylaluminum hydride
  • Another Homer Emmons reaction performed on the aldehydes of Formula 31 with the reagent diethyl(E)- 3-ethoxycarbonyl-2-methylallylphosphonate (Compound OI) provides compounds of Formula 32 which are within the scope of the present invention.
  • Compound OI can be prepared from commercially available ethyl (2)-3-formyl-2-butenoate according to the literature of Corey et al. J. Org. Chem. 1974, 39, 921.
  • the thiophenol compounds of Formula 33 are reacted with a carboxylic acid, or an activated form of the carboxylic acid, which forms a thioester and introduces the -CO-Y 2 (R 4 )-A-B moiety into the molecules.
  • carboxylic acid or an activated form of the carboxylic acid, which forms a thioester and introduces the -CO-Y 2 (R 4 )-A-B moiety into the molecules.
  • Those skilled in the art will understand that just as it is described in connection with the amide, ester and thioester formations in Reaction Scheme 5, various activated forms of carboxylic acids are suitable for this purpose.
  • the instant reaction scheme illustrates the method of using acid chlorides of the formula ClCO-Y 2 (R 4 )-A-B in these reactions.
  • Examples for the acid chlorides of formula ClCO-Y 2 (R 4 )-A-B are ClCOC 6 H 4 COOEt ClCOC 6 H 4 COOCH 2 H 5 (the monochlorides of terephthalic acid ethyl and benzyl esters), and ClCOC 5 NH 3 COOEt and ClCOC 5 NH 3 COOCH 2 C 6 H 5 (the monochlorides of pyridine 3,6,- dicarboxylic acid ethyl and benzyl esters).
  • the thioesters of Formula 34 are within the scope of the present invention.
  • the thioester is prepared first where the B group is -COOCH 2 C 6 H 5 .
  • the benzyl group is then removed by hydrogenation to provide the free acid.
  • the brominated aryl vinylphenyl compounds of Formula 10 are reacted with the cuprous salt of phthalimide and therafter with hydrazine to provide the (arylvinyl)aniline derivatives of Formula 35.
  • These are reacted with the acid chlorides of formula C1C0-Y 2 (R 4 )-A-B to yield the amides of Formula 36 which are within the scope of the invention.
  • the amides of Formula 36 are converted into thioamides of Formula 37 by treatment with [2,4-bis(4-methoxyphenyl)-l,3-dithia-2,4-diphosphetane-2,4- disulfide] (Lawesson's reagent).
  • the amides and thioamides of Formula 36 and 37 can be subjected to transformations (including saponification of an ester group when B is COOR 8 ) to yield further compounds within the scope of the present invention.
  • the (arylvinyl) aniline derivatives of Formula 35 are converted to diazonium salt and thereafter to (arylvinyl)phenol derivatives of Formula 38.
  • esters of Formula 39 are then converted into esters of Formula 39 by reaction with the acid chlorides of the formula ClCO-Y 2 (R 4 )-A-B or with other activated forms of the carboxylic acids of the general formula HOCO- Y 2 (R 4 )-A-B.
  • the ester formation may be affected with the free carboxylic acid in an aprotic solvent, such as pyridine, in the presence of dicyclohexylcarbodiimide (DCC) or more preferably 1- (3-dimethylaminopropyl)-3-ethylcarbodiimidehydrochloride (EDCI).
  • DCC dicyclohexylcarbodiimide
  • EDCI 1- (3-dimethylaminopropyl)-3-ethylcarbodiimidehydrochloride
  • Examples for reagents of formula ON-Y 2 (R 4 )-A-B are ethyl 4-nitrosobenzoate, ethyl 6-nitroso-2-naphthoate, ethyl 4-nitrosobenzoate, ethyl 6-nitroso-nicotinate, ethyl 2-nitroso-furan-5-carboxylate, and ethyl 2-nitroso-thiophen-5-carboxylate.
  • the azo compounds of Formula 40 can be converted to the azoxy compounds of Formula 41 by oxidation with oxidizing agents known in the art, for example with meta- chloroperoxybenzoic acid (MCPBA).
  • the acetophenone derivatives of Formula 29 (obtained by Stille coupling as shown in Reaction Scheme 7) are reacted in a condensation reaction with a reagent of the formula OHC ⁇ Y 2 (R 4 )-A-B to yield compounds of Formula 42 which are within the scope of the invention.
  • An example for the reagent OHC ⁇ Y 2 (R 4 -A-B is 4-carboxybenzaldehyde that is available commercially.
  • Examples of other reagents suitable for the condensation reaction and for the synthesis of compounds of Formula 42 are: 5-carboxy-pyridine-2-aldehyde, 4-carboxy-pyridine-2-aldehyde, 4-carboxy-thiophene-2-aldehyde, 5-carboxy-thiophene-2-aldehyde, 4-carboxy-furan-2-aldehyde, 5-carboxy-furan-2-aldehyde, 4-carboxyacetophenone, 2-acetyl-pyridine-5-carboxylic acid, 2-acetyl-pyridine-4-carboxylic acid, 2-acetyl-thiophene-4-carboxylic acid, 2-acetyl-thiophene-5-carboxylic acid, 2-acetyl-furan-4-carboxylic acid, and 2-acetyl-furan-5-carboxylic acid.
  • the latter compounds are available in accordance with the chemical literature; see for example Decroix et al. J. Chem Res. (S), 1978, 4, 134; Dawson et al. J. Med. Chem., 1983, 29, 1282; and Queguiner et al, Bull. Spc. Chimique de France, 1969, No. 10, pp 3678 - 3683.
  • the condensation reaction between the compounds of Formula 29 and the aldehyde of the formula OHC ⁇ Y 2 (R 4 )-A-B (or an analoguous ketone compound) is conducted in the presence of base in an alcoholic solvent.
  • the reaction is conducted in ethanol in the presence of sodium hydroxide.
  • the benzaledehyde derivatives of Formula 43 are subjected to a Homer Emmons type reaction, in the presence of strong base such as n -butyl lithium in hexane, with a 1-aryl or 1-heteroaryl 1-diethoxyphosphoryl- 3,3-dimethoxypropane derivative, such as ethyl 4-(diethoxyphosphoryl- 3,3-dimethoxypropyl)benzoate (Compound PI).
  • Ethyl 4- (diethoxyphosphoryl-3,3-dimethoxypropyl)benzoate (Compound PI) is available in accordance with the procedure of EPO Application No.
  • Examples for phoshonates analogous to Compound PI in that they are suitable for a Homer Emmons reaction with the benzaldehyde derivatives of Formula 43 are ethyl 2-(diethoxyphosphoryl-3,3-dimethoxypropyl)pyridine-5- carboxylate, ethyl 2-(diethoxyphosphoryl-3,3-dimethoxypropyl)pyridine- 6-carboxylate, ethyl 2-(diethoxyphosphoryl-3,3- dimethoxypropyl)thiophene-4-carboxylate, ethyl 2-(diethoxyphosphoryl- 3,3-dimethoxypropyl)thiophene-5-carboxylate, ethyl 2- (diethoxyphosphoryl-3,3-dimethoxypropyl)furan-4-carboxylate, ethyl 2- (diethoxyphosphoryl-3,3-dimethoxypropyl)furan-5-carboxylate.
  • the disubstituted ethene compounds of Formula 44 are cyclized, for example by heating in a neutral solvent (such as dischloromethane), in the presence of SnCl 4 or other suitable Friedel Crafts type catalyst, to form the "B ring" of the naphthalene derivatives of the invention, as shown in Formula 45.
  • the compounds of Formula 45 can be converted into further compounds of the invention by reaction well known to the synthetic organic chemist, such as saponification, esterification, amide formation and homologation. This is indicated in Reaction Scheme 11 as conversion to "homologs and derivatives".
  • reaction mixture was allowed to stir at ambient temperature for 17 hours, poured into 75 mL of ice water and extracted and partitioned between 10% HC1 (aq.) solution and ethyl ether. The layers were separated and the organic phase was washed with water and brine, dried over MgS0 4 , filtered and concentrated in vacuo to give an inseparable mixture of tertiary alcohols (4-bromo-2-[(l-hydroxy-l-p-tolyl)ethyl]phenol and 4- bromo-l-methoxymethoxy-2-[(l-hydroxy-l-p-tolyl)ethyl]benzene (approximately 2.5 to 1 ratio, respectively) following flash chromatography.
  • the mixture was dissolved in 15 mL of ethanol (under a blanket of argon) and 5 mL of 10% HC1 (aq) solution was added.
  • the resultant reaction mixture was stirred at ambient temperature for 4 hours, heated in an oil bath (90 °C) for 2 hours, cooled to ambient temperature and stirred overnight (14 hours).
  • the reaction mixture was concentrated in vacuo, extracted and partitioned between ethyl acetate and sat. NaHC0 3 (aq.) solution and the layers were separated.
  • the organic phase was washed with water and brine, dried over MgS0 4 , filtered and concentrated in vacuo to a yellow oil.
  • Ethyl 4-[(3'-acetyl-4'-methoxy)phenylethynyl]benzoate (Compound 1) To a sparged solution of 10 mL of diethylamine (a stream of argon was bubbled vigorously into the solution for several minutes) was added a mixture of 440 mg (2.5 mmol) of 5-ethynyl-2- methoxyacetophenone (Compound El), 770 mg (2.8 mmol) of ethyl 4- iodobenzoate (Compound A) and 10 mL of diethylamine.
  • Ethyl 4-[[4 , -methoxymethoxy-3'-r4"- methyl)benzoyl]phenylethynyl]benzoate (Compound 3)
  • ethyl 4-[(3'-acetyl-4'-methoxy)phenylethynyl]benzoate (Compound 1)
  • 44 mg (0.2 mmol) of 5-ethynyl-2-methoxymethoxy-4'-methylbenzophenone Compound Gl
  • Ethyl 4-[[4'-acetoxy-3'-(l-/?-toly ⁇ vinyl]phenylethynyl]benzoate (Compound 6)
  • Compound 1 128 mg (0.5 mmol) of 4-ethynyl-2-[(l-/?-tolyl)vinyl]phenyl acetate (Compound HI) was converted into the title compound using 128 mg (0.5 mmol) of ethyl 4-iodobenzoate (Compound A), 65 mg (0.09 mmol) of bis(triphenylphosphine)palladium (II) chloride, 17 mg (0.09 mmol) of cuprous iodide and 6 mL of triethylamine.
  • Ethyl 4-[[4'-methoxymethoxy-3'-(l p-tolyl)vinyl]phenylethynyl]benzoate (Compound 7)
  • ethyl 4-[(3'-acetyl-4'-methoxy)phenylethynyl]benzoate (Compound 1)
  • 87 mg (0.3 mmol) of 4-ethynyl-l-methoxymethoxy-2-[(l-p- tolyl)vinyl]benzene (Compound Jl) was converted into the title compound using 94 mg (0.3 mmol) of ethyl 4-iodobenzoate (Compound A), 42 mg (0.06 mmol) of bis(triphenylphosphine)palladium (II) chloride, 12 mg (0.06 mmol) of cuprous iodide and 6 mL of triethylamine.
  • Ethyl 4-[(3'-acetyl-4'-methoxymethoxy)phenylethynyl]benzoate (Compound 14) was converted in a step-wise set of reaction conditions resulting in the final isolation of the title compound as a white solid.
  • Ethyl 4-[(3'-acetyl)phenylethynyl]benzoate (Compound 17)
  • ethyl 4-[(3'-acetyl-4'-methoxy)phenylethynyl]benzoate (Compound 1)
  • 600 mg (4.2 mmol) of 3-ethynylacetophenone (Compound Kl) was converted into the title compound using 1.3 g (4.6 mmol) of ethyl 4- iodobenzoate (Compound A), 585 mg (0.8 mmol) of bis(triphenylphosphine)palladium (II) chloride, 156 mg (0.8 mmol) of cuprous iodide and 16 mL of triethylamine.
  • Ethyl 4-[[3'-( -hvdroxy-l-p-tolv ⁇ ethyl]phenylethvnyl]benzoate (Compound 18)
  • a cold solution (0 °C) of 112 mg (0.4 mmol) of ethyl 4-[(3'- acetyl)phenylethynyl]benzoate (Compound 17) in 3 mL of tetrahydrofuran (under a blanket of argon) was added 0.6 mL (0.6 mmol) of /?-tolylmagnesium bromide (IM in ethyl ether).
  • Ethyl 4-[[3'-(l-p-tolyl)vinyl]phenylethynyl]benzoate (Compound 19) Employing the same general procedure as for the preparation of ethyl 4-[[4'-methoxy-3'-(l-/?-tolyl)vinyl]phenylethynyl]benzoate (Compound 11), 47 mg (0.1 mmol) of ethyl 4-[[3'-(l-hydroxy-l- j p- tolyl)ethyl]phenylethynyl]benzoate (Compound 18) was converted into the title compound using 8.5 mg of p-toluene sulfonic acid monohydrate and 2 mL of toluene.
  • Ethyl 4-[[4'-hvdroxy-2'-methyl-5'-(4"-methvnbenzoyl] ⁇ henylethvnyl]-2- fluoro-benzoate (Compound 24)
  • ethyl 4-[[4'-hydroxy-3'-(4"-methyl)benzoyl]phenylethynyl]benzoate (Compound 4)
  • 13 mg (0.03 mmol) of ethyl 4-[[4'-methoxymethoxy-2'- methyl-5'-(4"-methyl)benzoyl]phenylethynyl]-2-fluoro-benzoate (Compound 23) was converted into the title compound (yellow oil) using 1 drop of c.
  • Ethyl 4-[[4'-iso ⁇ ro ⁇ oxy-3 , - i-p-tolv ⁇ vinyl] ⁇ henylethvnyl]benzoate (Compound 26)
  • ethyl 4-[(3'-acetyl-4'-methoxy)phenylethynyl]benzoate (Compound 1)
  • 20 mg (0.07 mmol) 4-ethynyl-l-isopropoxy-2-[(l-p-tolyl)vinyl]benzene (Compound Ml) was converted into the title compound using 24 mg (0.09 mmol) of ethyl 4-iodobenzoate (Compound A), 13 mg (0.02 mmol) of bis(triphenylphosphine)palladium (II) chloride, 4 mg (0.02 mmol) of cuprous iodide and 3.5 mL of triethylamine.
  • Ethyl 4-[[4'-isopropoxy-3'-( - -tolyl)vinyl]phenylethynyl]benzoate (Compound 30)
  • ethyl 4-[(3'-acetyl-4'-methoxy)phenylethynyl]benzoate (Compound 1)
  • 14 mg (0.05 mmol) of 4-ethynyl-l-isopropoxy-2-[(l- -tolyl)vinyl]benzene (Compound Nl) was converted into the title compound using 14 mg (0.04 mmol) of ethyl 4-iodobenzoate (Compound A), 9 mg (0.01 mmol) of bis(triphenylphosphine)palladium (II) chloride, 2 mg (0.01 mmol) of cuprous iodide and 3 mL of triethylamine.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compounds of the formulawhere the symbols have the meaning defined in the specification, have retinoid, retinois antagonist or retinoid inverse agonist type biological activity.

Description

TRISUBSTITUTED PHENYL DERIVATIVES HAVING RETINOID AGONIST, ANTAGONIST OR INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to novel compounds having retinoid-like, retinoid antagonist and/or retinoid inverse-agonist-like biological activity. More specifically, the present invention relates to trisubstituted phenyl derivatives which have retinoid-like, retinoid antagonist or retinoid inverse agonist-like biological activity. 2. Background Art Compounds which have retinoid-like activity are well known in the art, and are described in numerous United States and other patents and in scientific publications. It is generally known and accepted in the art that retinoid-like activity is useful for treating animals of the mammalian species, including humans, for curing or alleviating the symptoms and conditions of numerous diseases and conditions. In other words, it is generally accepted in the art that pharmaceutical compositions having a retinoid-like compound or compounds as the active ingredient are useful as regulators of cell proliferation and differentiation, and particularly as agents for treating skin-related diseases, including, actinic keratoses, arsenic keratoses, inflammatory and non-inflammatory acne, psoriasis, ichthyoses and other keratinization and hyperproliferative disorders of the skin, eczema, atopic dermatitis, Darriers disease, lichen planus, prevention and reversal of glucocorticoid damage (steroid atrophy), as a topical anti-microbial, as skin anti-pigmentation agents and to treat and reverse the effects of age and photo damage to the skin. Retinoid compounds are also useful for the prevention and treatment of cancerous and precancerous conditions, including, premalignant and malignant hyperproliferative diseases such as cancers of the breast, skin, prostate, cervix, uterus, colon, bladder, esophagus, stomach, lung, larynx, oral cavity, blood and lymphatic system, metaplasias, dysplasias, neoplasias, leukoplakias and papillomas of the mucous membranes and in the treatment of Kaposi's sarcoma. In addition, retinoid compounds can be used as agents to treat diseases of the eye, including, without limitation, proliferative vitreoretinopathy (PVR), retinal detachment, dry eye and other corneopathies, as well as in the treatment and prevention of various cardiovascular diseases, including, without limitation, diseases associated with lipid metabolism such as dyslipidemias, prevention of post-angioplasty restenosis and as an agent to increase the level of circulating tissue plasminogen activator (TPA). Other uses for retinoid compounds include the prevention and treatment of conditions and diseases associated with human papilloma virus (HPV), including warts and genital warts, various inflammatory diseases such as pulmonary fibrosis, ileitis, colitis and Krohn's disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and stroke, improper pituitary function, including insufficient production of growth hormone, modulation of apoptosis, including both the induction of apoptosis and inhibition of T-Cell activated apoptosis, restoration of hair growth, including combination therapies with the present compounds and other agents such as MinoxidilR, diseases associated with the immune system, including use of the present compounds as immunosuppressants and immunostimulants, modulation of organ transplant rejection and facilitation of wound healing, including modulation of chelosis. Several United States Patents assigned to the same assignee as the present application and patents and publications cited therein describe or relate to substituted phenyl derivatives having retinoid like biological activity. Examples of such patents are: 4,980,369; 4,992,468; 5,006,550; 5,013,744; 5,015,658; 5,068,252; 5,130,355; 5,134,159; 5,162,546; 5,202,471; 5,231,113; 5,278,318; 5,324,744; 5,324;840; 5,326,898; 5,346,915; 5,348,975; 5,349,105; 5,391,753; 5,414,007; 5,434,173; 5,498,755; 5,498,795; 5,534,641, and 5,556,996. Still further, several co-pending applications and recently issued patents which are assigned to the assignee of the present application, are directed to further compounds having retinoid-like activity. Although pharmaceutical compositions containing retinoids have well established utility (as is demonstrated by the foregoing citation of patents and publications from the voluminous literature devoted to this subject) retinoids also cause a number of undesired side effects at therapeutic dose levels, including headache, teratogenesis, mucocutaneous toxicity, musculoskeletal toxicity, dyslipidemias, skin irritation, headache and hepatotoxicity. These side effects limit the acceptability and utility of retinoids for treating disease. It is now general knowledge in the art that two main types of retinoid receptors exist in mammals (and other organisms). The two main types or families of receptors are respectively designated the RARs and RXRs. Within each type there are subtypes; in the RAR family the subtypes are designated RARtt, RARβ and RARγ, in RXR the subtypes are: RXR„, RXBβ and RXRγ. It has also been established in the art that the distribution of the two main retinoid receptor types, and of the several sub-types is not uniform in the various tissues and organs of mammalian organisms. Moreover, it is generally accepted in the art that many unwanted side effects of retinoids are mediated by one or more of the RAR receptor subtypes. Accordingly, among compounds having agonist-like activity at retinoid receptors, specificity or selectivity for one of the main types or families, and even specificity or selectivity for one or more subtypes within a family of receptors, is considered a desirable pharmacological property. Some compounds bind to one or more RAR receptor subtypes, but do not trigger the response which is triggered by agonists of the same receptors. A compound that binds to a biological receptor but does not trigger an agonist-like response is usually termed an antagonist. Accordingly, the "effect" of compounds on retinoid receptors may fall in the range of having no effect at all, (inactive compound, neither agonist nor antagonist), the compound may elicit an agonist-like response on all receptor subtypes (pan-agonist), or a compound may be a partial agonist and/or partial antagonist of certain receptor subtypes if the compound binds to but does not activate certain receptor subtype or subtypes but elicits an agonist-like response in other receptor subtype or subtypes. A pan-antagonist is a compound that binds to all known retinoid receptors but does not elicit an agonist-like response in any of the receptors. Recently a two-state model for certain receptors, including the above-mentioned retinoid receptors, have emerged. In this model, an equilibrium is postulated to exist between inactive receptors and spontaneously active receptors which are capable of coupling with a G protein in the absence of a ligand (agonist). In this model, so-called "inverse agonists" shift the equilibrium toward inactive receptors, thus bringing about an overall inhibitory effect. Neutral antagonists do not effect the receptor equilibrium but are capable of competing for the receptors with both agonists (ligands) and with inverse agonists. It has been recently discovered and described in pending applications assigned to the same assignee as the present application that the above mentioned retinoid antagonist and/or inverse agonist- like activity of a compound is also a useful property, in that such antagonist or inverse agonist-like compounds can be utilized to block certain undesired side effects of retinoids, to serve as antidotes to retinoid overdose or poisoning, and may lend themselves to other pharmaceutical applications as well. More particularly, regarding the published scientific and patent literature in this field, published PCT application WO 94/14777 describes certain heterocyclic carboxylic acid derivatives which bind to RAR retinoid receptors and are said in the application to be useful for treatment of certain diseases or conditions, such as acne, psoriasis, rheumatoid arthritis and viral infections. A similar disclosure is made in the article by Yoshimura et al. J Med. Chem. 1995, 38, 3163-3173. Kaneko et al. Med. Chem Res. (1991) 1:220-225; Apfel et al. Proc. Natl. Acad. Sci. USA Vol 89 pp 7129-7133 August 1992 Cell Biology; Eckhardt et al. Toxicology Letters, 70 (1994) 299-308; Keidel et al. Molecular and Cellular Biology, Vol 14, No. 1, Jan. 1994, p 287-298; and Eyrolles et al. J. Med. Chem. 1994, 37, 1508-1517 describe compounds which have antagonist like activity at one or more of the RAR retinoid subtypes. SUMMARY OF THE INVENTION The present invention relates to compounds of Formula 1 Y, (R5)-C-Y3(R1) (R4)m-Z-Y2(R4)-A-B. ii X Formula 1 where X is O, S, C(R2) or NOR*, R* is H, .6 alkyl or phenyl; Rr is H, lower alkyl of 1 to 10 carbons, F, Cl, Br, I, CF3, OR2 SR2, OCH^OC^ alkyl or CF2CF3; ; R2 is independently H, lower alkyl of 1 to 10 carbons, R3Si, or COR3 where R3 is independently H, lower alkyl of 1 to 6 carbons or phenyl; R4 is lower alkyl of 1 to 6 carbons, F, Cl, Br, I, CF3, CF2CF3, N02, N(R6)2, CN, COR3, or N(R6)-COR3; m is an integer between 0 and 3; Yx is phenyl, naphthyl or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl, naphthyl and heteroaryl groups being unsubstituted or substituted with one to three Rj groups, where R5 is alkyl of 1 to 10 carbons, fluoro-substituted alkyl of 1 to 10 carbons, alkenyl of 2 to 10 carbons and having 1 to 3 double bonds, alkynyl having 2 to 10 carbons and 1 to 3 triple bonds, F, Cl, Br, I, N02, CN, COOH, COOC^alkyl; N3; N(R6)2, OH, OR3; SR3; OCOR3, or SCOR3;
Z is -C≡C-
-N=N-,
-N(0)=N-,
-N=N(0)-,
N=CR6-,
-CR6=N,
-(CR6=CR6)n- where n is an integer having the value 0 - 5,
-CS-NR,-,
-NR6-CO,
-COO-,
-OCO-;
-CSO-;
-OCS-;
-CO-CR6=CR6- e is independently H or lower alkyl of 1 to 6 carbons;
Y2 is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and heteroaryl groups being unsubstituted or substituted with one or two R4 groups, or when Z is and n is 3, 4 or 5 then Y2 represents a direct valence bond between said (CR6=CR6)n group and B; Y3 is phenyl, pyridyl, thienyl or furyl unsubstituted or substituted with up to 3 R, groups and unsubstituted or substituted with up to 3 R4 groups; A is (CH2)q where q is 0-5, lower branched chain alkyl having 3-6 carbons, cycloalkyl having 3-6 carbons, alkenyl having 2-6 carbons and 1 or 2 double bonds, alkynyl having 2-6 carbons and 1 or 2 triple bonds; B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, COOR8, CONR9R10, -CH2OH, CH2ORn, CH2OCORn, CHO, CH(OR12)2, CH(OR130), -COR7, CR7(ORu)2, CR7(OR130), or Si(C,. 6alkyl)3, where R7 is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbons, R8 is an alkyl group of 1 to 10 carbons or (trimethylsilyl)alkyl where the alkyl group has 1 to 10 carbons, or a cycloalkyl group of 5 to 10 carbons, or R8 is phenyl or lower alkylphenyl, R, and R10 independently are hydrogen, an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5-10 carbons, or phenyl, hydroxyphenyl or lower alkylphenyl, Rn is lower alkyl, phenyl or lower alkylphenyl, Rn *s lower alkyl, and R13 is divalent alkyl radical of 2-5 carbons. In a second aspect, this invention relates to the use of the compounds of Formula 1 for the treatment of skin-related diseases, including, without limitation, actinic keratoses, arsenic keratoses, inflammatory and non-inflammatory acne, psoriasis, ichthyoses and other keratinization and hyperproliferative disorders of the skin, eczema, atopic dermatitis, Darriers disease, lichen planus, prevention and reversal of glucocorticoid damage (steroid atrophy), as a topical anti-microbial, as skin anti-pigmentation agents and to treat and reverse the effects of age and photo damage to the skin. The compounds are also useful for the prevention and treatment of cancerous and precancerous conditions, including, premalignant and malignant hyperproliferative diseases such as cancers of the breast, skin, prostate, cervix, uterus, colon, bladder, esophagus, stomach, lung, larynx, oral cavity, blood and lymphatic system, metaplasias, dysplasias, neoplasias, leukoplakias and papillomas of the mucous membranes and in the treatment of Kaposi's sarcoma. In addition, the present compounds can be used as agents to treat diseases of the eye, including, without limitation, proliferative vitreoretinopathy (PVR), retinal detachment, dry eye and other corneopathies, as well as in the treatment and prevention of various cardiovascular diseases, including, without limitation, diseases associated with lipid metabolism such as dyslipidemias, prevention of post-angioplasty restenosis and as an agent to increase the level of circulating tissue plasminogen activator (TPA). Other uses for the compounds of the present invention include the prevention and treatment of conditions and diseases associated with Human papilloma virus (HPV), including warts and genital warts, various inflammatory diseases such as pulmonary fibrosis, ileitis, colitis and Krohn's disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and stroke, improper pituitary function, including insufficient production of growth hormone, modulation of apoptosis, including both the induction of apoptosis and inhibition of T-Cell activated apoptosis, restoration of hair growth, including combination therapies with the present compounds and other agents such as MinoxidilR, diseases associated with the immune system, including use of the present compounds as immunosuppressants and immunostimulants, modulation of organ transplant rejection and facilitation of wound healing, including modulation of chelosis. Alternatively, those compounds of the invention which act as antagonists or inverse agonists of one or more retinoid receptor subtypes are useful to prevent certain undesired side effects of retinoids which are administered for the treatment or prevention of certain diseases or conditions. For this purpose the retinoid antagonist and/or inverse agonist compounds of the invention may be co-administered with retinoids. The retinoid antagonist and inverse agonist compounds of the present invention are also useful in the treatment of acute or chronic toxicity resulting from overdose or poisoning by retinoid drugs or Vitamin A. This invention also relates to a pharmaceutical formulation comprising a compound of Formula 1 in admixture with a pharmaceutically acceptable excipient, said formulation being adapted for administration to a mammal , including a human being, to treat or alleviate the conditions which were described above as treatable by retinoids, to be co-administered with retinoids to eliminate or reduce side effects of retinoids, or to treat retinoid or Vitamin A overdose or poisoning. BIOLOGICAL ACTIVITY, MODES OF ADMINISTRATION Assays of Retinoid-like or Retinoid Antagonist and Inverse Aαonist- like Biological Activity A classic measure of retinoic acid activity involves measuring the effects of retinoic acid on ornithine decarboxylase. The original work on the correlation between retinoic acid and decrease in cell proliferation was done by Verma & Boutwell, Cancer Research, 1977, 37, 2196-2201. That reference discloses that ornithine decarboxylase (ODC) activity increased precedent to polyamine biosynthesis. It has been established elsewhere that increases in polyamine synthesis can be correlated or associated with cellular proliferation. Thus, if ODC activity could be inhibited, cell hyperproliferation could be modulated. Although all cases for ODC activity increases are unknown, it is known that 12-0-tetradecanoylρhorbol-13-acetate (TPA) induces ODC activity. Retinoic acid inhibits this induction of ODC activity by TPA. An assay essentially following the procedure set out in Cancer Research: 1662-1670,1975 may be used to demonstrate inhibition of TPA induction of ODC by compounds of this invention. "I o" is that concentration of the test compound which causes 60% inhibition in the ODC assay. By analogy, "IC80", for example, is that concentration of the test compound which causes 80% inhibition in the ODC assay. Other assays described below, measure the ability of the compounds of the present invention to bind to, and/or activate various retinoid receptor subtypes. When in these assays a compound binds to a given receptor subtype and activates the transcription of a reporter gene through that subtype, then the compound is considered an agonist of that receptor subtype. Conversely, a compound is considered an antagonist of a given receptor subtype if in the below described co-tranfection assays the compound does not cause significant transcriptional activation of the receptor regulated reporter gene, but nevertheless binds to the receptor with a K,, value of less than approximately 1 micromolar. In the below described assays the ability of the compounds to bind to RARα, RARβ, RARγ, RXRα, RXRβ and RXRr receptors, and the ability or inability of the compounds to activate transcription of a reporter gene through these receptor subtypes can be tested. Specifically, a chimeric receptor transactivation assay which tests for agonist-like activity in the RARα, RARβ, RARγ, RXRα receptor subtypes, and which is based on work published by Feigner P. L. and Holm M. (1989) Focus, 112 is described in detail in United States Patent No. 5,455,265 the specification of which is hereby expressly incorporated by reference. A holoreceptor transactivation assay and a ligand binding assay which measure the antagonist/agonist like activity of the compounds of the invention, or their ability to bind to the several retinoid receptor subtypes, respectively, are described in published PCT Application No. WO W093/11755 (particularly on pages 30 - 33 and 37 - 41) published on June 24, 1993, the specification of which is also incorporated herein by reference. A detailed experimental procedure for holoreceptor transactivations has been described by Heyman et al. Cell 68, 397 - 406, (1992); Allegretto et al. J. Biol. Chem. 268, 26625 - 26633, and Mangelsdorf et al. The Retinoids: Biology, Chemistry and Medicine, pp 319 - 349, Raven Press Ltd., New York, which are expressly incorporated herein by reference. The results obtained in this assay are expressed in EC50 numbers, as they are also in the chimeric receptor transactivation assay. The results of ligand binding assay are expressed in Kj numbers. (See Cheng et al. Biochemical Pharmacology Vol. 22 pp 3099-3108, expressly incorporated herein by reference.) Still another transactivation assay, the "PGR assay" is described in the publication Klein et al. J. Biol. Chem. 271, 22692-22696 (1996) which is expressly incorporated herein by reference, and a detailed description is also provided below. The results of the PGR assay are also expressed in EC50 numbers (nanomolar concentration). RAR-P-GR holoreceptor Transactivation Assay CV-1 cells (4 x 105 cells/well) were transiently transfected with the luciferase reporter plasmid MTV-4(R5G)-Luc (0.7 μg/well) containing four copies of the R5G retinoid DNA response element along with the RXRα expression plasmid pRS-hRXRα (0.1 μg/well) and one of the RAR-P-GR expression plasmids (0.05 μg/well) in 12 well plates via calcium phosphate precipitation Chen et al. (1987) Mol. Cell. Biol. 7, 2745-2752, as described by Klein et al. in J. Biol. Chem. 271, 22692, referenced above. The three different RAR-P-GR expression plasmids, pRS-RARα-P-GR, pcDNA3-RAR/3-P-GR and pcDNA3-RARγ-P-GR, express RARα, RAR/3 and RARγ receptors, respectively, which contain modified DNA binding domains such that their "P-boxes" have been altered to that of the glucocorticoid receptor. These RAR-P-GR receptors bind to DNA as heterodimeric complexes with RXR. Specifically, the RAR-P-GR receptors bind retinoic acid response elements designated R5G, comprised of two RAR half sites (nucleotide sequence 5'-GGTTCA-3') separated by 5 base pairs in which the 3'-half site has been modified to that of a glucocorticoid receptor half site, 5'- AGAACA-3'. To allow for various in transfection efficiency a β- galactosidase expression plasmid (0.01 ug/well) was used as an internal control. Alternatively, the assay was performed in a 96-well microtiter plate format (5000 cells/well) in a manner which was identical to that described above except 1/5 of the amount of the DNA-calcium phosphate precipitant (20 μl instead of 100 μl) was applied to each well. Eighteen hours after introduction of the DNA precipitants, cells were rinsed with phosphate buffered saline (PBS) and fed with D-MEM (Gibco-BRL) containing 10% activated charcoal extracted fetal bovine serum (Gemini Bio-Products). Cells were treated for 18 hours with the compounds indicated in the figures. After rinsing with PBS, cells were lysed and luciferase activity was measured as previously described in de Wet et al. (1987) Mol. Cell. Biol. 7, 725-737. Luciferase values represent the mean±SEM of triplicate determinations normalized to β- galactosidase activity. Table 1 below shows the results of the PGR assay for certain exemplary compounds of the invention for the receptor subtypes in the RAR group and Table 2 shows the results of the ligand binding assay for the same compounds. As it can be seen from the Tables, these exemplary compounds do not transactivate but bind to the receptor and therefore have retinoid antagonist (or inverse agonist) effects. TABLE 1
PGR Assay Data (transactivation)
' "% Efficiency" is percentage of efficiency of the test compounds in this assay relative to all-trøns-retinoic acid.
2 "NA" stands for NOT ACTIVE (> 10,000 nM) TABLE 2
Ligand Binding Assay
Inverse agonists are ligands that are capable of inhibiting the basal receptor activity of unliganded receptors. Recently, retinoic acid receptors (RARs) have been shown to be responsive to retinoid inverse agonists in regulating basal gene transcriptional activity. Moreover, the biological effects associated with retinoid inverse agonists are distinct from those of retinoid agonists or antagonists. For example, RAR inverse agonists, but not RAR neutral antagonists, cause a dose- dependent inhibition of the protein MRP-8 in cultured human keratinocytes differentiated with serum. MRP-8 is a specific marker of cell differentiation, which is also highly expressed in psoriatic epidermis, but is not detectable in normal human skin. Thus, retinoid inverse agonists may offer a unique way of treating diseases such as psoriasis. The activity of retinoid inverse agonists can be tested by the procedure of Klein et al. J. Biol. Chem. 271, 22692 - 22696 (1996) which is expressly incorporated herein by reference. In this assay, retinoid inverse agonists are able to repress the basal activity of a RARγ -VP- 16 chimeric receptor where the constituitively active domain of the herpes simplex virus (HSV) VP-16 is fused to the N-terminus of RARγ. CV-1 cells are cotransfected with RARγ-VP-16, an ER-RXRα chimeric receptor and an ERE-tk-Luc chimeric reporter gene to produce a basal level of luciferase activity, as shown by Nagpal et al. EMBO J. 12, 2349 -2360 (1993) expressly incorporated herein by reference. Retinoid inverse agonists are able to inhibit the basal luciferase activity in these cells in a dose dependent manner and IC50s measured. Modes of Administration The compounds of this invention may be administered systemically or topically, depending on such considerations as the condition to be treated, need for site-specific treatment, quantity of drug to be administered, and numerous other considerations. In the treatment of dermatoses, it will generally be preferred to administer the drug topically, though in certain cases such as treatment of severe cystic acne or psoriasis, oral administration may also be used. Any common topical formulation such as a solution, suspension, gel, ointment, or salve and the like may be used. Preparation of such topical formulations are well described in the art of pharmaceutical formulations as exemplified, for example, by Remington's Pharmaceutical Science, Edition 17, Mack Publishing Company, Easton, Pennsylvania. For topical application, these compounds could also be administered as a powder or spray, particularly in aerosol form. If the drug is to be administered systemically, it may be confected as a powder, pill, tablet or the like or as a syrup or elixir suitable for oral administration. For intravenous or intraperitoneal administration, the compound will be prepared as a solution or suspension capable of being administered by injection. In certain cases, it may be useful to formulate these compounds by injection. In certain cases, it may be useful to formulate these compounds in suppository form or as extended release formulation for deposit under the skin or intramuscular injection. Other medicaments can be added to such topical formulation for such secondary purposes as treating skin dryness; providing protection against light; other medications for treating dermatoses; medicaments for preventing infection, reducing irritation, inflammation and the like. Treatment of dermatoses or any other indications known or discovered to be susceptible to treatment by retinoic acid-like compounds will be effected by administration of the therapeutically effective dose of one or more compounds of the instant invention. A therapeutic concentration will be that concentration which effects reduction of the particular condition, or retards its expansion. In certain instances, the compound potentially may be used in prophylactic manner to prevent onset of a particular condition. A useful therapeutic or prophylactic concentration will vary from condition to condition and in certain instances may vary with the severity of the condition being treated and the patient's susceptibility to treatment. Accordingly, no single concentration will be uniformly useful, but will require modification depending on the particularities of the disease being treated. Such concentrations can be arrived at through routine experimentation. However, it is anticipated that in the treatment of, for example, acne, or similar dermatoses, that a formulation containing between 0.01 and 1.0 milligrams per milliliter of formulation will constitute a therapeutically effective concentration for total application. If administered systemically, an amount between 0.01 and 5 mg per kg per day of body weight would be expected to effect a therapeutic result in the treatment of many diseases for which these compounds are useful. The partial or pan retinoid antagonist and/or retinoid inverse agonist compounds of the invention, when used to take advantage of their antagonist and/or inverse agonist property, can be co-administered to mammals, including humans, with retinoid agonists and, by means of pharmacological selectivity or site-specific delivery, preferentially prevent the undesired effects of certain retinoid agonists. The antagonist and/or inverse agonist compounds of the invention can also be used to treat Vitamin A overdose, acute or chronic, resulting either from the excessive intake of vitamin A supplements or from the ingestion of liver of certain fish and animals that contain high levels of Vitamin A. Still further, the antagonist and/or inverse agonist compounds of the invention can also be used to treat acute or chronic toxicity caused by retinoid drugs. It has been known in the art that the toxicities observed with hypervitaminosis A syndrome (headache, skin peeling, bone toxicity, dyslipidemias) are similar or identical with toxicities observed with other retinoids, suggesting a common biological cause, that is RAR activation. Because the antagonist or inverse agonist compounds of the present invention block or diminish RAR activation, they are suitable for treating the foregoing toxicities. Generally speaking, for therapeutic applications in mammals, the antagonist and/or inverse agonist compounds of the invention can be admistered enterally or topically as an antidote to vitamin A, or antidote to retinoid toxicity resulting from overdose or prolonged exposure, after intake of the causative factor (vitamin A, vitamin A precursor, or other retinoid) has been discontinued. Alternatively, the antagonist and/or inverse agonist compounds of the invention are co-administered with retinoid drugs, in situations where the retinoid provides a therapeutic benefit, and where the co-administered antagonist and/or inverse agonist compound alleviates or eliminates one or more undesired side effects of the retinoid. For this type of application the antagonist and/or inverse agonist compound may be administered in a site-specific manner, for example as a topically applied cream or lotion while the co-administered retinoid may be given enterally. For therapeutic applications the antagonist compounds of the invention, like the retinoid agonists compounds, are incorporated into pharmaceutical compositions, such as tablets, pills, capsules, solutions, suspensions, creams, ointments, gels, salves, lotions and the like, using such pharmaceutically acceptable excipients and vehicles which per se are well known in the art. For topical application, the antagonist and/or inverse agonist compounds of the invention could also be administered as a powder or spray, particularly in aerosol form. If the drug is to be administered systemically, it may be confected as a powder, pill, tablet or the like or as a syrup or elixir suitable for oral administration. For intravenous or intraperitoneal administration, the compound will be prepared as a solution or suspension capable of being administered by injection. In certain cases, it may be useful to formulate these compounds by injection. In certain cases, it may be useful to formulate these compounds in suppository form or as extended release formulation for deposit under the skin or intramuscular injection. The antagonist and/or inverse agonist compounds also, like the retinoid agonists of the invention, will be administered in a therapeutically effective dose. A therapeutic concentration will be that concentration which effects reduction of the particular condition, or retards its expansion. When co-administering the compounds of the invention to block retinoid-induced toxicity or side effects, the antagonist and/or inverse agonist compounds of the invention are used in a prophylactic manner to prevent onset of a particular condition, such as skin irritation. A useful therapeutic or prophylactic concentration will vary from condition to condition and in certain instances may vary with the severity of the condition being treated and the patient's susceptibility to treatment. Accordingly, no single concentration will be uniformly useful, but will require modification depending on the particularities of the chronic or acute retinoid toxicity or related condition being treated. Such concentrations can be arrived at through routine experimentation. However, it is anticipated that a formulation containing between 0.01 and 1.0 milligrams of the active compound per mililiter of formulation will constitute a therapeutically effective concentration for total application. If administered systemically, an amount between 0.01 and 5 mg per kg per day of body weight would be expected to effect a therapeutic result. GENERAL EMBODIMENTS AND SYNTHETIC METHODOLOGY Definitions The term alkyl refers to and covers any and all groups which are known as normal alkyl, branched-chain alkyl and cycloalkyl. The term alkenyl refers to and covers normal alkenyl, branch chain alkenyl and cycloalkenyl groups having one or more sites of unsaturation. Similarly, the term alkynyl refers to and covers normal alkynyl, and branch chain alkynyl groups having one or more triple bonds. Lower alkyl means the above-defined broad definition of alkyl groups having 1 to 6 carbons in case of normal lower alkyl, and as applicable 3 to 6 carbons for lower branch chained and cycloalkyl groups. Lower alkenyl is defined similarly having 2 to 6 carbons for normal lower alkenyl groups, and 3 to 6 carbons for branch chained and cyclo- lower alkenyl groups. Lower alkynyl is also defined similarly, having 2 to 6 carbons for normal lower alkynyl groups, and 4 to 6 carbons for branch chained lower alkynyl groups. The term "ester" as used here refers to and covers any compound falling within the definition of that term as classically used in organic chemistry. It includes organic and inorganic esters. Where B of Formula 1 is -COOH, this term covers the products derived from treatment of this function with alcohols or thiols preferably with aliphatic alcohols having 1-6 carbons. Where the ester is derived from compounds where B is -CH2OH, this term covers compounds derived from organic acids capable of forming esters including phosphorous based and sulfur based acids, or compounds of the formula -CH2OCORu where Rn is any substituted or unsubstituted aliphatic, aromatic, heteroaromatic or aliphatic aromatic group, preferably with 1-6 carbons in the aliphatic portions. Unless stated otherwise in this application, preferred esters are derived from the saturated aliphatic alcohols or acids of ten or fewer carbon atoms or the cyclic or saturated aliphatic cyclic alcohols and acids of 5 to 10 carbon atoms. Particularly preferred aliphatic esters are those derived from lower alkyl acids and alcohols. Also preferred are the phenyl or lower alkyl phenyl esters. Amides has the meaning classically accorded that term in organic chemistry. In this instance it includes the unsubstituted amides and all aliphatic and aromatic mono- and di- substituted amides. Unless stated otherwise in this application, preferred amides are the mono- and di-substituted amides derived from the saturated aliphatic radicals of ten or fewer carbon atoms or the cyclic or saturated aliphatic-cyclic radicals of 5 to 10 carbon atoms. Particularly preferred amides are those derived from substituted and unsubstituted lower alkyl amines. Also preferred are mono- and disubstituted amides derived from the substituted and unsubstituted phenyl or lower alkylphenyl amines. Unsubstituted amides are also preferred. Acetals and ketals include the radicals of the formula-CK where K is (-OR)2. Here, R is lower alkyl. Also, K may be -OR70- where R7 is lower alkyl of 2-5 carbon atoms, straight chain or branched. A pharmaceutically acceptable salt may be prepared for any compounds in this invention having a functionality capable of forming a salt, for example an acid functionality. A pharmaceutically acceptable salt is any salt which retains the activity of the parent compound and does not impart any deleterious or untoward effect on the subject to which it is administered and in the context in which it is administered. Pharmaceutically acceptable salts may be derived from organic or inorganic bases. The salt may be a mono or polyvalent ion. Of particular interest are the inorganic ions, sodium, potassium, calcium, and magnesium. Organic salts may be made with amines, particularly ammonium salts such as mono-, di- and trialkyl amines or ethanol amines. Salts may also be formed with caffeine, tromethamine and similar molecules. Where there is a nitrogen sufficiently basic as to be capable of forming acid addition salts, such may be formed with any inorganic or organic acids or alkylating agent such as methyl iodide. Preferred salts are those formed with inorganic acids such as hydrochloric acid, sulfuric acid or phosphoric acid. Any of a number of simple organic acids such as mono-, di- or tri- acid may also be used. Some of the compounds of the present invention may have trans and cis (E and Z) isomers. In addition, the compounds of the present invention may contain one or more chiral centers and therefore may exist in enantiomeric and diastereomeric forms. The scope of the present invention is intended to cover all such isomers per se, as well as mixtures of cis and trans isomers, mixtures of diastereomers and racemic mixtures of enantiomers (optical isomers) as well. Generally speaking, compounds of the invention where Z is an ethyne function are obtained in a sequence of reactions which initially involve the synthesis of a halogenated, preferably brominated, phenyl derivative, that has in the position meta to the halogene (preferrably bromo) group an Y(R5)-CO ketone function and which may be obtained as a result of a Friedel-Crafts or like reaction. The bromo compound is reacted with (trimethylsilyl)acetylene to provide a [l-(2- trimethylsilyl)ethynyl]phenyl derivative, from which the trimethylsilyl group is removed by treatment with base. The Y(R5)-CO ketone function may be subjected to a Grignard reaction, followed by dehydration of the resulting tertiary alcohol to provide compouds of the invention where X is CH2. The ethyne compounds are coupled with a reagent of the formula X2-Y2(R4)-A-B where X2 is a halogen and the remaining symbols are defined in connection with Formula 1. Compounds of the invention where Z is other than the above- described ethyne function, are obtained by utilizing the reactive nature of the bromo group, either to couple the bromo phenyl ketone compound (bromine is in the phenyl group) directly, such as in a Heck reaction, to provide compounds where the Y2(R4)A-B group is attached directly to the phenyl group. Alternatively the bromo function may be converted into other reactive groups, such as NH2 SH, or COOH which is then coupled to a reagent that together with the NH2 SH, or COOH completes the moiety designated Z in Formula 1, and which also introduces the Y2(R4)-A-B moiety of the compounds of the invention. Compounds of the invention where Z represents an ester, amide, thioester, thioamide, or azo linkage can, for example, be prepared in accordance with this general synthetic methodology. During the synthetic manipulation the OH or SH function in the para position of the phenyl ring may be protected by appropriate acid or base labile protecting groups, such as methoxymethyl (MOM), acetyl or trialkylsilyl. Still further, the Z-Y2(R4)-A-B moiety can be formed in multiple steps starting with the introduction of a two-carbon moiety (such as the CH3CO group) in place of the reactive bromo group of the substituted phenyl nucleus. This type of reaction sequence is suitable, for example, for the preparation of compounds of the invention where Z is -(CR6=CR6)n-, n is 3, 4 or 5 and Y2 represents a direct valence bond between the (CR6=CR6)n, group and B. Details of the above-outlined generalized synthetic schemes are provided below in connection with the description of the specific embodiments and specific examples. The synthetic methodology employed for the synthesis of the compounds of the present invention may also include transformations of the group designated -A-B in Formula 1. Generally speaking, these transformations involve reactions well within the skill of the practicing organic chemist. In this regard the following well known and published general principles and synthetic methodology are briefly described. Carboxylic acids are typically esterified by refluxing the acid in a solution of the appropriate alcohol in the presence of an acid catalyst such as hydrogen chloride or thionyl chloride. Alternatively, the carboxylic acid can be condensed with the appropriate alcohol in the presence of dicyclohexylcarbodiimide (DCC) and 4- (dimethylamino)pyridine (DMAP). The ester is recovered and purified by conventional means. Acetals and ketals are readily made by the method described in March, "Advanced Organic Chemistry," 2nd Edition, McGraw-Hill Book Company, p 810). Alcohols, aldehydes and ketones all may be protected by forming respectively, ethers and esters, acetals or ketals by known methods such as those described in McOmie, Plenum Publishing Press, 1973 and Protecting Groups. Ed. Greene, John Wiley & Sons, 1981. To increase the value of q in the compounds of the invention (or precursors thereof) before affecting the coupling or linkage with the phenyl nucleus (where such compounds are not available from a commercial source) aromatic or heteroaromatic carboxylic acids are subjected to homologation by successive treatment under Arndt-Eistert conditions or other homologation procedures. Alternatively, derivatives which are not carboxylic acids may also be homologated by appropriate procedures. The homologated acids can then be esterified by the general procedure outlined in the preceding paragraph. Compounds of the invention as set forth in Formula 1 (or precursors thereof) where A is an alkenyl group having one or more double bonds can be made for example, by synthetic schemes well known to the practicing organic chemist; for example by Wittig and like reactions, or by introduction of a double bond by elimination of halogen from an alpha-halo-arylalkyl-carboxylic acid, ester or like carbox- aldehyde. Compounds of the invention or precursors thereof, where the A group has a triple (acetylenic) bond, can be made by reaction of a corresponding aromatic methyl ketone with strong base, such as lithium diisopropylamide, reaction with diethyl chlorophosphate and subsequent addition of lithium diisopropylamide. The acids and salts derived from compounds of the invention are readily obtainable from the corresponding esters. Basic saponification with an alkali metal base will provide the acid. For example, an ester of the invention may be dissolved in a polar solvent such as an alkanol, preferably under an inert atmosphere at room temperature, with about a three molar excess of base, for example, lithium hydroxide or potassium hydroxide. The solution is stirred for an extended period of time, between 15 and 20 hours, cooled, acidified and the hydrolysate recovered by conventional means. The amide may be formed by any appropriate amidation means known in the art from the corresponding esters or carboxylic acids. One way to prepare such compounds is to convert an acid to an acid chloride and then treat that compound with ammonium hydroxide or an appropriate amine. For example, the ester is treated with an alcoholic base solution such as ethanolic KOH (in approximately a 10% molar excess) at room temperature for about 30 minutes. The solvent is removed and the residue taken up in an organic solvent such as diethyl ether, treated with a dialkyl formamide and then a 10-fold excess of oxalyl chloride. This is all effected at a moderately reduced temperature between about -10 degrees and +10 degrees C. The last mentioned solution is then stirred at the reduced temperature for 1-4 hours, preferably 2 hours. Solvent removal provides a residue which is taken up in an inert organic solvent such as benzene, cooled to about 0 degrees C and treated with concentrated ammonium hydroxide. The resulting mixture is stirred at a reduced temperature for 1 - 4 hours. The product is recovered by conventional means. Alcohols are made by converting the corresponding acids to the acid chloride with thionyl chloride or other means (J. March, "Advanced Organic Chemistry", 2nd Edition, McGraw-Hill Book Company), then reducing the acid chloride with sodium borohydride (March, Ibid, pg. 1124), which gives the corresponding alcohols. Alternatively, esters may be reduced with lithium aluminum hydride at reduced temperatures. Alkylating these alcohols with appropriate alkyl halides under Williamson reaction conditions (March, Ibid, pg. 357) gives the corresponding ethers. These alcohols can be converted to esters by reacting them with appropriate acids in the presence of acid catalysts or dicyclohexylcarbodiimide and dimethylaminopyridine. Aldehydes can be prepared from the corresponding primary alcohols using mild oxidizing agents such as pyridinium dichromate in methylene chloride (Corey, E. J., Schmidt, G., Tet. Lett.. 399, 1979), or dimethyl sulfoxide/oxalyl chloride in methylene chloride (Omura, K., Swern, D., Tetrahedron. 1978. 34. 1651). Ketones can be prepared from an appropriate aldehyde by treating the aldehyde with an alkyl Grignard reagent or similar reagent followed by oxidation. Acetals or ketals can be prepared from the corresponding aldehyde or ketone by the method described in March, Ibid, p 810. Compounds of the invention, or precursors thereof, where B is H can be prepared from the corresponding halogenated aromatic or heteroaromatic compounds, preferably where the halogen is I. SPECIFIC EMBODIMENTS With reference to the symbol Yx in Formula 1, the preferred compounds of the invention are those where Yt is phenyl, pyridyl, thienyl, furyl and thiazolyl. Among these the phenyl group and particularly methyl substituted phenyl are more preferred. Furthermore, substitution of the Yi phenyl group with the carbonyl group and the methyl group is preferred in the 1,4 (para) and 1,3 (meta) positions. The X group is preferably O (carbonyl function) or =CH2. The preferred Z (linker) groups are -C≡C-, -CH=CH-, -CONH- , -COO-, -OCO-, -NHCO-, -(CR^CR^- and n is 3, or the Z group is absent (n is zero and Y is directly attached to the phenyl ring). Among the foregoing even more preferred are the following: -C≡C-, -C=C-, and -CONH-. Presently -C≡C- is most preferred. The Y2 group is preferably phenyl, naphthyl, pyridyl, thienyl or furyl. Even more preferred are compounds where Y2 is phenyl. As far as substititutions on the Y2 (phenyl), Y2 (pyridyl) and (Y2) naphthyl groups are concerned, compounds are preferred where the phenyl group is 1,4 (para) substituted, the naphthyl group is 2,6 substituted and where the pyridine ring is 2,5 substituted. (Substitution in the 2,5 positions in the "pyridine" nomenclature corresponds to substitution in the 6-ρosition in the "nicotinic acid" nomenclature.) In the preferred compounds of the invention there is no or only one optional R4 substituent on the Y2 group, and the preferred R4 substituent is fluoro (F). Y3 is preferably phenyl. The Y3 phenyl group is preferably substituted in the 1,3 (meta) positions by the Y1(R5)CX and Z groups. The Rj group is preferably in the 4 (para) position relative ot the Z, and in the 2 (ortho) position relative to the YJR5)CX group. The A-B group of the preferred compounds is (CH2)qCOOH or (CH2)q-COOR8, where R8 is defined as above. Even more preferably q is zero and R8 is lower alkyl. In the preferred compounds of the invention m is 0, that is, there is no R4 substituent on the phenyl ring. The Rx group of the preferred compounds of the invention is OH, or OR2 where R2 is preferably H, lower alkyl of 1 to 10 carbons, methoxymethyl or dimethyl-t-butylsilyl. Among the R2 alkyl groups methyl and isopropyl are especially preferred. The most preferred compounds in accordance with Formula 1 are listed below in Table 3 for Formula 2 and with reference to that formula.
Formula 2 TABLE 3
The compounds of this invention can be made by the general procedures outlined above under the title ""GENERAL EMBODIMENTS AND SYNTHETIC METHODOLOGY". The following chemical pathways represent the presently preferred synthetic routes to certain classes of the compounds of the invention and to certain specific exemplary compounds. However, the synthetic chemist will readily appreciate that the conditions set out here for these specific embodiments can be generalized to any and all of the compounds represented by Formula 1.
Foπrmila 3
Formula 8 Formula 9
HOMOLOGS and DERIVATIVES
Reaction Scheme 1 Referring now to Reaction Scheme 1 a synthetic process is disclosed whereby exemplary compounds of the invention are obtained in which, with reference to Formula 1, the Z group is ethynyl (-C≡C-) and the X group is CH2. The compounds shown in this reaction scheme and in the other reactions schemes of this specification, include an OR2* substituent where the R2* group represents the moieties defined as R2 in connection with Formula 1. However, for the purposes of the reaction schemes the R2* moiety is distinguished from the R2 group of the "final" biologically active compounds of the invention, because the synthetic steps involved in the synthesis of the compounds of the invention may require the R2* to act as protecting group, and not all of the R2 groups are necessarily suitable for this purpose. Therefore, during the synthetic steps which are only generally described in connection with the reaction schemes, removal and attachments of the various R2* groups may become necessary as protection and deprotection of the OH or SH groups. However, these protection and deprotection steps and how to perform them will be readily apparent to those skilled in the art in light of the present disclosure. The synthetic processes disclosed in the reaction schemes of this specification can also be applied for the preparation of compounds where, with reference to Formula 1 the Rx group is other than OR2, or SR2. The compounds of Formula 3 in Reaction Scheme 1 may be available commercially or can be obtained in synthetic steps which are well known in the chemistry of benzene derivatives. An example for a compound of Formula 3 is 5-bromo-2-methoxyacetophenone, which can be obtained through a Friedel Crafts reaction from 4-bromoanisol, as is described in detail in the Specific Examples. Another example is 5- bromo-2-methoxymethoxyacetophenone which can be obtained from 5- bromo-2-hydroxyacetophenone by treatment with chloromethyl methyl ether in the presence of base. As is shown in Reaction Scheme 1, compounds of Formula 3 are reacted with (trimethylsilyl)acetylene in the presence of copper(I)iodide, diethylamine and bis(triphenylphosphine)palladium(II) chloride to yield the acetophenone derivatives substituted in the meta position with the (trimethylsilyl)ethynyl group (Formula 4). The trimethylsilyl group is removed from the compounds of Formula 4 by treatment with base, such as potassium carbonate, in alcoholic solvent (eg. methanol), to yield the ethynyl substituted acetophenone derivatives of Formula 5. The ethynyl substituted acetophenone derivatives of Formula 5 are then coupled with the reagent of the formula X2-Y2(R4)-A-B (Formula 6), where X2 is halogen and the remaining symbols are defined in connection with Formula 1. The coupling reaction is conducted in the presence of copper(I)iodide, diethylamine and bis(triphenylphosphine)palladium(II) chloride to provide the disubstituted acetylene compounds of Formula 7. Examples for the reagent X2-Y2(R4)-A-B (Formula 6) are ethyl 4-iodobenzoate, ethyl 6- bromo-2-naphthoate, ethyl 6-iodonicotinate, ethyl 2-iodofuran-5- carboxylate, and ethyl 2-iodothiophen-5-carboxylate. Precise conditions of the reactions leading from compounds of Formula 3 to the compounds of Formula 7 are described in connection with the specific examples. These reactions are analogous to the reaction described in several United States Letters Patent, such as United States Patent Nos. 5,348,972 and 5,346,915, assigned to the assignee of the present application, where introduction of an ethynyl group into a heteroaryl nucleus and subsequent coupling with a halogenated aryl or heteroaryl function are described. The specifications of United States Patent Nos. 5,348,972 and 5,346,915 are specifically incorporated herein by reference. The disubstituted acetylene compounds of Formula 7 are then reacted with a Grignard (or similar organometal) reagent having the formula YrMgBr, where Yx is defined as in connection with Formula 1. An example for the YrMgBr reagent is the Grignard reagent obtained from /rørø-tolylbromide, other examples are Grignard or organometal reagents obtained from halogenated heteroaryl compounds. The product of the Grignard (or like) reaction is a tertiary alcohol of Formula 8, which is dehydrated by treatment with acid, to provide compounds of Formula 9. The compounds of Formula 9 are within the scope of the invention (X = CH2), and can be converted into further homologs and derivatives in reactions of the type generally described above. A frequently used reaction in this regard is saponification whereby an ester function (represented in Formula 9 by the symbol B) is converted into a carboxylic acid function. Similarly the R2* group may represent an acyl function that can be removed by saponification, or R2* may represent an acid labile group (such as methoxymethyl) that can be removed to yield compounds of the invention where R2 is H.
Formula 3 Formula 10
Formula 11 Formula 12
HOMOLOGS and DERIVATIVES
Formula 9
Reaction Scheme 2 Reaction Scheme 2 discloses another process for synthesizing exemplary compounds of the invention where, with reference to Formula 1, X represents CH2. The reactions in this scheme differ from the reactions illustrated in Scheme 1 primarily in the sequence in which they are conducted. As is shown in Reaction Scheme 2, the brominated acetophenone derivative of Formula 3 is reacted with the Grignard (or similar organometal) reagent having the formula YrMgBr, to provide a tertiary alcohol that is dehydrated by treatment with acid, to yield the brominated vinylphenyl compounds of Formula 10. The brominated vinylphenyl compounds of Formula 10 are then coupled with (trimethylsilyl)acetylene, the resulting the (trimethylsilyl)ethynylphenyl compounds (Formula 11) are reacted with base to give ethynylphenyl compounds (Formula 12) which are then coupled with the reagent X2-Y2(R4)-A-B (Formula 6), in a series of reactions of the type described above in connection with Reaction Scheme 1. The product of the coupling reaction with the reagent X2- Y2(R4)-A-B (Formula 6) is the disubstituted ethynyl derivative of Formula 9 that is within the scope of Formula 1 (X = CH2). The compounds of Formula 9 can be converted to further homologs and derivatives, as described above and indicated in the reaction scheme.
Formula 14 Formula 15 Formula 10
Formula 17 Formula 18
HO.MOLOGS and DERTVATTVES
Reaction Scheme 3 Reaction Scheme 3 discloses a process for synthesis of exemplary compounds of the invention where X of Formula 1 is O. Starting material for this synthesis is a halogen, preferably bromo-substituted phenol derivative of Formula 14 that is protected in the phenolic hydroxyl group. An example is 4-bromoanisole. The compound of Formula 14 is subjected to a Friedel Crafts (or like) reaction with a reagent of the formula YrCOCl. An example for this reagent, used for the preparation of several preferred compounds of the invention, is /κzrα-toluoyl chloride. Other examples are acid chlorides formed from such acids as benzoic acid, nicotinic acid, thiophene-2-carboxylic acid, and furan-2-carboxylic acid. The result of the Friedel Crafts reaction is a ketone compound of Formula 15; in the preferred example where the reagent is /rørα-toluoyl chloride the compound of Formula 15 is a benzophenone derivative. Thereafter, the ketone compound of Formula 15 is subjected to the sequence of reactions described above, namely coupling with (trimethylsilyl)acetylene, followed by treatment with base, and followed by coupling with the reagent X2-Y2(R4)-A-B (Formula 6), to provide, through the intermediates of Formulas 16 and 17, the ketone compounds within the scope of the invention (Formula 18). The compounds of Formula 18 can be converted into further homologs and derivatives, as described above. The intermediate brominated benzophenone (or like) derivatives of Formula 15 can also be subjected to a Grignard reaction with methylmagnesium bromide, to provide, after dehydration of the intermediary tertiary alcohol the brominated vinylphenyl compounds of Formula 10. As is described above, the compounds of Formula 10 serve as intermediates in accordance with Reaction Scheme 2 in the synthesis of exemplary compounds of the invention where X of Formula 1 is CH2.
Formula 3 Formula 19 j . Y,-MgBr :• H*. heat
HOMOLOGS and DERΓVATΓVES
Formula 10 Formula 20
" ,. Y,— MgBr 2- H\ heat
Formula 15 Formula 21
HOMOLOGS and DERIVATIVES
Reaction Scheme 4 Reaction Scheme 4 discloses synthetic processes for obtaining certain exemplary compounds of the invention in which, with reference to Formula 1, the Z group is -CH=CH-. In accordance with this process brominated acetophenone derivatives of Formula 3 are reacted in a Heck reaction with vinylaryl compounds of the formula CH2=CH-Y2(R4)-A-B. Examples for suitable vinylaryl compounds are ethyl 4-vinylbenzoate, ethyl 6-vinyl nicotinate, ethyl 5-vinylfuran-2- carboxylate and ethyl 5-vinylthiophen-2-carboxylate. The Heck reaction is typically conducted in the presence of triethylamine, copper(I)iodide, palladium(II)acetate and tri-(σ-tolyl)phosphine. The Heck reaction provides compounds of Formula 19 which are within the scope of the present invention. Depending on the precise nature of the starting compound of Formula 3, its ketone function may need to be protected before the Heck coupling reaction is performed, and the protective group is then removed after the Heck reaction. Suitable protective groups for this purpose are ketal groups, such as the ketal formed under acidic condition with ethyleneglycol. Protection and deprotection of the ketone group of Formula 3 is not shown in the scheme, but will become readily apparent to those skilled in the art in light of the nature of the compound of Formula 3 and the present disclosure. The need for protection and deprotection of the ketone group in the form of a ketal, may also arise in connection with other reactions described in this specification. After the Heck reaction (and deprotection of the ketone function if necessary) the compounds of Formula 19 are reacted in a Grignard (or like organometal) reaction with the reagent Y MgBr (or other suitable organometal reagent, YrMe where Me is metal such as lithium) to provide after dehydration of the intermediary tertiary alcohol the aryl vinylphenyl compounds of Formula 20 which are within the scope of the invention. The compounds of Formula 20 can be converted to further homologs and derivatives still within the scope of the present invention, as described above. As is further disclosed in Reaction Scheme 4 the Heck reaction can also be performed on the intermediate brominated arylvinylphenyl compounds of Formula 10, and on the brominated diaryl ketone compounds of Formula 15, which are obtained in accordance with Reaction Schemes 2 and 3, respectively. The products of the Heck reaction of the compounds of Formula 10 with the reagent of the formula CH2=CH-Y2(R4)-A-B are the arylvinylphenyl compounds of the invention of Formula 20. The products of the Heck reaction of the compounds of Formula 15 with the reagent of the formula CH2=CH- Y2(R4)-A-B are the diaryl ketone compounds of the invention of Formula 21, and the latter can be converted into compounds of Formula 20 by reaction with the Grignard reagent CH3MgBr, followed by dehydration of the tertiary alcohol. The following Reaction Schemes 5, 6, 7 and 8 describe synthetic processes to provide exemplary compounds of the invention starting with the brominated aryl vinylphenyl compounds of Formula 10. However, those skilled in the art will readily understand that the herein described synthetic steps and processes can be applied with such modifications that are within the skill of the practicing organic chemist, to the brominated acetophenone derivatives of Formula 3 and to the brominated diaryl ketone compounds of Formula 15, and by extension of the herein described generic principles to still further compounds of the invention as well.
HOMOLOGS and DERIVATIVES
Formula 10 Formula 22
Reaction Scheme 5 Referring now specifically to Reaction Scheme 5, it discloses synthetic routes to compounds of the invention where, with reference to Formula 1, Z is -CONH- (amides), -COO- (esters) -COS- (thioesters) and -CSNH- (thioamides). In accordance with this scheme the brominated aryl vinylphenyl compounds of Formula 10 are reacted with rc-butyl lithium and carbon dioxide to "capture" the carbon dioxide and to provide the aryl vinylbenzoic acid derivatives of Formula 22. The aryl vinylbenzoic acid derivatives of Formula 22 can be converted into amides of Formula 23 by reaction with reagents of the formula H2N- Y2(R4)-A-B, into esters of Formula 25 by reaction with reagents of the formula HO-Y2(R4)-A-B, and into thioesters of Formula 26 by reaction with reagents of the formula HS- Y2(R4)-A-B, where the symbols are defined as in connection with Formula 1. Examples for the reagents of formula H2N-Y2(R4)-A-B are ethyl 4-aminobenzoate and ethyl 6- aminonicotinate, for the reagents of the formula HO-Y2(R4)-A-B ethyl 4-hydroxybenzoate and ethyl 6-hydroxynicotinate, and for the reagents of the formula HS-Y2(R4)-A-B ethyl 4-mercaptobenzoate and ethyl 6- mercaptonicotinate. The reactions between the carboxylic acids of Formula 22 and the reagents of the formulas H2N-Y2(R4)-A-B, HO- Y2(R4)-A-B and HS-Y2(R4)-A-B, can be performed in several ways in which amides, esters and thioesters are normally prepared. For example, the carboxylic acids of Formula 22 can be activated to form an acid chloride or an activated ester which is thereafter reacted with the amines, alcohols or thioalcohols of the above formulas. More advantageously, however, the formation of the amides, esters or thioesters is performed by condensation of the carboxylic acid of Formula 22 with the amines, alcohols or thiols in a suitable aprotic solvent, such as pyridine, in the presence of a condensing agent such as dicyclohexylcarbodiimide (DCC) or more preferably l-(3- dimethylaminopropyl)-3-ethylcarbodiimidehydrochloride (EDCI). The amide derivatives of Formula 23 can be readily converted to the thioamides of Formula 24 by reaction with [2,4-bis(4-methoxyphenyl)- l,3-dithia-2,4-diphosρhetane-2,4-disulfide] (Lawesson's reagent). The amide derivatives of Formula 23 where the symbol B represents an ester function (such as COOEt) can be readily saponified by treatment with aqueous base, for example LiOH, to yield the corresponding amide derivatives where B represents a free carboxylic acid or its salt. Similar saponification of the esters of Formula 25, or of the thioesters of Formula 26, however is problematic because of the lability of the internal ester and thioester functions. The free acids of these derivatives (where B is COOH or a salt thereof) can be obtained by hydrogenation of the corresponding benzyl esters in which B represents COOCH2C6H5.
X;— Y:(R4)— A-B Pd(Ph3)4, Na2C03, MeOH
Formula 28
HOMOLOGS and DERIVATIVES
Reaction Scheme 6 Reaction Scheme 6 discloses a synthetic process for preparing compounds of the invention where, with reference to Formula 1, the Z group is -(CR6=CR6)n- and n is 0. In other words, this is a reaction scheme for obtaining compounds of the invention where the -Y2(R4)-A-B moiety is directly linked to the position of the phenyl ring which is meta to the YrC(CH2)- moiety. Pursuant to this reaction scheme, the brominated aryl vinylphenyl compounds of Formula 10 are reacted with t-butyl lithium and subsequently with triisopropylborate to provide the boronic acid derivative intermediates of Formula 27. The boronic acid derivatives of Formula 27 react with compounds of the formula X2- Y2(R4)-A-B (where the symbols are defined as above and X2 is preferably bromine) in the presence of tetrakis[triphenylphosphine]palladium [Pd(PPh3)4] and a base, such as sodium carbonate, to yield compounds of Formula 28. Examples of preferred reagents of formula X2-Y2(R4)-A-B are ethyl 6-bromo-2- naphthoate, ethyl 4-iodobenzoate, ethyl 6-iodonicotinate, ethyl 2- iodofuran-5-carboxylate, and ethyl 2-iodothiophen-5-carboxylate. The compounds of Formula 28 can be converted into further compounds of the invention by the reactions described above, such as saponification, amide formation, homologation and the like.
Formula 10 Formula 29
Formula 30 Formula 31
HOMOLOGS and DERIVATIVES
Formula 32
Reaction Scheme 7 Reaction Scheme 7 discloses a synthetic route for the preparation of compounds where, with reference to Formula 1, Z is -(CR6=CR6)n- , n is 3 and the B group is directly attached to the Z group. Thus, in accordance with this scheme the brominated aryl vinylphenyl compounds of Formula 10 are reacted with (l-ethoxyvinyl)tributyltin in the presence of bis(triphenylphosphine)palladium(II) chloride to introduce the acetyl group into the position of the phenyl ring which is meta to the YrC(CH2)- moiety, and yield the acetophenone derivatives of Formula 29. The latter reaction is known in the art as a Stille coupling. The acetophenone derivatives of Formula 29 are then reacted in a Homer Emmons reaction, in the presence of strong base such as lithium diisopropylamide (LDA), with diethylcyanomethyl phosphonate. The latter reagent is commercially available. The product of the Homer Emmons reaction is an arylvinylphenyl compound of Formula 30 that is substituted in the meta position with a l-methyl-2- cyanoethenyl group. Those skilled in the art will readily understand that instead of a Homer Emmons reaction the compounds of Formula 30 can also be obtained as a result of an analogous Wittig reaction. Referring still to Reaction Scheme 7, the cyano function of the compounds of Formula 30 is reduced with a mild reducing agent, such as diisobutylaluminum hydride (Dibal-H) to provide the aldehyde compounds of Formula 31. Another Homer Emmons reaction performed on the aldehydes of Formula 31 with the reagent diethyl(E)- 3-ethoxycarbonyl-2-methylallylphosphonate (Compound OI) provides compounds of Formula 32 which are within the scope of the present invention. Compound OI can be prepared from commercially available ethyl (2)-3-formyl-2-butenoate according to the literature of Corey et al. J. Org. Chem. 1974, 39, 921. It will be readily apparent to those skilled in the art that the herein described exemplary synthetic process can be readily adapted or modified by utilizing analogous phosphonate or phosponium salt reagents in Homer Emmons or Wittig reactions, respectively, to obtain additional compounds within the scope of Formula 1 in which Z is -(CR6=CR6)n- , and n is 3 - 5. The compounds of Formula 32 can be converted into further compounds within the scope of the invention by reactions such as saponification, amide formation, reduction to the aldehyde or alcohol stage, and the like. This is indicated in the reaction scheme by conversion to
"homo logs and derivative ΪS".
Formula 33 1 /
34
HOMOLOGS
Formula 35 and DERIVATIVES
a (oy— γ 2(Rd— A— B i
Foπnιla 36 Formula 37 i
T 1
1
HOMOLOGS HOMOLOGS and DERIVATIVES aod DERIVATIVES
Reaction Scheme 8
Formula 40
HOMOLOGS and DERIVATIVES
MCPBA
Formula 41
I i
HOMOLOGS and DERIVATIVES
Reaction Scheme 9 Synthetic routes for the preparation of compounds of Formula 1 where the Z is -SCO- (thioester), -NHCO- (amide) -NHCS- (thioamide) -OCO- (ester) of the order "reverse" to the one described in connection with Reaction Scheme 5, as well as where Z is -N=N- (azo) and - N=N(=0)- (azoxide) are disclosed in Reaction Schemes 8 and 9. As is first shown in Reaction Scheme 8 the brominated aryl vinylphenyl compounds of Formula 10 are reacted with t-butyl lithium, and thereafter with sulfur to provide the (arylvinyl)thiophenol compounds of Formula 33. The thiophenol compounds of Formula 33 are reacted with a carboxylic acid, or an activated form of the carboxylic acid, which forms a thioester and introduces the -CO-Y2(R4)-A-B moiety into the molecules. Those skilled in the art will understand that just as it is described in connection with the amide, ester and thioester formations in Reaction Scheme 5, various activated forms of carboxylic acids are suitable for this purpose. The instant reaction scheme illustrates the method of using acid chlorides of the formula ClCO-Y2(R4)-A-B in these reactions. Examples for the acid chlorides of formula ClCO-Y2(R4)-A-B are ClCOC6H4COOEt ClCOC6H4COOCH2 H5 (the monochlorides of terephthalic acid ethyl and benzyl esters), and ClCOC5NH3COOEt and ClCOC5NH3COOCH2C6H5 (the monochlorides of pyridine 3,6,- dicarboxylic acid ethyl and benzyl esters). The thioesters of Formula 34 are within the scope of the present invention. In order to obtain compounds within the scope of Formula 34 where the B group is a free carboxylic acid (or salt thereof), the thioester is prepared first where the B group is -COOCH2C6H5. The benzyl group is then removed by hydrogenation to provide the free acid. As is shown further in Reaction Scheme 8, the brominated aryl vinylphenyl compounds of Formula 10 are reacted with the cuprous salt of phthalimide and therafter with hydrazine to provide the (arylvinyl)aniline derivatives of Formula 35. These are reacted with the acid chlorides of formula C1C0-Y2(R4)-A-B to yield the amides of Formula 36 which are within the scope of the invention. The amides of Formula 36 are converted into thioamides of Formula 37 by treatment with [2,4-bis(4-methoxyphenyl)-l,3-dithia-2,4-diphosphetane-2,4- disulfide] (Lawesson's reagent). The amides and thioamides of Formula 36 and 37 can be subjected to transformations (including saponification of an ester group when B is COOR8) to yield further compounds within the scope of the present invention. Referring now to Reaction Scheme 9, the (arylvinyl) aniline derivatives of Formula 35 are converted to diazonium salt and thereafter to (arylvinyl)phenol derivatives of Formula 38. The (arylvinyl)phenol derivatives of Formula 38 are then converted into esters of Formula 39 by reaction with the acid chlorides of the formula ClCO-Y2(R4)-A-B or with other activated forms of the carboxylic acids of the general formula HOCO- Y2(R4)-A-B. As it is described in connection with Reaction Scheme 5, the ester formation may be affected with the free carboxylic acid in an aprotic solvent, such as pyridine, in the presence of dicyclohexylcarbodiimide (DCC) or more preferably 1- (3-dimethylaminopropyl)-3-ethylcarbodiimidehydrochloride (EDCI). In order to obtain free carboxylic acids within the scope of Formula 39 (compounds where B is COOH or a salt therof) the benzyl ester (B = COOCH2C6H5) is prepared first, and the benzyl protecting group is thereafter removed by hydrogenation. In order to obtain compounds of Formula 1 where the Z group is -N=N- (azo) or -N(0)=N- (azoxy) the (arylvinyl)aniline derivatives of Formula 35 are reacted with nitroso compounds of the formula ON- Y2(R4)-A-B. Examples for reagents of formula ON-Y2(R4)-A-B are ethyl 4-nitrosobenzoate, ethyl 6-nitroso-2-naphthoate, ethyl 4-nitrosobenzoate, ethyl 6-nitroso-nicotinate, ethyl 2-nitroso-furan-5-carboxylate, and ethyl 2-nitroso-thiophen-5-carboxylate. The azo compounds of Formula 40 can be converted to the azoxy compounds of Formula 41 by oxidation with oxidizing agents known in the art, for example with meta- chloroperoxybenzoic acid (MCPBA).
Formula 29
HOMOLOGS and DERIVATIVES
Reaction Scheme 10 Reaction Scheme 10 discloses a synthetic route for the preparation of exemplary compounds where, with reference to Formula 1, Z is -CO-CR6=CR6-, that is the preparation of compounds which are α-unsaturated ketone derivatives (chalcones). In accordance with this scheme the acetophenone derivatives of Formula 29 (obtained by Stille coupling as shown in Reaction Scheme 7) are reacted in a condensation reaction with a reagent of the formula OHC~Y2(R4)-A-B to yield compounds of Formula 42 which are within the scope of the invention. An example for the reagent OHC~Y2(R4-A-B is 4-carboxybenzaldehyde that is available commercially. Examples of other reagents suitable for the condensation reaction and for the synthesis of compounds of Formula 42 are: 5-carboxy-pyridine-2-aldehyde, 4-carboxy-pyridine-2-aldehyde, 4-carboxy-thiophene-2-aldehyde, 5-carboxy-thiophene-2-aldehyde, 4-carboxy-furan-2-aldehyde, 5-carboxy-furan-2-aldehyde, 4-carboxyacetophenone, 2-acetyl-pyridine-5-carboxylic acid, 2-acetyl-pyridine-4-carboxylic acid, 2-acetyl-thiophene-4-carboxylic acid, 2-acetyl-thiophene-5-carboxylic acid, 2-acetyl-furan-4-carboxylic acid, and 2-acetyl-furan-5-carboxylic acid. The latter compounds are available in accordance with the chemical literature; see for example Decroix et al. J. Chem Res. (S), 1978, 4, 134; Dawson et al. J. Med. Chem., 1983, 29, 1282; and Queguiner et al, Bull. Spc. Chimique de France, 1969, No. 10, pp 3678 - 3683. The condensation reaction between the compounds of Formula 29 and the aldehyde of the formula OHC~Y2(R4)-A-B (or an analoguous ketone compound) is conducted in the presence of base in an alcoholic solvent. Preferably, the reaction is conducted in ethanol in the presence of sodium hydroxide. Those skilled in the art will recognize this condensation reaction as an aldol condensation, and in case of the herein described preferred examples (condensing a ketone of Formula 29 with an aldehyde) as a Claisen-Schmidt reaction. (See March: Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, pp 694 695 McGraw Hill (1968). The compounds of Formula 42 are within the scope of the present invention, and can also be subjected to further transformations resulting in additional compounds of the invention designated in the scheme as "homologs and derivatives". Compound PI nBuLi
Formula 10 Formula 43
Formula 44 Formula 45
HOMOLOGS and DERIVATIVES
Reaction Scheme 11 Reaction Scheme 11 provides an example for synthesis of compounds of the invention where the Y3 group is naphthyl substituted in the 1,7 positions by the YJ^R^CX and Z groups, and where Z is -(CR6=CR6)n- , and n is 0. More specifically, Reaction Scheme 11 provides an example for synthesis of compounds of the invention where the Y3 naphthyl group is directly attached to the Y2-A-B group. In accordance with this reaction scheme, the bromo compounds of Formula 10 are reacted with dimethylformamide in the presence of t- butyl lithium to yield the benazaldehyde derivatives of Formula 43. The benzaledehyde derivatives of Formula 43 are subjected to a Homer Emmons type reaction, in the presence of strong base such as n -butyl lithium in hexane, with a 1-aryl or 1-heteroaryl 1-diethoxyphosphoryl- 3,3-dimethoxypropane derivative, such as ethyl 4-(diethoxyphosphoryl- 3,3-dimethoxypropyl)benzoate (Compound PI). Ethyl 4- (diethoxyphosphoryl-3,3-dimethoxypropyl)benzoate (Compound PI) is available in accordance with the procedure of EPO Application No. 0 210 929 (published on February 4, 1987, Shroot et al.) which is incorporated herein by reference. In accordance with the Shroot et al. reference the reagent ethyl 4-(diethoxyphosphoryl-3,3- dimethoxypropyl)benzoate is made starting with ethyl 4-bromobenzoate that is reacted with dimetyl acetal of acryl aldehyde, the product is hydrogenated and subsequently brominated (with /V-bromo succinimide) and thereafter reacted with triethylphosphite. Examples for phoshonates analogous to Compound PI in that they are suitable for a Homer Emmons reaction with the benzaldehyde derivatives of Formula 43 are ethyl 2-(diethoxyphosphoryl-3,3-dimethoxypropyl)pyridine-5- carboxylate, ethyl 2-(diethoxyphosphoryl-3,3-dimethoxypropyl)pyridine- 6-carboxylate, ethyl 2-(diethoxyphosphoryl-3,3- dimethoxypropyl)thiophene-4-carboxylate, ethyl 2-(diethoxyphosphoryl- 3,3-dimethoxypropyl)thiophene-5-carboxylate, ethyl 2- (diethoxyphosphoryl-3,3-dimethoxypropyl)furan-4-carboxylate, ethyl 2- (diethoxyphosphoryl-3,3-dimethoxypropyl)furan-5-carboxylate. These and analogous phosphonate reagents can be obtained by appropriate modification of the procedure described in the Shroot et al. reference. The product of the Homer Emmons reaction between the benzaldehyde derivatives of Formula 43 and ethyl 4- (diethoxyphosphoryl-3,3-dimethoxypropyl)benzoate (Compound PI) is a disubstituted ethene compound of Formula 44. Those skilled in the art will readily understand that instead of a Homer Emmons reaction, a Wittig reaction can also be employed, utilizing the appropriate phosphonium derivative, to provide compounds of Formula 44. The disubstituted ethene compounds of Formula 44 are cyclized, for example by heating in a neutral solvent (such as dischloromethane), in the presence of SnCl4 or other suitable Friedel Crafts type catalyst, to form the "B ring" of the naphthalene derivatives of the invention, as shown in Formula 45. The compounds of Formula 45 can be converted into further compounds of the invention by reaction well known to the synthetic organic chemist, such as saponification, esterification, amide formation and homologation. This is indicated in Reaction Scheme 11 as conversion to "homologs and derivatives". SPECIFIC EXAMPLES Ethyl 4-iodobenzoate (Compound A) To a suspension of 24.9 g (100.4 mmol) of 4-iodobenzoic acid in 46.25 g (58.9 mL, 1.0 mol) of ethanol was added 3 mL of c. sulfuric acid. The resulting mixture was refluxed for 60 minutes, distilled until a clear, homogeneous solution was obtained and then allowed to cool to room temperature. The reaction mixture was extracted and partitioned between pentane (250 mL) and water (250 mL) and the layers were separated. The aqueous phase was washed with 3 x 100 mL-portions of pentane. All organic phases were combined, washed with brine, dried over MgS04, filtered and concentrated in vacuo to a dark yellow oil. Purification by flash chromatography (silica, 10% ethyl acetate in hexane) yielded the title compound as a clear, light yellow oil. PMR (CDC13): δ 1.39 (3H, t, J = 7.2 Hz), 4.37 (2H, q, J = 7.2 Hz), 7.73-7.82 (4H, m). 2-Fluoro-4-iodobenzoic acid (Compound B) A round bottom (RB) flask containing a solution of 8.0 g (27.0 mmol) of sodium dichromate in 44 mL of glacial acetic acid was placed in an external water bath (21 °C) and left exposed to air. To the resultant orange slurry was added 3.2 g (13.6 mmol) of 2-fluoro-4- iodotoluene followed by the dropwise addition of 22 mL of c. sulfuric acid via syringe (caution: if added too quickly there is a tendency for the mixture to erupt). After the addition of approximately 8 mL of sulfuric acid, a green solid precipitated and the water bath temperature had risen (25 °C). The green reaction mixture was heated in an oil bath (90 °C) for one hour, allowed to cool to ambient temperature, diluted with IN NaOH solution (aq.) and ethyl acetate (500 mL) and then quenched with sat. NaHC03 (aq.) solution. The organic phase was separated and washed with water and brine, dried over MgS04, filtered and concentrated in vacuo to an orange oil. Residual acetic acid was removed by further extraction between ethyl acetate and sat. NaHC03 (aq.) solution and washing of the organic phase with water and brine. The organic phase was dried over MgS04, filtered and concentrated in vacuo to give the title compound as an orange solid. PMR (DMSO-d6): δ 7.61 (1H, t, J = 8.0 Hz, J (C-F) = 8.0 Hz), 7.67 (1H, dd, J = 1.5, 8.2 Hz), 7.78 (1H, dd, J = 1.5 Hz, J (C-F) = 8.9 Hz). Ethyl 2-fluoro-4-iodobenzoate (Compound C) To a solution of 2.5 g (27.0 mmol) of 2-fluoro-4-iodobenzoic acid (Compound B) in 11 mL (8.6 g, 187.5 mmol) of ethanol was added 0.3 mL of c. sulfuric acid. The reaction mixture was heated to reflux in an oil bath (90 °C) for 1.75 hours, fitted with a short path distillation apparatus, distilled and then allowed to cool to ambient temperature. The reaction mixture was extracted and partitioned between pentane and water and the layers were separated. The aqueous phase was washed with pentane and the organic phases were combined. The combined organic phase was washed sequentially with sat. NaHC03 (aq.) solution, water and brine, dried over MgS04, filtered and concentrated in vacuo to a purple oil. Purification by flash chromatography (silica, 10% ethyl acetate in hexane) gave the title compound as an orange oil. PMR (CDC13): δ 1.39 (3H, t, J = 7.1 Hz), 4.39 (2H, q, J = 7.1 Hz), 7.52-7.67 (3H, m). 4-bromophenyl acetate (Compound D) To a solution of 10.0 g (57.8 mmol) of 4-bromoρhenol in 100 mL of acetonitrile was added 9.6 g (69.5 mmol) of potassium carbonate. A white slurry was obtained to which was added 8.6 mL (121.0 mmol) of acetyl chloride and the resultant reaction mixture was stirred at ambient temperature for 17.5 hours. The reaction mixture was filtered, washed with ethyl acetate and the filtrate was concentrated in vacuo to a yellow oil. Purification by flash chromatography (silica, 10% ethyl acetate in hexane) gave the title compound as a clear, nearly colorless oil. PMR (CDC13): δ 2.30 (3H, s), 6.98 (2H, d, J = 8.9 Hz), 7.49 (2H, d, J = 8.9 Hz). 4-Bromo-l-methoxy-3-methylbenzene (Compound E) To a solution of 0.8 g (4.4 mmol) of 4-bromo-3-methylphenol in 20 mL of acetone was added 1.5 g (10.9 mmol) of potassium carbonate. A yellow slurry was obtained to which was added 0.55 mL (1.25 g, 8.8 mmol) of methyl iodide. The resultant reaction mixture was stirred at ambient temperature for 12.25 hours, filtered and extracted between ethyl ether and water. The layers were separated and the organic phase was washed with sat. Na2S03 (aq.) solution, dried over MgS04, filtered and then concentrated in vacuo to a yellow oil. Purification by flash chromatography (silica, 10% ethyl acetate in hexane) gave the title compound as a yellow oil. PMR (CDCI3): δ 2.36 (3H, s), 6.63 (1H, dd, J = 3, 8.8 Hz), 6.79 (H, d, J = 3 Hz), 7.40 (1H, d, J = 8.8 Hz). 5-Bromo-2-hydroxyacetophenone (Compound F) Under a blanket of argon, an amalgam of 10.0 g (46.4 mmol) of 4-bromophenyl acetate (Compound D) and 6.9 g (51.8 mmol) of aluminum chloride was heated in an oil bath (130 °C) for 30 minutes to give a yellow slurry. The slurry was cooled to 0 °C in an ice bath, diluted with 200 mL of crushed ice and extracted with dichloromethane (twice). The organic phases were combined and then washed with water and brine, dried over MgS04, filtered and concentrated in vacuo to give a yellow-green solid. Purification by flash chromatography (silica, 5% ethyl acetate in hexane) gave the title compound as a white solid. PMR (CDC13): δ 2.63 (3H, s), 6.90 (1H, d, J = 8.9 Hz), 7.54 (1H, dd, J = 2.5, 8.9 Hz), 7.84 (1H, d, J = 2.5 Hz), 12.17 (1H, s). 5-Bromo-2-methoxyacetophenone (Compound G) To a slurry of 8.55 g (64.2 mmol) of aluminum chloride in 75 mL of dichloromethane cooled to 0 °C (under a blanket of argon) was added dropwise a solution of 10.0 g (53.5 mmol) of 4-bromoanisole and 4.6 mL (64.2 mmol) of acetyl chloride in 25 mL of dichloromethane. After the addition was complete, the clear yellow solution was stirred at 0 °C for 15 minutes, poured into 200 mL of 10% HC1 (aq.) solution, cooled to 0 °C in an ice bath and then extracted with dichloromethane (3 x 200-mL portions). The organic phases were combined and then washed with water and brine, dried over MgS04, filtered and concentrated in vacuo to give a yellow semi-solid. Purification by flash chromatography (silica, 10% ethyl acetate in hexane) gave the title compound as a white solid. PMR (CDC13): δ 2.60 (3H, s), 3.91 (3H, s), 6.86 (1H, d, J = 8.9 Hz), 7.55 (1H, dd, J = 2.7, 8.9 Hz), 7.84 (1H, d, J = 2.7 Hz). 5-Bromo-2-methoxy-4'-methylbenzophenone (Compound H) Employing the same general procedure as for the preparation of 5-bromo-2-methoxyacetophenone (Compound G), 1.3 mL (1.7 g, 9.2 mmol) of 4-bromoanisole was converted into the title compound using 1.5 g (11.3 mmol) of aluminum chloride, 1.3 mL (1.6 g, 10.1 mmol) of /?-toluoyl chloride and 20 mL of dichloromethane. Deviations from the general procedure involved continued overnight stirring (ambient temperature, 16.75 hours) following stirring at 0 °C for 35 minutes and using a 10% solution of c. H2S04 in crushed ice (v/v) instead of cold 10% HC1 (aq.) solution during the subsequent workup procedure. Purification by flash chromatography (silica, 10% ethyl acetate in hexane) gave the title compound as a white solid. PMR (CDC13): δ 2.42 (3H, s), 3.72 (3H, s), 6.87 (1H, d, J = 8.9 Hz), 7.24 (2H, d, J = 8 Hz), 7.43 (1H, d, J = 2.6 Hz), 7.54 (1H, dd, J = 2.6, 8.9 Hz), 7.70 (2H, d, J = 8 Hz). 5-Bromo-2-methoxy-4-methyl-4'-methylbenzophenone (Compound I) Employing the same general procedure as for the preparation 5- bromo-2-methoxy-4'-methylbenzophenone (Compound H), 780 mg (3.9 mmol) of 4-bromo-l-methoxy-3-methylbenzene (Compound E) was converted into the title compound using 260 mg (1.9 mmol) of aluminum chloride, 0.6 mL (0.7 g, 4.7 mmol) of -toluoyl chloride and 17 mL of dichloromethane. Purification by flash chromatography (silica, 5% ethyl acetate in hexane) gave the title compound as a white solid. PMR (CDC13): δ 2.40 (3H, s), 2.44 (3H, s), 3.69 (3H, s), 6.86 (1H, s), 7.22 (2H, d, J = 8.2 Hz), 7.48 (1H, s), 7.69 (2H, d, J = 8.2 Hz). 5-Bromo-2-methoxy-3'-methylbenzophenone (Compound J) Employing the same general procedure as for the preparation 5- bromo-2-methoxy-4'-methylbenzophenone (Compound H), 1.0 mL (1.5 g, 8.0 mmol) of 4-bromoanisole was converted into the title compound using 0.5 g (4.0 mmol) of aluminum chloride, 1.3 mL (1.5 g, 9.6 mmol) of -toluoyl chloride and 20 mL of dichloromethane. Purification by flash chromatography (silica, 10% ethyl acetate in hexane) gave the title compound as a white solid. PMR (CDC13): δ 2.40 (3H, s), 3.72 (3H, s), 6.88 (IH, d, J = 8.8 Hz), 7.29-7.36 (IH, m), 7.36-7.42 (IH, m), 7.43 (IH, d, J = 2.5 Hz), 7.52-7.58 (2H, m), 7.65 (IH, br s). 5-Bromo-2-hydroxy-4'-methylbenzophenone (Compound K) To a solution of 190 mg (0.6 mmol) of 5-bromo-2-methoxy-4'- methylbenzophenone (Compound H) in 15 mL of dichloromethane was added 0.9 mL (0.9 mmol) of boron tribromide (IM in dichloromethane) at ambient temperature. The orange solution was stirred at ambient temperature for 3 hours under a blanket of argon. The reaction mixture was cooled to -78 °C, quenched with methanol and then extracted between ethyl acetate and sat. NaHC03 (aq.) solution. The layers were separated and the organic phase was dried over MgS04, filtered and concentrated in vacuo to give a pale yellow solid. Purification by flash chromatography (silica, 5% ethyl acetate in hexane) gave the title compound as a white solid. PMR (CDCI3): δ 2.47 (3H, s), 6.97 (IH, d, J = 8.8 Hz), 7.33 (2H, d, J = 8.2 Hz), 7.54-7.62 (3H, m), 7.72 (IH, d, J = 2.5 Hz), 11.93 (IH, s). 5-Bromo-2-hydroxy-3'-methylbenzophenone (Compound L) Employing the same general procedure as for the preparation 5- bromo-2-hydroxy-4'-methylbenzophenone (Compound K), 533 mg (1.7 mmol) of 5-bromo-2-methoxy-3'-methylbenzophenone (Compound J) was converted into the title compound using 2.6 mL (2.6 mmol) of boron tribromide (IM in dichloromethane) and 15 mL of dichloromethane. Purification by flash chromatography (silica, 10% ethyl acetate in hexane) gave the title compound as a white solid. PMR (CDCI3): 2.45 (3H, s), 6.98 (IH, d, J = 8.9 Hz), 7.36-7.52 (4H, m), 7.58 (IH, dd, J = 2.4, 8.9 Hz), 7.70 (IH, d, J = 2.4 Hz), 11.94 (IH, s). 5-Bromo-2-hvdroxy-4-methyl-4'-methylbenzophenone (Compound M) Employing the same general procedure as for the 5-bromo-2- hydroxy-4'-methylbenzophenone (Compound K), 319 mg (1.0 mmol) of 5-bromo-2-methoxy-4-methyl-4'-methylbenzophenone (Compound I) was converted into the title compound using 2.4 mL (2.4 mmol) of boron tribromide (IM in dichloromethane) and 10 mL of dichloromethane. Purification by flash chromatography (silica, 10% ethyl acetate in hexane) gave the title compound as a pale yellow solid. PMR (CDC13): δ 2.42 (3H, s), 2.46 (3H, s), 6.97 (IH, s), 7.33 (IH, d, J = 8.0 Hz), 7.58 (IH, d, J = 8.0 Hz), 7.74 (IH, s), 11.93 (IH, s). 4-Bromo-2-|Yl-m-tolyl)vinyl]phenol (Compound N) To a cold solution (-78 °C) of 99 mg (0.3 mmol) of 5-bromo-2- hydroxy-3'-methylbenzophenone (Compound L) in 5 mL of tetrahydrofuran (under a blanket of argon) was added 1.0 mL (3.0 mmol) of methyl magnesium chloride (3M in tetrahydrofuran). With the addition, the solution turned yellowish-orange in color. The -78 °C bath was removed and the solution was allowed to warm to ambient temperature and stirred for 2 hours. The reaction mixture was concentrated in vacuo, extracted between ethyl acetate and sat. NH4C1 (aq.) solution and the layers were separated. The organic phase was washed with water and brine, dried over MgS04, filtered and concentrated in vacuo to give crude 4-bromo-2-[(l-ra-tolyl-l- hydroxy)ethyl]phenol as a yellow oil. The crude alcohol was dissolved in 2 mL of toluene, placed under a blanket of argon and 5.9 mg of p- toluene sulfonic acid monohydrate was added. The resultant mixture was heated at 70 °C for 45 minutes, cooled to ambient temperature and purified by flash chromatography (silica, 5% ethyl acetate in hexane) to give the title compound as a clear, colorless oil. PMR (CDCI3): δ 2.34 (3H, s), 5.09 (IH, s), 5.40 (IH, br s), 5.84 (IH, br s), 6.83 (IH, d, J = 8.6 Hz), 7.11-7.20 (3H, m),7.22-7.30 (IH, m), 7.35 (IH, dd, J = 2.5, 8.6 Hz). 2-Acetoxy-5-bromo-4'-methylbenzophenone (Compound O) To a yellow solution of 229 mg (0.8 mmol) of 5-bromo-2-hydroxy- 4'-methylbenzophenone (Compound K) in 15 mL of dichloromethane (under a blanket of argon) was added 0.07 mL (69 mg, 0.9 mmol) of pyridine followed by 0.07 mL (74 mg, 0.9 mmol) of acetyl chloride. The resultant reaction mixture was stirred at ambient temperature overnight (16.75 hours), poured into 10% HC1 (aq.) solution and extracted with ethyl acetate. The layers were separated and the aqueous phase was washed with ethyl acetate. The organic phases were combined and then sequentially washed with sat. NaHC03 (aq.) solution, water and brine, dried over MgS04, filtered and concentrated in vacuo to give a yellow oil. Purification by flash chromatography (silica, 20% ethyl acetate in hexane) gave the title compound as a clear, colorless oil. PMR (CDC13): δ 1.95 (3H, s), 2.43 (3H, s), 7.09 (IH, d, J = 8.1 Hz), 7.27 (2H, d, J = approximately 8 Hz), 7.60-7.70 (4H, m). 5-Bromo-2-methoxymethoxyacetophenone (Compound P) To a cold solution (0 °C) of 4.5 g (21.0 mmol) of 5-bromo-2- hydroxyacetophenone (Compound F) in 160 mL of dichloromethane (under a blanket of argon) was added 22 mL (16.3 g, 126.3 mmol) of N,N-diisopropylethylamine followed by 2.6 mL (2.8 g, 34.2 mmol) of chloromethyl methyl ether and 52 mg of tetrabutylammonium iodide. The resultant yellow solution was heated to reflux in an oil bath (45 °C) overnight (14.75 hours), cooled to ambient temperature, concentrated in vacuo and then extracted and partitioned between ethyl acetate and sat. NaHC03 (aq.) solution. The layers were separated and the organic phase was washed with water and brine, dried over MgS04, filtered and concentrated in vacuo to a yellow oil. Purification by flash chromatography (silica, 10% ethyl acetate in hexane) gave the title compound as a yellow oil. PMR (CDC13): δ 2.62 (3H, s), 3.51 (3H, s), 5.26 (2H, s), 7.10 (IH, d, J = 8.7 Hz), 7.51 (IH, dd, J = 2.6, 8.7 Hz), 7.81 (IH, d, J = 2.6 Hz). 5-Bromo-2-methoxymethoxy-4-methyl-4'-methylbenzophenone (Compound Q) Employing the same general procedure as for the preparation 5- bromo-2-methoxymethoxyacetophenone (Compound P), 250 mg (0.8 mmol) 5-bromo-2-hydroxy-4-methyl-4'-methylbenzophenone (Compound M) was converted into the title compound using 0.2 mL (0.2 g, 2.5 mmol) of chloromethyl methyl ether, 0.85 mL (0.6 g, 4.9 mmol) of N,N- diisopropylethylamine, 10 mL of dichloromethane and a catalytic amount of tetrabutylammonium iodide (< 5 mg). Purification by flash chromatography (silica, 10% ethyl acetate in hexane) gave the title compound as a white solid. PMR (CDCI3): δ 2.42 (3H, s), 2.44 (3H, s), 3.32 (3H, s), 5.03 (2H, s), 7.11 (IH, s), 7.24 (2H, d, J = 8.2 Hz), 7.49 (IH, s), 7.72 (2H, d, J = 8.2 Hz). 4-Bromo-2-[(l-Jp-tolyl)vinyl]phenol (Compound R) To a solution of 2.2 g (8.5 mmol) of 5-bromo-2- methoxymethoxyacetophenone (Compound P) in 25 mL of ethyl ether (under a blanket of argon) was added 25.5 mL (25.5 mmol) of p- tolylmagnesium bromide (IM in ether) via syringe. The yellow solution effervesced as the Grignard reagent was being added. The reaction mixture was allowed to stir at ambient temperature for 17 hours, poured into 75 mL of ice water and extracted and partitioned between 10% HC1 (aq.) solution and ethyl ether. The layers were separated and the organic phase was washed with water and brine, dried over MgS04, filtered and concentrated in vacuo to give an inseparable mixture of tertiary alcohols (4-bromo-2-[(l-hydroxy-l-p-tolyl)ethyl]phenol and 4- bromo-l-methoxymethoxy-2-[(l-hydroxy-l-p-tolyl)ethyl]benzene (approximately 2.5 to 1 ratio, respectively) following flash chromatography. The mixture was dissolved in 15 mL of ethanol (under a blanket of argon) and 5 mL of 10% HC1 (aq) solution was added. The resultant reaction mixture was stirred at ambient temperature for 4 hours, heated in an oil bath (90 °C) for 2 hours, cooled to ambient temperature and stirred overnight (14 hours). The reaction mixture was concentrated in vacuo, extracted and partitioned between ethyl acetate and sat. NaHC03 (aq.) solution and the layers were separated. The organic phase was washed with water and brine, dried over MgS04, filtered and concentrated in vacuo to a yellow oil. Purification by flash chromatography (silica, 10% ethyl acetate in hexane) gave the title compound as a clear oil. PMR (CDC13): δ 2.35 (3H, s), 5.15 (IH, s), 5.35 (IH, br s), 5.81 (IH, br s), 6.81 (IH, d, J = 8.6 Hz), 7.15 (2H, d, J = 8.2 Hz), 7.23 (2H, d, J = 8.2 Hz), 7.27 (IH, d, J = 2.5 Hz), 7.33 (IH, dd, J = 2.5, 8.6 Hz). 4-Bromo- 1 -isopropoxy-2- [( 1 -p-tolyl inyljbenzene (Compound S) To a cold solution (0 °C) of 125 mg (0.4 mmol) of 4-bromo-2-[(l- /?-tolyl)vinyl]phenol (Compound R) in 5 mL of tetrahydrofuran was added 125 mg (0.5 mmol) of triphenylphosphine and 0.04 mL (31 mg, 0.5 mmol) of isopropanol followed by 0.07 mL (82 mg, 0.5 mmol) of diethylazodicarboxylate. The dark yellow solution was removed from the ice bath, allowed to warm to ambient temperature on its own and stirred overnight (22.5 hours). The reaction mixture was concentrated in vacuo to a gummy yellow solid. Purification by flash chromatography (silica, 1% ethyl acetate in hexane) gave the title compound as a yellow oil. PMR (CDC13): δ 0.98 (6H, d, J = 6.1 Hz), 2.33 (3H, s), 4.30 (IH, heptet, J = 6.1 Hz), 5.25 (IH, d, J = 1.3 Hz), 5.58 (IH, d, J = 1.3 Hz), 6.74 (IH, d, J = 8.6 Hz), 7.07 (2H, d, J = 8.2 Hz), 7.14 (2H, d, J = 8.2 Hz), 7.36 (IH, dd, J = 2.5, 8.6 Hz), 7.39 (IH, d, J = 2.5 Hz). 4-Bromo-l-isopropoxy-2-[(l- -tolyl)vinyl]phenol (Compound T) Employing the same general procedure as for the preparation of 4-bromo-l-isopropoxy-2-[(l-Jp-tolyl)vinyl]benzene (Compound S), 81.5 mg (0.3 mmol) of 4-bromo-2-[(l- -tolyl)vinyl]phenol (Compound N) was converted into the title compound using 164 mg (0.6 mmol) of triphenylphosphine, 0.10 mL (108 mg, 0.6 mmol) of diethylazodicarboxylate, 0.05 mL (39 mg, 0.6 mmol) of isopropanol and 3 mL of tetrahydrofuran. The reaction was sluggish necessitating addition (after 23 hours of stirring at ambient temperature) of another equivalent of reagents (initially only 1/2 of the above amounts were added) and stirring for 4 additional days. Purification by flash chromatography (silica, 10% ethyl acetate in hexane) gave the title compound as a pink oil. PMR (CDC13): δ 0.97 (6H, d, J = 6.0 Hz), 2.30 (3H, s), 4.31 (IH, heptet, J = 6.0 Hz), 5.29 (IH, d, J = 1.4 Hz), 5.59 (IH, d, J = 1.4 Hz), 6.73 (IH, d, J = 8.6 Hz), 7.02-7.10 (3H, m), 7.12-7.20 (IH, m ), 7.36 (IH, dd, J = 2.6, 8.6 Hz), 7.40 (IH, d, J = 2.6 Hz). 4-Bromo-l- tgrt-butyldimethylsilanyloxy-2-[(l-p-tolyπvinyl]benzene (Compound U) To a solution of 82 mg (0.3 mmol) of 4-bromo-2-[(l- - tolyl)vinyl]phenol (Compound R) in 3 mL of dichloromethane (under a blanket of argon) was added 0.05 mL (36 mg, 0.34 mmol) of triethylamine followed by 0.3 mL (0.3 mmol) of tert- butyldimethylsilylchloride (IM in dichloromethane). The resultant yellow solution was stirred at ambient temperature overnight (23.7 hours), concentrated in vacuo and purified by flash chromatography (silica, 100% hexane) to give the title compound as a clear, colorless oil. PMR (CDC13): δ 0.03 (6H, s), 0.71 (9H, s), 2.32 (3H, s), 5.22 (IH, br s), 5.69 (IH, br s), 6.69 (IH, d, J = 8.5 Hz), 7.07 (2H, d, J = 8.2 Hz), 7.16 (2H, d, J = 8.2 Hz), 7.30 (IH, dd, J = 2.6, 8.5 Hz), 7.34 (IH, d, J = 2.56 Hz). 4-Bromo-2-[(l-p-tolyl)vinyl]phenyl acetate (Compound V) To a solution of 1.3 g (4.6 mmol) of 4-bromo-2-[(l-/?- tolyl)vinyl]phenol (Compound R) in 15 mL of dichloromethane (under a blanket of argon) was added 0.77 mL (0.6 g, 5.6 mmol) of triethylamine and 0.4 mL (0.4 g, 5.6 mmol) of acetyl chloride. A white precipitate immediately formed upon addition of acetyl chloride. The reaction mixture was stirred at ambient temperature for 14.5 hours and then concentrated in vacuo. Purification by flash chromatography (silica, 10% ethyl acetate in hexane) gave the title compound as a clear, colorless oil. PMR (CDC13): δ 2.34 (3H, s), 5.29 (IH, br s), 5.64 (IH, d, J = 1.1 Hz), 6.96 (IH, d, J = 8.6 Hz), 7.08-7.17 (4H, m), 7.47 (IH, dd, J = 2.5, 8.6 Hz), 7.51 (IH, d, J = 2.5 Hz). 2-Methoxy-5-trimethylsilanylethynyl acetophenone (Compound W) To a sparged solution (a stream of argon was bubbled vigorously into the solution for several minutes) of diethylamine (5 mL) in a pressure tube vessel was added a solution of 1.85 g (8.1 mmol) of 5- bromo-2-methoxyacetophenone (Compound G) in 20 ml of diethylamine. After sparging with argon for 5 minutes, 0.4 g (2.0 mmol) of cuprous iodide was added to the solution and the resultant mixture was sparged with argon for 2 minutes. To this reaction mixture was then added 1.4 g (2.0 mmol) of bis(triphenylphosρhine)palladium(II) chloride. After sparging with argon for 3 minutes, 4.3 mL (40.4 mmol) of trimethylsilyl acetylene was added to the reaction mixture. The pressure tube was then sealed and heated in an oil bath (55 °C) for 5 days. The reaction mixture was filtered through celite and washed with ethyl ether (400 mL). The filtrate was extracted with water (3 x 200 mL-portions) and brine, dried over MgS04, filtered and concentrated in vacuo to give a dark brown residue. Purification by flash chromatography (preabsorbed onto silica with chloroform, 10% ethyl acetate in hexane) gave the title compound as a yellow solid. PMR (CDC13): δ 0.24 (9H, s), 2.01 (2H, t, J = 7.1 Hz), 2.59 (3H, s), 3.92 (3H, s), 6.90 (IH, d, J = 8.6 Hz), 7.55 (IH, dd, J = 2.2, 8.6 Hz), 7.84 (IH, d, J = 2.2 Hz). 2-Acetoxy-5-trimethylsilanylethynyl-4'-methylbenzophenone (Compound X) Employing the same general procedure as for the preparation of 2-methoxy-5-trimethylsilanylethynyl acetophenone (Compound W), 228.5 mg (0.7 mmol) of 2-acetoxy-5-bromo-4'-methylbenzophenone (Compound O) was converted into the title compound using 120 mg (0.2 mmol) of bis(triphenylphosphine)palladium (II) chloride, 33 mg (0.2 mmol) of cuprous iodide, 0.73 mL (670 mg, 6.9 mmol) of trimethylsilyl acetylene and 10 mL of triethylamine (heated at 75 °C). Purification by flash chromatography (silica, 5% ethyl acetate in hexane) gave the title compound as an oil. PMR (CDCI3): δ 0.23 (9H, s), 1.98 (3H, s), 2.43 (3H, s), 7.14 (IH, d, J = 8.2 Hz), 7.27 (2H, d, J = 8.1 Hz), 7.57-7.63 (2H, m), 7.67 (2H, d, J = 8.1 Hz). 4-Trimethylsilanylethynyl-2-[(l-p-tolyl)vinyl]phenyl acetate (Compound Y) Employing the same general procedure as for the preparation of 2-methoxy-5-trimethylsilanylethynyl acetophenone (Compound W), 515 mg (1.6 mmol) of 4-bromo-2-[(l-p-tolyl)vinyl]phenyl acetate (Compound V) was converted into the title compound using 219 mg (0.3 mmol) of bis(triphenylρhosρhine)palladium (II) chloride, 58 mg (0.3 mmol) of cuprous iodide, 1.66 mL (1.5 g, 15.6 mmol) of trimethylsilyl acetylene and 10 mL of triethylamine (heated at 75 °C). Purification by flash chromatography (silica, 5% ethyl acetate in hexane) gave the title compound as a tan solid. PMR (CDC13): δ 0.27 (9H, s), 1.80 (3H, s), 2.36 (3H, s), 5.31 (IH, br s), 5.65 (IH, br s), 7.04 (IH, d, J = 8.3 Hz), 7.10-7.19 (4H, m), 7.47 (IH, dd, J = 2.0, 8.3 Hz), 7.52 (IH, d, J = 2.0 Hz). 3-Trimethylsilanylethynyl acetophenone (Compound Z) Employing the same general procedure as for the preparation of 2-methoxy-5-trimethylsilanylethynyl acetophenone (Compound W), 0.66 mL (1.0 g, 5.0 mmol) of 3-bromoacetophenone was converted into the title compound using 0.9 g (1.3 mmol) of bis(triphenylphosphine)palladium (II) chloride, 0.2 g (1.0 mmol) of cuprous iodide, 5.4 mL (5.0 g, 50.7 mmol) of trimethylsilyl acetylene and 12 mL of triethylamine (heated at 75 °C). Purification by flash chromatography (silica, 5% ethyl acetate in hexane) gave the title compound as a yellow oil. PMR (CDCI3): δ 0.27 (9H, s), 2.61 (3H, s), 7.38-7.44 (IH, m), 7.62-7.67 (IH, m), 7.84-7.86 (IH, m), 8.10-8.25 (IH, m). 2-Methoxymethoxy-4-methyl-5-trimethylsilanylethynyl-4'- methylbenzophenone (Compound Al) Employing the same general procedure as for the preparation of 2-methoxy-5-trimethylsilanylethynyl acetophenone (Compound W), 264 mg (0.76 mmol) of 5-bromo-2-methoxymethoxy-4-methyl-4'- methylbenzophenone (Compound Q) was converted into the title compound using 133 mg (0.2 mmol) of bis(triphenylphosphine)palladium (II) chloride, 36 mg (0.2 mmol) of cuprous iodide, 0.8 mL (0.7 g, 7.6 mmol) of trimethylsilyl acetylene and 10 mL of triethylamine (heated at 75 °C). Purification by flash chromatography (silica, 5% ethyl acetate in hexane) gave the title compound as a yellow oil. PMR (CDC13): δ 0.23 (9H, s), 2.41 (3H, s), 2.48 (3H, s), 3.32 (3H, s), 5.06 (2H, s), 7.04 (IH, s), 7.21 (2H, d, J = 8.2 Hz), 7.43 (IH, s), 7.70 (2H, d, J = 8.2 Hz). l-Isopropoxy-4-trimethylsilanylethynyl-2-[(l-p-tolyπvinyl]benzene (Compound Bl) Employing the same general procedure as for the preparation of 2-methoxy-5-trimethylsilanylethynyl acetophenone (Compound W), 64 mg (0.2 mmol) of 4-bromo-l-isopropoxy-2-[(l-/?-tolyl)vinyl]benzene (Compound S) was converted into the title compound using 33.5 mg (0.05 mmol) of bis(triphenylphosphine)palladium (II) chloride, 9 mg (0.05 mmol) of cuprous iodide, 0.3 mL (0.3 g, 2.8 mmol) of trimethylsilyl acetylene and 5 mL of triethylamine (heated at 75 °C). Purification by flash chromatography (silica, 2% ethyl acetate in hexane) gave the title compound as a yellow oil. PMR (CDCI3): δ 0.26 (9H, s), 0.99 (6H, d, J = 6.0 Hz), 2.34 (3H, s), 4.37 (IH, heptet, J = 6.0 Hz), 5.26 (IH, d, J = 1.5 Hz), 5.58 (IH, d, J = 1.5 Hz), 6.79 (IH, d, J = 8.4 Hz), 7.05-7.18 (4H, m), 7.38-7.46 (2H, m). l-Isopropoxy-4-trimethylsilanylethvnyl-2-[(l- -tolyπvinyl]benzene (Compound Cl) Employing the same general procedure as for the preparation of 2-methoxy-5-trimethylsilanylethynyl acetophenone (Compound W), 37 mg (0.1 mmol) of 4-bromo-l-isopropoxy-2-[(l-rø-tolyl)vinyl]benzene (Compound T) was converted into the title compound using 20 mg (0.03 mmol) of bis(triphenylphosphine)palladium (II) chloride, 6 mg (0.03 mmol) of cuprous iodide, 0.12 mL (111 mg, 1.1 mmol) of trimethylsilyl acetylene and 3 mL of triethylamine (heated at 75 °C). Purification by flash chromatography (silica, 1% ethyl acetate in hexane) gave the title compound as a yellow oil. PMR (CDCI3): δ 0.24 (9H, s), 0.95 (6H, d, J = 6.1 Hz), 2.29 (3H, s), 4.37 (IH, heptet, J = 6.1 Hz), 5.28 (IH, d, J = 1.5 Hz), 5.57 (IH, d, J = 1.5 Hz), 6.77 (IH, d, J = 8.4 Hz), 7.00-7.10 (3H, m), 7.10-7.20 (IH, m), 7.40 (IH, dd, J = 2.2, 8.4 Hz), 7.43 (IH, d, J = 2.2 Hz). l-tgrt-Butyldimethylsilanyloxy-4-trimethylsilanylethynyl-2-[(l-p- tolyl)vinyl]benzene (Compound DI) Employing the same general procedure as for the preparation of 2-methoxy-5-trimethylsilanylethynyl acetophenone (Compound W), 43.4 mg (0.1 mmol) of l-tert-butyldimethylsilanyloxy-4-bromo-2-[(l-/?- tolyl)vinyl]benzene (Compound U) was converted into the title compound using 19 mg (0.03 mmol) of bis(triphenylphosphine)palladium (II) chloride, 6.8 mg (0.03 mmol) of cuprous iodide, 0.11 mL (101 mg, 1.1 mmol) of trimethylsilyl acetylene and 4 mL of triethylamine (heated at 75 °C). Purification by flash chromatography (silica, 2% ethyl acetate in hexane) gave the title compound as a yellow oil. PMR (CDC13): δ 0.04 (6H, s), 0.24 (9H, s), 0.71 (9H,s), 2.32 (3H, s), 5.22 (IH, d, J = 1.3 Hz), 5.68 (IH, d, J = 1.3 Hz), 6.74 (IH, d, J = 8.3 Hz), 7.02-7.10 (2H, m), 7.12-7.20 (2H, m), 7.33 (IH, dd, J = 2.2, 8.3 Hz), 7.38 (IH, d, J = 2.2 Hz). 5-Ethynyl-2-methoxyacetophenone (Compound El) To a solution of 990 mg (4.0 mmol) of 2-methoxy-5- trimethylsilanylethynylacetophenone (Compound W) in 100 mL of methanol was added 144 mg (1.0 mmol) of potassium carbonate. The mixture was stirred for 2.5 hours at ambient temperature (under a blanket of argon). The dark brown solution was concentrated in vacuo to a brown residue, diluted with dichloromethane (5 mL) and sat. NaHC03 (aq.) solution (100 mL), and then stirred at ambient temperature for approx. 30 minutes. The mixture was extracted between dichloromethane and water, the layers were separated and the aqueous phase was washed with dichloromethane. The organic phases were combined and sequentially washed with water and brine, dried over MgS04, filtered and concentrated in vacuo. Purification by column chromatography (silica, 10% ethyl acetate in hexane) yielded the title compound as a white solid. PMR (CDC13): δ 2.60 (3H, s), 3.01 (IH, s), 3.93 (3H, s), 6.92 (IH, d, J = 8.5 Hz), 7.58 (IH, dd, J = 2.1, 8.5 Hz), 7.86 (IH, d, J = 2.1 Hz). 5-Ethvnyl-2-hvdroxy-4'-methylbenzophenone (Compound Fl) To a solution of 100 mg (0.3 mmol) of 2-acetoxy-5- trimethylsilanylethynyl-4'-methylbenzophenone (Compound X) in 5 mL of tetrahydrofuran (under a blanket of argon) was added 0.86 mL (0.86 mmol) of tetrabutylammonium fluoride (IM in tetrahydrofuran). The resultant yellow solution was stirred at ambient temperature for 30 minutes, diluted with water (1 mL), extracted between ethyl ether and 10% HC1 (aq.) solution, the layers separated and the aqueous phase washed with ethyl ether. The organic phases were combined, dried over MgS04, filtered and concentrated in vacuo. Purification by flash chromatography (silica, 3% ethyl acetate in hexane) gave the title compound as an oil. PMR (CDC13): δ 2.46 (3H, s), 2.96 (IH, s), 7.03 (IH, d, J = 8.6 Hz), 7.33 (2H, d, J = 7.8 Hz), 7.58-7.64 (3H, m), 7.78 (IH, d, J = 2.0 Hz), 12.17 (IH, s). 5-Ethvnyl-2-methoxmethoxy-4'-methylbenzophenone (Compound Gl) Employing the same general procedure as for the preparation of 5-bromo-2-methoxymethoxyacetophenone (Compound P), 70 mg (0.3 mmol) of 5-ethynyl-2-hydroxy-4'-methylbenzophenone (Compound Fl) was converted into the title compound using 0.3 mL (1.7 mmol) of N,N- diisopropylethylamine, 0.7 mL (0.9 mmol) of chloromethyl methyl ether, a catalytic amount of tetrabutylammonium iodide ( < 5 mg) and 5 mL of dichloromethane. The yellow residue obtained was of sufficient purity to be used without further purification. PMR (CDC13): 8 2.41 (3H, s), 3.01 (IH, s), 3.31 (3H, s), 5.07 (2H, s), 7.16 (IH, d, J = 8.7 Hz), 7.23 (2H, d, J = approximately 8 Hz), 7.46 (IH, d, J = 2.1 Hz), 7.55 (IH, dd, J = 2.1, 8.7 Hz), 7.71 (2H, d, J = approximately 8 Hz). 4-Ethvnyl-2-[fl-j7-tolylYvinyl]phenyl acetate (Compound HI) and - Ethynyl-2-[(l-p-tolyl)vinyl]phenol (Compound II) Employing the same general procedure as for the preparation of 5-ethynyl-2-hydroxy-4'-methylbenzophenone (Compound Fl), 500 mg (1.4 mmol) of 4-trimethylsilanylethynyl-2-[(l-p-tolyl)vinyl]phenyl acetate (Compound Y) was converted into the title compounds using 3.2 mL (3.2 mmol) of tetrabutylammonium fluoride (IM in tetrahydrofuran) and 20 mL of tetrahydrofuran. Purification by flash chromatography (silica, 10% ethyl acetate in hexane) gave the title compounds as clear oils in a 1:1 ratio. PMR: 4-Ethynyl-2-[(l-/?-tolyl)vinyl]phenyl acetate (Compound HI): (CDC13): δ 1.78 (3H, s), 3.07 (IH, s), 5.29 (IH, br s), 5.63 (IH, br s), 7.03 (IH, d, J = 8.2 Hz), 7.10-7.16 (4H, m), 7.47 (IH, dd, J = 2.0, 8.2 Hz), 7.52 (IH, d, J = 2.0 Hz). PMR: 4-Ethynyl-2-[(l- ?-tolyl)vinyl]phenol (Compound II): (CDC13): δ 2.36 (3H, s), 2.98 (IH, s), 5.31 (IH, s), 5.37 (IH, br s), 5.84 (IH, br s), 6.89 (IH, d, J = 8.4 Hz), 7.20, (2H, d, J = 8 Hz), 7.24 (2H, d, J = 8 Hz), 7.32 (IH, d, J = 2.1 Hz), 7.39 (IH, dd, J = 2.1, 8.4 Hz). 4-Ethynyl-l-methoxymethoxy-2-[ i-p-tolvπvinyl]benzene (Compound Jl) Employing the same general procedure as for the preparation of 5-bromo-2-methoxymethoxy acetophenone (Compound P), 109 mg (0.5 mmol) of 4-ethynyl-2-[(l- ?-tolyl)vinyl]phenol (Compound II) was converted into the title compound using 0.11 mL (117 mg, 1.45 mmol) of chloromethyl methyl ether, 0.49 mL (360 mg, 2.8 mmol) of N, N- diisopropylethylamine, a catalytic amount of tetrabutylammonium iodide (< 5 mg) and 5 mL of dichloromethane. Purification by flash chromatography (silica, 10% ethyl acetate in hexane) gave the title compound as a clear, colorless oil. PMR (CDC13): δ 2.32 (3H, s), 3.01 (IH, s), 3.17 (3H, s), 4.96 (2H, s), 5.25 (IH, s), 5.68 (IH, br s), 7.00-7.10 (3H, m), 7.17 (2H, d, J = approximately 8 Hz), 7.41-7.46 (2H, m). 3-Ethynylacetophenone (Compound Kl) Employing the same general procedure as for the preparation of 5-ethynyl-2-methoxyacetophenone (Compound El), 1.1 g (5.0 mmol) of 3-trimethylsilanylethynyl acetophenone (Compound Z) was converted into the title compound using 172 mg (1.25 mmol) of potassium carbonate and 10 mL of methanol. Purification by flash chromatography (silica, 10% ethyl acetate in hexane) gave the title compound as a yellow solid. PMR (CDCI3): δ 2.61 (3H, s), 3.15 (IH, s), 7.40-7.50 (IH, m), 7.65-7.68 (IH, m), 7.90-7.95 (IH, m), 8.05-8.08 (IH, m). 5-Ethynyl-2-methoxymethoxy-4-methyl-4'-methylbenzophenone (Compound LI) Employing the same general procedure as for the preparation of 5-ethynyl-2-methoxyacetophenone (Compound El), 260 mg (0.8 mmol) of 2-methoxymethoxy-4-methyl-5-trimethylsilanylethynyl-4'- methylbenzophenone (Compound Al) was converted into the title compound using 26 mg (0.2 mmol) of potassium carbonate and 5 mL of methanol. Purification by flash chromatography (silica, 5% ethyl acetate in hexane) gave the title compound as a white solid. PMR (CDCI3): δ 2.41 (3H, s), 2.50 (3H, s), 3.22 (IH, s), 3.32 (3H, s), 5.07 (2H, s), 7.06 (IH, s), 7.23 (2H, d, J = 8.4 Hz), 7.46 (IH, s), 7.71 (2H, d, J = 8.4 Hz). 4-Ethynyl-l-isopropoxy-2-[(l-p-tolvπvinyl]benzene (Compound Ml) Employing the same general procedure as for the preparation of 5-ethynyl-2-methoxyacetophenone (Compound El), 53 mg (0.15 mmol) l-isopropoxy-4-trimethylsilanylethynyl-2-[(l-/?-tolyl)vinyl]benzene (Compound Bl) was converted into the title compound using 8 mg (0.06 mmol) of potassium carbonate and 4 mL of methanol. Purification by flash chromatography (silica, 5% ethyl acetate in hexane) gave the title compound as a yellow oil. PMR (CDC13): δ 0.99 (6H, d, J = 6.0 Hz), 2.33 (3H, s), 3.00 (IH, s), 4.37 (IH, heptet, J = 6.0 Hz), 5.25 (IH, d, J = 1.5 Hz), 5.57 (IH, d, J = 1.5 Hz), 6.79 (IH, d, J = 8.7 Hz), 7.06 (2H, d, J = 8.2 Hz), 7.14 (2H, d, J = 8.2 Hz), 7.40-7.45 (2H, m). 4-Ethvnyl-l-isopropoxy-2-[(l-m-tolyl)vinyl]benzene (Compound Nl) Employing the same general procedure as for the preparation of 5-ethynyl-2-methoxyacetophenone (Compound El), 22 mg (0.07 mmol) l-isopropoxy-4-trimethylsilanylethynyl-2-[(l- -tolyl)vinyl]benzene (Compound Cl) was converted into the title compound using 3 mg (0.02 mmol) of potassium carbonate and 3 mL of methanol. Purification by flash chromatography (silica, 1% ethyl acetate in hexane) gave the title compound as a yellow oil. PMR (CDCI3): δ 0.98 (6H, d, J = 6.0 Hz), 2.30 (3H, s), 3.01 (IH, s), 4.37 (IH, heptet, J = 6.0 Hz), 5.29 (IH, br s), 5.58 (IH, d, J = 1.5 Hz), 6.79 (IH, d, J = 8.5 Hz), 7.00-7.10 (3H, m), 7.10-7.20 (IH, m), 7.40-7.50 (2H, m). l-tgrt-Butyldimethylsilanyloxy-4-ethvnyl-2-[(l-p-tolvπvinyl]benzene (Compound OI) Employing the same general procedure as for the preparation of 5-ethynyl-2-methoxyacetophenone (Compound El), 25 mg (0.06 mmol) l-tert-butyldimethylsilanyloxy-4-trimethylsilanylethynyl-2-[(l p- tolyl)vinyl]benzene (Compound DI) was converted into the title compound using 4 mg (0.03 mmol) of potassium carbonate and 1 mL of ethanol. Purification by flash chromatography (silica, 5% ethyl acetate in hexane) gave the title compound as a yellow oil. PMR (CDC13): δ 0.05 (6H, s), 0.71 (9H,s), 2.31 (3H, s), 3.00 (IH, s), 5.22 (IH, br s), 5.68 (IH, br s), 6.75 (IH, d, J = 8.2 Hz), 7.06 (2H, d, J = 8.2 Hz), 7.16 (2H, d, J = 8.2 Hz), 7.35 (IH, dd, J = 2.1, 8.2 Hz), 7.38 (IH, d, J = 2.1 Hz). Ethyl 4-[(3'-acetyl-4'-methoxy)phenylethynyl]benzoate (Compound 1) To a sparged solution of 10 mL of diethylamine (a stream of argon was bubbled vigorously into the solution for several minutes) was added a mixture of 440 mg (2.5 mmol) of 5-ethynyl-2- methoxyacetophenone (Compound El), 770 mg (2.8 mmol) of ethyl 4- iodobenzoate (Compound A) and 10 mL of diethylamine. After sparging with argon for 5 minutes, 96 mg (0.5 mmol) of cuprous iodide was added to the solution and the resultant mixture was sparged with argon for 3 minutes. The mixture was cooled to 0 °C in an ice bath and then 440 mg (0.6 mmol) of bis(triphenylphosphine)palladium (II) chloride was added. The reaction mixture was stirred at 0 °C for 30 minutes (initial 5 minutes performed under sparging conditions), allowed to warm to ambient temperature and then stirred at ambient temperature for 27 hours. The reaction mixture was filtered through celite, washed with ethyl ether (250 mL) and the collected filtrate washed with water (3 x 200 mL-portions) and brine (150 mL). The organic phase was dried over MgS04, filtered and concentrated in vacuo to a solid residue. Purification by flash chromatography (preabsorbed onto silica with chloroform, 10% ethyl acetate in hexane) gave the title compound as a pale yellow solid. PMR (CDC13): δ_1.41 (3H, t, J = 7.1 Hz), 2.63 (3H, s), 3.96 (3H, s), 4.39 (2H, q, J = 7.1 Hz), 6.98 (IH, d, J = 8.6 Hz), 7.56 (2H, d, J = 8.4 Hz), 7.64 (IH, dd, J = 2.2, 8.6 Hz), 7.93 (IH, d, J = 2.2 Hz), 8.02 (2H, d, J = 8.4 Hz). 4-[ '-Acetyl-4'-methoxy^phenylethvnyl]benzoic acid (Compound 2) To a solution of 102.5 mg (0.3 mmol) of ethyl 4-[(3'-acetyl-4'- methoxy)phenylethynyl]benzoate (Compound 1) in 15 mL of tetrahydrofuran was added 3.2 mL (3.2 mmol) of LiOH solution (IM in water). The reaction mixture was allowed to stir at ambient temperature for 3 days, concentrated in vacuo, and extracted between hexane and water. The layers were separated and the aqueous phase was diluted with ethyl ether, cooled to 0 °C in an ice bath and acidified with IN H2S04 (aq.) solution to pH 3-4. The solution was diluted with brine and the organic phase was separated. The organic phase was dried over Na2S04, filtered and concentrated in vacuo to give the title compound as a white solid. PMR (DMSO-d6): δ_2.54 (3H, s), 3.93 (3H, s), 7.25 (IH, d, J = 9 Hz), 7.65 (2H, d, J = approximately 8 Hz), 7.73-7.78 (2H, m), 7.95 (2H, d, J = approximately 8 Hz). Ethyl 4-[[4,-methoxymethoxy-3'-r4"- methyl)benzoyl]phenylethynyl]benzoate (Compound 3) Employing the same general procedure as for the preparation of ethyl 4-[(3'-acetyl-4'-methoxy)phenylethynyl]benzoate (Compound 1), 44 mg (0.2 mmol) of 5-ethynyl-2-methoxymethoxy-4'-methylbenzophenone (Compound Gl) was converted into the title compound using 46 mg (0.2 mmol) of ethyl 4-iodobenzoate (Compound A), 22 mg (0.03 mmol) of bis(triphenylphosphine)palladium (II) chloride, 6 mg (0.03 mmol) of cuprous iodide and 6 mL of triethylamine. Purification by flash chromatography (silica, 10-20% ethyl acetate in hexane) gave the title compound as a yellow solid. PMR (CDC13): δ 1.40 (3H, t, J = 7.1 Hz), 2.42 (3H, s), 3.33 (3H, s), 4.38 (2H, q, J = 7.1 Hz), 5.10 (2H, s), 7.22 (IH, d, J = 8.6 Hz), 7.25 (2H, d, J = 8.2 Hz), 7.52-7.58 (3H, m), 7.61 (IH, dd, J = 2.1, 8.6 Hz), 7.74 (2H, d, J = 8.3 Hz), 8.01 (2H, d, J = 8.3 Hz). Ethyl 4-[[4'-hvdroxy-3'- 4"-methvπbenzoyl]phenylethvnyl]benzoate (Compound 4) To a solution of 34 mg (0.08 mmol) of ethyl 4-[[4'- methoxymethoxy-3'-(4"-methyl)benzoyl]phenylethynyl]benzoate (Compound 3) in 3 mL of ethanol (under a blanket of argon) was added 3 drops of c. HC1 via pipet. The reaction mixture was heated to reflux in an oil bath (95 °C) for 35 minutes, cooled to ambient temperature and concentrated in vacuo. The residue was extracted and partitioned between ethyl acetate and sat. NaHC03 (aq.) solution. The layers were separated and the organic phase was washed with water and brine, dried over MgS04, filtered and concentrated in vacuo to a yellow solid. Purification by flash chromatography (silica, 10% ethyl acetate in hexane) gave the title compound as a yellow solid. PMR (CDC13): δ 1.41 (3H, t, J = 7.1 Hz), 2.48 (3H, s), 4.39 (2H, q, J = 7.1 Hz), 5.10 (2H, s), 7.09 (IH, d, J = 8.7 Hz), 7.36 (2H, d, J = 8.0 Hz), 7.54 (2H, d, J = 8.5 Hz), 7.63-7.69 (3H, m), 7.83 (IH, d, J = 2.1 Hz), 8.01 (2H, d, J = 8.5 Hz), 12.22 (IH, s). 4-[[4'-hydroxy-3,-f4"-methyl)benzoyl]phenylethynyl]benzoic acid (Compound 5) To a solution of 16.5 mg (0.04 mmol) of ethyl 4-[[4'-hydroxy-3'- (4"-methyl)benzoyl]phenylethynyl]benzoate (Compound 4) in 2 mL of ethanol and 0.4 mL of tetrahydrofuran (under a blanket of argon) was added 0.4 mL (0.4 mmol) of NaOH solution (IM in water). The yellow solution was stirred at ambient temperature for 20 hours, concentrated in vacuo, acidified with 0.6 mL of IN (aq) H2S04 solution and then extracted between ethyl ether and brine. The layers were separated and the organic phase was dried over MgS04, filtered and concentrated in vacuo to a yellow solid. Recrystallization from methanol gave the title compound as a yellow needles. PMR (CDC13): 8 2.48 (3H, s), 5.10 (2H, s), 7.09 (IH, d, J = 8.7 Hz), 7.37 (2H, d, J = 8.1 Hz), 7.57 (2H, d, J = 8.4 Hz), 7.63-7.69 (3H, m), 7.84 (IH, d, J = 2.1 Hz), 8.06 (2H, d, J = 8.4 Hz), 12.23 (IH, s). Ethyl 4-[[4'-acetoxy-3'-(l-/?-tolyπvinyl]phenylethynyl]benzoate (Compound 6) Employing the same general procedure as for the preparation of ethyl 4-[(3'-acetyl-4'-methoxy)phenylethynyl]benzoate (Compound 1), 128 mg (0.5 mmol) of 4-ethynyl-2-[(l-/?-tolyl)vinyl]phenyl acetate (Compound HI) was converted into the title compound using 128 mg (0.5 mmol) of ethyl 4-iodobenzoate (Compound A), 65 mg (0.09 mmol) of bis(triphenylphosphine)palladium (II) chloride, 17 mg (0.09 mmol) of cuprous iodide and 6 mL of triethylamine. Purification by flash chromatography (silica, 10% ethyl acetate in hexane) gave the title compound as a clear, colorless oil which solidified upon standing to a waxy, white solid. PMR (CDC13): δ 1.41 (3H, t, J = 7.1 Hz), 1.81 (3H, s), 2.35 (3H, s), 4.39 (2H, q, J = 7.1 Hz), 5.33 (IH, br s), 5.66 (IH, br s), 7.07-7.19 (5H, m), 7.52-7.60 (4H, m), 8.03 (2H, d, J = 8.1 Hz). Ethyl 4-[[4'-methoxymethoxy-3'-(l p-tolyl)vinyl]phenylethynyl]benzoate (Compound 7) Employing the same general procedure as for the preparation of ethyl 4-[(3'-acetyl-4'-methoxy)phenylethynyl]benzoate (Compound 1), 87 mg (0.3 mmol) of 4-ethynyl-l-methoxymethoxy-2-[(l-p- tolyl)vinyl]benzene (Compound Jl) was converted into the title compound using 94 mg (0.3 mmol) of ethyl 4-iodobenzoate (Compound A), 42 mg (0.06 mmol) of bis(triphenylphosphine)palladium (II) chloride, 12 mg (0.06 mmol) of cuprous iodide and 6 mL of triethylamine. Purification by flash chromatography (silica, 5% ethyl acetate in hexane) gave the title compound as a white solid. PMR (CDC13): δ 1.40 (3H, t, J = 7.1 Hz), 2.33 (3H, s), 3.19 (3H, s), 4.39 (2H, q, J = 7.1 Hz), 5.00 (2H, s), 5.30 (IH, br s), 5.72 (IH, br s), 7.06-7.12 (3H, m), 7.20 (2H, d, J = 8.2 Hz), 7.46-7.52 (2H, m), 7.57 (2H, d, J = 8.4 Hz), 8.02 (2H, d, J = 8.4 Hz). 4-[[4'-Hydroxy-3'-(l-p-tolyl)vinyl]phenylethynyl]benzoic acid (Compound 8) Employing the same general procedure as for the preparation of 4-[[4'-hydroxy-3'-(4"-methyl)benzoyl]phenylethynyl]benzoic acid (Compound 5), 84 mg (0.2 mmol) of ethyl 4-[[ 4'-acetoxy-3'-(l- - tolyl)vinyl]phenylethynyl]benzoate (Compound 6) was converted into the title compound (pale yellow solid) using 2.0 mL (2.0 mmol) of NaOH solution (IM in water), 8 mL of ethanol and 1 mL of tetrahydrofuran. PMR (Aceton-d6): δ 2.31 (3H, s), 5.32 (IH, d, J = 1.4 Hz), 5.77 (IH, br s), 6.96 (IH, d, J = 8.3 Hz), 7.12 (2H, d, J = 7.9 Hz), 7.23 (2H, d, J = 8.3 Hz), 7.35 (IH, d, J = 2.1 Hz), 7.44 (IH, dd, J = 2.1, 8.4 Hz), 7.62 (2H, d, J = 8.4 Hz), 8.03 (2H, d, J = 8.4 Hz), 8.52 (IH, br s). 4-[[ 4'-methoxymethoxy-3'-fl ρ-tolyl)vinyl]phenylethynyl]benzoic acid (Compound 9) Employing the same general procedure as for the preparation of 4-[[4'-hydroxy-3'-(4"-methyl)benzoyl]phenylethynyl]benzoic acid (Compound 5), 18 mg (0.04 mmol) of ethyl 4-[[4'-methoxymethoxy-3'-(l- /?-tolyl)vinyl]phenylethynyl]benzoate (Compound 7) was converted into the title compound using 0.4 mL (0.4 mmol) of NaOH solution (IM in water), 2 mL of ethanol and 0.8 mL of tetrahydrofuran. PMR (Aceton-d6): δ 2.30 (3H, s), 3.14 (3H, s), 5.05 (2H, s), 5.27 (IH, br s), 5.73 (IH, br s), 7.12 (2H, d, J = 7.9 Hz), 7.15-7.22 (3H, m), 7.43 (IH, d, J = 2.1 Hz), 7.56 (IH, dd, J = 2.1, 8.4 Hz), 7.65 (2H, d, J = 8.3 Hz), 8.05 (2H, d, J = 8.3 Hz). Ethyl 4-[[4'-methoxy-3'-(l-hydroxy-l-p-tolyl)ethyl]phenylethynyl]benzoate (Compound 10) To a cold solution (-78 °C) of 132.5 mg (0.4 mmol) of ethyl 4-[(3'- acetyl-4'-methoxy)phenylethynyl]benzoate (Compound 1) in 5 mL of tetrahydrofuran (under a blanket of argon) was added 0.6 mL (0.6 mmol) of /?-tolylmagnesium bromide (IM in ethyl ether). The clear, colorless solution immediately turned orange-reddish in color. The -78 °C bath was removed, the reaction mixture was allowed to slowly warm on its own to ambient temperature, stirred at ambient temperature for 2.25 hours, and concentrated in vacuo. Purification by flash chromatography (silica, 10% ethyl acetate in hexane) gave the title compound as a white solid. PMR (CDC13): δ 1.41 (3H, t, J = 7.1 Hz), 1.85 (3H, s), 2.31 (3H, s), 3.64 (3H, s), 4.39 (2H, q, J = 7.1 Hz), 4.43 (IH, s), 6.86 (IH, d, J = 8.5 Hz), 7.07 (2H, d, J = 8.1 Hz), 7.19 (2H, d, J = 8.1 Hz), 7.50 (IH, dd, J = 2.1, 8.5 Hz), 7.59 (2H, d, J = 8.4 Hz), 7.67 (IH, d, J = 2.1 Hz), 8.03 (2H, d, J = 8.4 Hz). Ethyl 4-[[4'-methoxy-3'-fl-p-tolvπvinyl]phenylethvnyl]benzoate (Compound 11) To a solution of 40.5 mg (0.1 mmol) of ethyl 4-[[4'-methoxy-3'-(l- hydroxy-l- -tolyl)ethyl]phenylethynyl]benzoate (Compound 10) in 2 mL of toluene (under a blanket of argon) was added approximately 8 mg of -toluene sulfonic acid monohydrate. The reaction mixture was heated at 70 °C for 20 minutes, cooled to ambient temperature and then concentrated in vacuo. Purification by flash chromatography (silica, 10% ethyl acetate in hexane) gave the title compound as a white solid. PMR (CDCI3): δ 1.40 (3H, t, J = 7.1 Hz), 2.34 (3H, s), 3.68 (3H, s), 4.38 (2H, q, J = 7.1 Hz), 5.28 (IH, d, J = 1.3 Hz), 5.73 (IH, br s), 6.89 (IH, d, J = 8.6 Hz), 7.09 (2H, d, J = 8.2 Hz), 7.19 (2H, d, J = 8.2 Hz), 7.45 (IH, d, J = 2.1 Hz), 7.50-7.58 (3H, m), 8.01 (2H, d, J = 8.5 Hz). 4-[[4'-Methoxy-3'-(l-p-tolyl)vinyl]phenylethynyl]benzoic acid (Compound 12) Employing the same general procedure as for the preparation of 4-[[4'-hydroxy-3'-(4"-methyl)benzoyl]phenylethynyl]benzoic acid (Compound 5), 25 mg (0.06 mmol) of ethyl 4-[[4'-methoxy-3'-(l-p- tolyl)vinyl]phenylethynyl]benzoate (Compound 11) was converted into the title compound (white solid) using 0.6 mL (0.6 mmol) of NaOH solution (IM in water), 2.5 mL of ethanol and 0.5 mL of tetrahydrofuran. PMR (Aceton-d6): 8 2.30 (3H, s), 3.69 (3H, s), 5.24 (IH, d, J = 1.5 Hz), 5.72 (IH, br s), 7.08-7.16 (3H, m), 7.17 (2H, d, J = 8.4 Hz), 7.39 (IH, d, J = 2.2 Hz), 7.58 (IH, dd, J = 2.2, 8.7 Hz), 7.64 (2H, d, J = 8.3 Hz), 8.04 (2H, d, J = 8.3 Hz). 4-[[4'-methoxymethoxy-3'-f4"-methvπbenzoyl]phenylethvnyl]benzoic acid (Compound 13) Employing the same general procedure as for the preparation of 4-[[4'-hydroxy-3'-(4"-methyl)benzoyl]phenylethynyl]benzoic acid (Compound 5), 14 mg (0.03 mmol) of ethyl 4-[[4'-methoxymethoxy-3'- (4"-methyl)benzoyl]phenylethynyl]benzoate (Compound 3) was converted into the title compound (white solid) using 0.3 mL (0.3 mmol) of NaOH solution (IM in water), 3.2 mL of ethanol and 0.2 mL of tetrahydrofuran. The white solid obtained was rinsed with 2 mL of 20% ethyl acetate in hexane to give the title compound. PMR (Aceton-d6): 8 2.41 (3H, s), 3.27 (3H, s), 5.16 (2H, s), 7.31-7.38 (3H, m), 7.53 (IH, d, J = 2.1 Hz), 7.64-7.73 (5H, m), 8.05 (2H, d, J = 8.4 Hz). Ethyl 4-[ 3'-acetyl-4'-methoxymethoxy^phenylethvnyl]benzoate (Compound 14) 5-bromo-2-methoxymethoxyacetophenone (Compound P) was converted into the title compound in a step-wise set of reaction conditions resulting in the final isolation of the title compound as a white solid. Employing the same general procedure as for the preparation of 2-methoxy-5-trimethylsilanylethynyl acetophenone (Compound W), 598 mg (2.3 mmol) of 5-bromo-2- methoxymethoxyacetophenone (Compound P) was converted into 2- methoxymethoxy-5-trimethylsilanylethynyl acetophenone using 405 mg (0.6 mmol) of bis(triphenylphosphine)palladium (II) chloride, 90 mg (0.5 mmol) of cuprous iodide, 2.5 mL (2.7 g, 27.6 mmol) of trimethylsilyl acetylene and 6 mL of triethylamine (heated at 75 °C). The reaction proceeded slowly and after 3 days of heating, an additional 2.5 mL (27.6 mmol) of trimethylsilyl acetylene and 406 mg (0.6 mmol) of bis(triphenylphosphine)palladium (II) chloride was added to the sealed tube (careful to keep the contents under a positive stream of argon) and the resultant mixture heated for 3 additional days (6 days total). Purification by flash chromatography (silica, 5-10% ethyl acetate in hexane) gave crude 2-methoxymethoxy-5-trimethylsilanylethynyl acetophenone. Employing the same general procedure as for the preparation of 5-ethynyl-2-methoxyacetophenone (Compound El), the crude TMS-acetylene derivative was then converted to 5-ethynyl-2- methoxymethoxy acetophenone using 104 mg (0.75 mmol) of K2C03 and 10 mL of methanol, and was isolated by flash chromatography (silica, 5% ethyl acetate in hexane) in >80% purity. Employing the same general procedure as for the preparation of ethyl 4-[(3'-acetyl-4'- methoxy)phenylethynyl]benzoate (Compound 1), the crude acetylene was converted into the title compound using 277 mg (1.0 mmol) of ethyl 4-iodobenzoate (Compound A), 137 mg (0.2 mmol) of bis(triphenylphosphine)palladium (II) chloride, 36 mg (0.2 mmol) of cuprous iodide and 6 mL of triethylamine. Purification by flash chromatography (silica, 10-20% ethyl acetate in hexane) gave the title compound as a white solid. PMR (CDC13): δ 1.41 (3H, t, J = 7.2 Hz), 2.65 (3H, s), 3.53 (3H, s), 4.37 (2H, t, J = 7.2 Hz), 4.38 (2H, q, J = 7.1 Hz), 5.32 (2H, s), 7.20 (IH, d, J = 8.7 Hz), 7.56 (2H, d, J = 8.4 Hz), 7.60 (IH, dd, J = 2.2, 8!7 Hz), 7.91 (IH, d, J = 2.2 Hz), 8.03 (2H, d, J = 8.4 Hz). Ethyl 4-[[4'-heptyloxy-3'-(l-p-tolvπvinyl]phenylethynyl]benzoate (Compound 15) Ethyl 4-[(3'-acetyl-4'-methoxymethoxy)phenylethynyl]benzoate (Compound 14) was converted in a step-wise set of reaction conditions resulting in the final isolation of the title compound as a white solid. Employing the same general procedure as for the preparation of ethyl 4-[[4'-methoxy-3'-(l-hydroxy-l- -tolyl)ethyl]phenylethynyl]benzoate (Compound 10), 0.4 mL (0.4 mmol) of p-tolylmagnesium bromide (IM in ethyl ether) was used to convert a solution of 100 mg (0.3 mmol) of ethyl 4-[(3'-acetyl-4'-methoxymethoxy)phenylethynyl]benzoate (Compound 14) in 3 mL of tetrahydrofuran into a 3:2 mixture of ethyl 4-[[4'-methoxymethoxy-3'-(l-hydroxy-l-p- tolyl)ethyl]phenylethynyl]benzoate and ethyl 4-[[4'-hydroxy-3'-(l-hydroxy- l-p-tolyl)ethyl]phenylethynyl]benzoate following flash chromatography (silica, 15% ethyl acetate in hexane). To a yellow solution of the crude mixture in 3 mL of ethanol (under a blanket of argon) was added 1 mL of 10% HC1 (aq.) solution. The resultant reaction mixture was stirred at ambient temperature for 6.5 hours, heated at 55 °C overnight and quenched with water followed by sat. NaHC03 (aq.) solution. The resultant mixture was extracted into ethyl acetate and the layers were separated. The organic phase was washed with water and brine, dried over MgS04, filtered and concentrated in vacuo to a yellow residue. Purification by flash chromatography (silica, 50% ethyl acetate in hexane) gave crude ethyl 4-[[4'-hydroxy-3'-(l-/?- tolyl)vinyl]phenylethynyl]benzoate. The crude material was converted into the title compound using the same general procedure as for the preparation of 4-bromo-l-methoxy-3-methylbenzene (Compound E), except using 30 mg (0.2 mmol) of potassium carbonate, 0.025 mL (32 mg, 0.1 mmol) of n-heptyl iodide and 5 mL of acetone. After stirring at ambient temperature for 22 hours, the reaction mixture was concentrated in vacuo and purified by flash chromatography (silica, 5% ethyl acetate in hexane) to give the title compound as a white solid. PMR (CDC13): δ 0.87 (3H, t, J = 7.3 Hz), 0.95-1.02 (2H, m), 1.08-1.30 (6H, m), 1.34-1.40 (5H, m), 2.33 (3H, s), 3.80 (2H, t, J =7.1 Hz), 4.38 (2H, q, J = 7.1 Hz), 5.28 (IH, d, J = 1.5 Hz), 5.63 (IH, d, J = 1.5 Hz), 6.83 (IH, d, J = 9.0 Hz), 7.07 (2H, d, J = 8.2 Hz), 7.17 (2H, d, J = 8.2 Hz), 7.47-7.52 (2H, m), 7.56 (2H, d, J = 8.4 Hz), 8.01 (2H, d, J = 8.4 Hz). 4-[[4'-Heptyloxy-3'-fl-p-tolyl inyl]phenylethvnyl]benzoic acid (Compound 16) Employing the same general procedure as for the preparation of 4-[[4'-hydroxy-3'-(4"-methyl)benzoyl]phenylethynyl]benzoic acid (Compound 5), 8.5 mg (0.02 mmol) of ethyl 4-[[4'-heptyloxy-3'-(l- ?- tolyl)vinyl]phenylethynyl]benzoate (Compound 15) was converted into the title compound (white solid) using 0.2 mL (0.2 mmol) of NaOH solution (IM in water), 0.8 mL of ethanol and 0.2 mL of tetrahydrofuran. The white solid obtained was rinsed with 1 mL of 10% ethyl acetate in hexane to give the title compound. PMR (CDC13): 8 0.86 (3H, t, J = 7.2 Hz), 0.90-1.45 (10H, m), 2.31 (3H, s), 3.87 (2H, t, J =6.1 Hz), 5.26 (IH, br s), 5.65 (IH, br s), 7.03 (IH, d, J = 8.5 Hz), 7.11 (2H, d, J = 8.3 Hz), 7.16 (2H, d, J = 8.3 Hz), 7.45 (IH, d, J = 2.1 Hz), 7.56 (IH, dd, J = 2.1, 8.5 Hz), 7.65 (2H, d, J = 8.4 Hz), 8.05 (2H, d, J = 8.4 Hz). Ethyl 4-[(3'-acetyl)phenylethynyl]benzoate (Compound 17) Employing the same general procedure as for the preparation of ethyl 4-[(3'-acetyl-4'-methoxy)phenylethynyl]benzoate (Compound 1), 600 mg (4.2 mmol) of 3-ethynylacetophenone (Compound Kl) was converted into the title compound using 1.3 g (4.6 mmol) of ethyl 4- iodobenzoate (Compound A), 585 mg (0.8 mmol) of bis(triphenylphosphine)palladium (II) chloride, 156 mg (0.8 mmol) of cuprous iodide and 16 mL of triethylamine. Purification by flash chromatography (silica, 10% ethyl acetate in hexane) gave the title compound as a yellow solid. PMR (CDC13): δ 1.40 (3H, t, J = 7.1 Hz), 2.62 (3H, s), 4.38 (2H, q, J = 7.1 Hz), 7.44-7.51 (2H, m), 7.59 (2H, d, J = 8.3 Hz), 7.69-7.75 (IH, m), 7.91-7.97 (IH, m), 8.03 (2H, d, J = 8.3 Hz), 8.10-8.14 (IH, m). Ethyl 4-[[3'-( -hvdroxy-l-p-tolvπethyl]phenylethvnyl]benzoate (Compound 18) To a cold solution (0 °C) of 112 mg (0.4 mmol) of ethyl 4-[(3'- acetyl)phenylethynyl]benzoate (Compound 17) in 3 mL of tetrahydrofuran (under a blanket of argon) was added 0.6 mL (0.6 mmol) of /?-tolylmagnesium bromide (IM in ethyl ether). The solution immediately turned orange and was stirred at 0 °C for 3 hours at which time an additional 0.3 mL (0.3 mmol) of ^-tolylmagnesium bromide (IM in ethyl ether ) was added. The reaction mixture was stirred at 0 °C for an additonal 15 minutes, quenched by adding sat. NH4C1 (aq.) solution and extracted into ethyl acetate. The layers were separated and the organic phase was washed with water and brine, dried over MgS04, filtered and concentrated in vacuo to a yellow oil. Purification by flash chromatography (silica, 5-10% ethyl acetate in hexane) gave the title compound as a clear film. PMR (CDC13): δ 1.40 (3H, t, J = 7.1 Hz), 1.95 (3H, s), 2.24 (IH, s), 2.33 (3H, s), 4.38 (2H, q, J = 7.1 Hz), 7.14 (2H, d, J = 7.9 Hz), 7.25- 7.33 (3H, m), 7.39-7.43 (2H, m), 7.56 (2H, d, J = 8.5 Hz), 7.63-7.65 (IH, m), 8.01 (2H, d, J = 8.5 Hz). Ethyl 4-[[3'-(l-p-tolyl)vinyl]phenylethynyl]benzoate (Compound 19) Employing the same general procedure as for the preparation of ethyl 4-[[4'-methoxy-3'-(l-/?-tolyl)vinyl]phenylethynyl]benzoate (Compound 11), 47 mg (0.1 mmol) of ethyl 4-[[3'-(l-hydroxy-l-jp- tolyl)ethyl]phenylethynyl]benzoate (Compound 18) was converted into the title compound using 8.5 mg of p-toluene sulfonic acid monohydrate and 2 mL of toluene. Purification by flash chromatography (silica, 10% ethyl acetate in hexane) gave the title compound as a white solid. PMR (CDC13): δ 1.40 (3H, t, J = 7.1 Hz), 2.37 (3H, s), 4.38 (2H, q, J = 7.1 Hz), 5.43 (IH, d, J = 1.1 Hz), 5.47 (IH, br s), 7.16 (2H, d, J = 8.2 Hz), 7.23 (2H, d, J = 8.2 Hz), 7.32-7.35 (2H, m), 7.47-7.51 (IH, m), 7.53-7.60 (3H, m), 8.01 (2H, d, J = 8.4 Hz). 4-[[3'-Q-p-TolylWinyl]phenylethvnyl]benzoic acid (Compound 20) Employing the same general procedure as for the preparation of 4-[[4'-hydroxy-3'-(4"-methyl)benzoyl]phenylethynyl]benzoic acid (Compound 5), 36 mg (0.1 mmol) of ethyl 4-[[3'-(l-p- tolyl)vinyl]phenylethynyl]benzoate (Compound 19) was converted into the title compound (white solid) using 1.0 mL (1.0 mmol) of NaOH solution (IM in water), 4.0 mL of ethanol and 0.5 mL of tetrahydrofuran. PMR (DMSO-d6): 8 2.33 (3H, s), 5.50-5.54 (2H, m), 7.19-7.23 (4H, br s), (IH, d, J = 1.1 Hz), 5.47 (IH, br s), 7.19-7.22 (4H, m), 7.36-7.40 (IH, m), 7.44-7.50 (2H, m), 7.56-7.61 (IH, m), 7.67 (2H, d, J = 8.5 Hz), 7.96 (2H, d, J = 8.5 Hz). Ethyl 4-[[4'-methoxy-3'-(4"-methyl)benzoyl]ρhenylethvnyl]benzoate (Compound 21) Employing the same general procedure as for the preparation of ethyl 4-[(3'-acetyl-4'-methoxymethoxy)phenylethynyl]benzoate (Compound 14), a crude sample of 5-bromo-2-methoxy-4'- methylbenzophenone (Compound H) was converted into the title compound (white needles) in a series of reactions. A crude sample (approximately 50% purity) of approximately 195 mg (0.6 mmol) of 5- bromo-2-methoxy-4'-methylbenzophenone (Compound H) was converted into crude 2-methoxy-5-trimethylsilanylethynyl-4'-methylbenzophenone using 112 mg (0.2 mmol) of bis(triphenylphosphine)palladium (II) chloride, 30 mg (0.2 mmol) of cuprous iodide, 0.7 mL (0.6 g, 6.4 mmol) of trimethylsilyl acetylene 10 mL of triethylamine (heated at 75 °C). After purification by flash chromatography (silica, 3% ethyl acetate in hexane), the crude TMS-acetylene derivative obtained was converted into crude 5-ethynyl-2-methoxy-4'-methylbenzophenone using 10 mg (0.07 mmol) of K2C03 and 10 mL of methanol. Purification by flash chromatography (silica, 5% ethyl acetate in hexane) gave the acetylene derivative in >90% purity. The crude acetylene was converted into the title compound using 86 mg (0.3 mmol) of ethyl 4-iodobenzoate (Compound A), 50 mg (0.07 mmol) of bis(triphenylphosphine)palladium (II) chloride, 13 mg (0.07 mmol) of cuprous iodide and 6 mL of triethylamine. Purification by flash chromatography (silica, 15% ethyl acetate in hexane) followed by recrystallization from methanol gave the title compound as white needles. PMR (CDC13): δ 1.40 (3H, t, J = 7.1 Hz), 2.43 (3H, s), 3.78 (3H, s), 6.99 (IH, d, J = 8.7 Hz), 7.25 (2H, d, J = ~ 8 Hz), 7.52 (IH, d, J = 2.1 Hz), 7.54 (2H, d, J = 8.4 Hz), 7.64 (IH, dd, J = 2.1, 8.7 Hz), 7.73 (2H, d, J = 8.3 Hz), 8.01 (2H, d, J = 8.3 Hz). 4-[[4'-methoxy-3'-(4"-methyl benzoyl]phenylethvnyl]benzoic acid (Compound 22) Employing the same general procedure as for the preparation 4- [(3'-acetyl-4'-methoxy)phenylethynyl]benzoic acid (Compound 2), 46 mg (0.1 mmol) ethyl 4-[[4'-methoxy-3'-(4"- methyl)benzoyl]phenylethynyl]benzoate (Compound 21) was converted into the title compound (white solid) using 1.2 mL (1.2 mmol) of LiOH solution (IM in water) and 5 mL of tetrahydrofuran. The white solid obtained was rinsed with 3 mL of 5% ethyl acetate in hexane to give the title compound. PMR (Aceton-d6): δ 2.38 (3H, s), 3.73 (3H, s), 7.26 (IH, d, J = 8.8 Hz), 7.33 (2H, d, J = 7.8 Hz), 7.50 (IH, d, J = 2.1 Hz), 7.59-7.65 (4H, m), 7.60 (IH, dd, J = 2.1, 8.6 Hz), 7.94 (2H, d, J = 8.6 Hz). Ethyl 4-[[4'-methoxymethoxy-2,-methyl-5'-(;4"- methyl)benzoyl]phenylethvnyl]-2-fluoro-benzoate (Compound 23) Employing the same general procedure as for the preparation of ethyl 4-[(3'-acetyl-4'-methoxy)phenylethynyl]benzoate (Compound 1), 123 mg (0.4 mmol) of 5-ethynyl-4-methyl-2-methoxymethoxy-4'- methylbenzophenone (Compound LI) was converted into the title compound using 136 mg (0.5 mmol) of ethyl 2-fluoro-4-iodobenzoate (Compound C), 74 mg (0.1 mmol) of bis(triphenylphosphine)palladium (II) chloride, 20 mg (0.1 mmol) of cuprous iodide and 5.0 mL of a 4:1 mixture of triethylamine:Λ Λ -dimethylformamide. Purification by flash chromatography (silica, 10% ethyl acetate in hexane) gave the title compound as a yellow solid. PMR (CDC13): δ 1.40 (3H, t, J = 7.1 Hz), 2.42 (3H, s), 2.56 (3H, s), 3.34 (3H, s), 4.40 (2H, q, J = 7.1 Hz), 5.09 (2H, s), 7.11 (IH, s), 7.20- 7.35 (4H, m), 7.51 (IH, s), 7.73 (2H, d, J = 8.2 Hz), 7.90 (IH, t, J = 7.9 Hz, J (C-F) = 7.9 Hz). Ethyl 4-[[4'-hvdroxy-2'-methyl-5'-(4"-methvnbenzoyl]ρhenylethvnyl]-2- fluoro-benzoate (Compound 24) Employing the same general procedure as for the preparation of ethyl 4-[[4'-hydroxy-3'-(4"-methyl)benzoyl]phenylethynyl]benzoate (Compound 4), 13 mg (0.03 mmol) of ethyl 4-[[4'-methoxymethoxy-2'- methyl-5'-(4"-methyl)benzoyl]phenylethynyl]-2-fluoro-benzoate (Compound 23) was converted into the title compound (yellow oil) using 1 drop of c. HC1 and and 2 mL of ethanol. Purification by flash chromatography (silica, 10% ethyl acetate in hexane) gave the title compound as a yellow oil. PMR (CDC13): δ 1.40 (3H, t, J = 7.1 Hz), 2.47 (3H, s), 2.53 (3H, s), 4.39 (2H, q, J = 7.1 Hz), 6.97 (IH, s), 7.22 (IH, dd, J = 1.5 Hz, J (C-F) = 9.1 Hz), 7.31 (IH, dd, J = 1.5, 8.1 Hz), 7.35 (2H, d, J = 8.1 Hz), 7.62 (2H, d, J = 8.1 Hz), 7.78 (IH, s), 7.89 (IH, t, J = 7.9 Hz, J (C-F) = 7.8 Hz), 12.27 (IH, s). 4-[[4'-Hvdroxy-2'-methyl-5'-(;4"-methvnbenzoyl]phenylethvnyl]-2-fluoro- benzoic acid (Compound 25) Employing the same general procedure as for the preparation of 4-[[4'-hydroxy-3'-(4"-methyl)benzoyl]phenylethynyl]benzoic acid (Compound 5), 10 mg (0.025 mmol) of ethyl 4-[[4'-hydroxy-2'-methyl-5,-(4"-methyl)benzoyl]ρhenylethynyl]-2- fluoro-benzoate (Compound 24) was converted into the title compound (yellow crystals) using 0.25 mL (0.25 mmol) of NaOH solution (IM in water), 1.0 mL of ethanol and 0.2 mL of tetrahydrofuran. Recrystallization from acetonitrile gave the title compound as yellow needles. PMR (Aceton-d6): 8 2.46 (3H, s), 2.57 (3H, s), 7.04 (IH, s), 7.37-7.46 (4H, m) 7.80 (IH, s), 7.62-7.70 (2H, d, J = 8.3 Hz), 7.96 (IH, t, J = 7.5 Hz, J (C-F) = 8.0 Hz). Ethyl 4-[[4'-isoρroρoxy-3,- i-p-tolvπvinyl]ρhenylethvnyl]benzoate (Compound 26) Employing the same general procedure as for the preparation of ethyl 4-[(3'-acetyl-4'-methoxy)phenylethynyl]benzoate (Compound 1), 20 mg (0.07 mmol) 4-ethynyl-l-isopropoxy-2-[(l-p-tolyl)vinyl]benzene (Compound Ml) was converted into the title compound using 24 mg (0.09 mmol) of ethyl 4-iodobenzoate (Compound A), 13 mg (0.02 mmol) of bis(triphenylphosphine)palladium (II) chloride, 4 mg (0.02 mmol) of cuprous iodide and 3.5 mL of triethylamine. Purification by flash chromatography (silica, 5% ethyl acetate in hexane) gave the title compound as a white solid. PMR (CDC13): δ 1.00 (6H, d, J = 6.0 Hz), 1.40 (3H, t, J = 7.0 Hz), 2.34 (3H, s), 4.32-4.44 (3H, m), 5.29 (IH, d, J = 1.4 Hz), 5.60 (IH, br s), 6.85 (IH, d, J = 8.2 Hz), 7.08 (2H, d, J = 8.2 Hz), 7.16 (2H, d, J = 8.2 Hz), 7.45-7.52 (2H, m), 7.56 (2H, d, J = 8.4 Hz), 8.01 (2H, d, J = 8.4 Hz). Ethyl 4-[[4'-isopropoxy-3'-(l p-tolyl)vinyl]phenylethynyl]-2-fluoro- benzoate (Compound 27) Employing the same general procedure as for the preparation of ethyl 4-[(3'-acetyl-4,-methoxy)phenylethynyl]benzoate (Compound 1), 16 mg (0.06 mmol) 4-ethynyl-l-isopropoxy-2-[(l-p-tolyl)vinyl]benzene (Compound Ml) was converted into the title compound using 17.5 mg (0.06 mmol) of ethyl 2-fluoro-4-iodobenzoate (Compound C), 10 mg (0.015 mmol) of bis(triphenylphosphine)palladium (II) chloride, 3.2 mg (0.02 mmol) of cuprous iodide and 3.5 mL of triethylamine. Purification by flash chromatography (silica, 5% ethyl acetate in hexane) gave the title compound as a yellow oil which later solidified to a yellow solid. PMR (CDC13): δ 1.00 (6H, d, J = 6.0 Hz), 1.40 (3H, t, J = 7.1 Hz), 2.34 (3H, s), 4.3-4.5 (3H, m), 5.28 (IH, d, J = 1.4 Hz), 5.60 (IH, d, J = 1.4 Hz), 6.85 (IH, d, J = 8.3 Hz), 7.08 (2H, d, J = 8.1 Hz), 7.15 (2H, d, J = 8.1 Hz), 7.25 (IH, dd, J = 1.5 Hz, J (C-F) = 11.4 Hz), 7.31 (IH, dd, J = 1.5, 8.1 Hz), 7.44-7.50 (2H, m), 7.90 (IH, t, J = 7.9 Hz, J (C-F) = 7.8 Hz). 4-[[4'-Isopropoxy-3,-fl-/7-tolylYvinyl]phenylethvnyl]benzoic acid (Compound 28) Employing the same general procedure as for the preparation of 4-[[4'-hydroxy-3'-(4"-methyl)benzoyl]phenylethynyl]benzoic acid (Compound 5), 17 mg (0.04 mmol) of ethyl 4-[[4'-isopropoxy-3'-(l p- tolyl)vinyl]phenylethynyl]benzoate (Compound 26) was converted into the title compound (white crystals) using 0.4 mL (0.4 mmol) of NaOH solution (IM in water), 1.6 mL of ethanol and 0.4 mL of tetrahydrofuran. Recrystallization from acetonitrile gave the title compound as white crystals. PMR (Aceton-d6): δ 0.99 (6H, d, J = 6.0 Hz), 2.31 (3H, s), 4.54 (IH, heptet, J = 6.0 Hz), 5.24 (IH, d, J = 1.5 Hz), 5.61 (IH, d, J = 1.5 Hz), 7.05 (IH, d, J = 8.5 Hz), 7.07-7.20 (4H, m), 7.43 (IH, d, J = 2.2 Hz), 7.54 (IH, dd, J = 2.2, 8.4 Hz), 7.64 (2H, d, J = 8.5 Hz), 8.04 (2H, d, J = 8.5 Hz). 4-[[4'-Isopropoxy-3'-(l-p-tolyl)vinyl]phenylethvnyl]-2-fluoro-benzoic acid (Compound 29) Employing the same general procedure as for the preparation of 4-[[4'-hydroxy-3'-(4"-methyl)benzoyl]phenylethynyl]benzoic acid (Compound 5), 10 mg (0.02 mmol) of ethyl 4-[[4,-isoρropoxy-3'-(l p- tolyl)vinyl]ρhenylethynyl]-2-fluoro-benzoate (Compound 27) was converted into the title compound (white solid) using 0.2 mL (0.2 mmol) of NaOH solution (IM in water), 1.0 mL of ethanol and 0.2 mL of tetrahydrofuran. The white solid obtained was rinsed with a small amount of 5% ethyl acetate in hexane to give the title compound. PMR (Aceton-d6): δ 0.99 (6H, d, J = 6.0 Hz), 2.31 (3H, s), 4.55 (IH, heptet, J = 6.0 Hz), 5.24 (IH, br s), 5.62 (IH, d, J = 1.6 Hz), 7.03-7.20 (5H, m), 7.36-7.60 (3H, m), 7.55 (IH, dd, J = 2.2, 8.5 Hz), 7.97 (IH, t, J = 8.0 Hz, J (C-F) = 7.8 Hz). Ethyl 4-[[4'-isopropoxy-3'-( - -tolyl)vinyl]phenylethynyl]benzoate (Compound 30) Employing the same general procedure as for the preparation of ethyl 4-[(3'-acetyl-4'-methoxy)phenylethynyl]benzoate (Compound 1), 14 mg (0.05 mmol) of 4-ethynyl-l-isopropoxy-2-[(l- -tolyl)vinyl]benzene (Compound Nl) was converted into the title compound using 14 mg (0.04 mmol) of ethyl 4-iodobenzoate (Compound A), 9 mg (0.01 mmol) of bis(triphenylphosphine)palladium (II) chloride, 2 mg (0.01 mmol) of cuprous iodide and 3 mL of triethylamine. Purification by flash chromatography (silica, 1% ethyl acetate in hexane) gave the title compound as a clear oil which later solidified to a white solid. PMR (CDC13): δ 0.99 (6H, d, J = 6.0 Hz), 1.40 (3H, t, J = 7.1 Hz), 2.30 (3H, s), 4.33-4.46 (3H, m), 5.32 (IH, d, J = 1.5 Hz), 5.61 (IH, br s), 6.84 (IH, d, J = 8.4 Hz), 7.05-7.20 (4H, m), 7.45-7.52 (2H, m), 7.57 (2H, d, J = 8.4 Hz), 8.02 (2H, d, J = 8.4 Hz). 4-[[4'-Isopropoxy-3'-(l- -tolyl)vinyl]phenylethynyl]benzoic acid (Compound 31) Employing the same general procedure as for the preparation of 4-[[4'-hydroxy-3'-(4"-methyl)benzoyl]phenylethynyl]benzoic acid (Compound 5), 10 mg (0.02 mmol) of ethyl 4-[[4'-isopropoxy-3'-(l-rø- tolyl)vinyl]phenylethynyl]benzoate (Compound 30) was converted into the title compound (white solid) using 0.3 mL (0.3 mmol) of NaOH solution (IM in water), 1.2 mL of ethanol and 0.3 mL of tetrahydrofuran. The white solid obtained was rinsed with 1.5 mL of 5% ethyl acetate in hexane to give the title compound. PMR (Aceton-d6): 8 0.97 (6H, d, J = 6.0 Hz), 2.28 (3H, s), 4.54 (IH, heptet, J = 6.0 Hz), 5.29 (IH, d, J = 1.5 Hz), 5.67 (IH, br s), 7.02-7.22 (5H, m), 7.46 (IH, d, J = 2.2 Hz), 7.54 (IH, dd, J = 2.2, 8.4 Hz), 7.65 (2H, d, J = 8.4 Hz), 8.05 (2H, d, J = 8.4 Hz). Ethyl 4-[[4,-tert-butyldimethylsilanyloxy-3'- -p- tolyl)vinyl]phenylethynyl]benzoate (Compound 32) Employing the same general procedure as for the preparation of ethyl 4-[(3'-acetyl-4'-methoxy)phenylethynyl]benzoate (Compound 1), 12 mg (0.04 mmol) of l-te^butyldimethylsilanyloxy-4-ethynyl-2-[(l-p- tolyl)vinyl]benzene (Compound OI) was converted into the title compound using 10 mg (0.04 mmol) of ethyl 4-iodobenzoate (Compound A), 6 mg (0.01 mmol) of bis(triphenylphosphine)ρalladium (II) chloride, 1.5 mg (0.01 mmol) of cuprous iodide and 2 mL of triethylamine. Purification by flash chromatography (silica, 1% ethyl acetate in hexane) gave the title compound as a yellow oil. PMR (CDC13): δ 0.07 (6H, s), 0.73 (9H, s), 1.40 (3H, t, J = 7.0 Hz), 2.32 (3H, s), 4.38 (2H, q, J = 7.0 Hz), 5.25 (IH, d, J = 1.2 Hz), 5.71 (IH, d, J = 1.2 Hz), 6.80 (IH, d, J = 8.2 Hz), 7.08 (2H, d, J = 8.4 Hz), 7.18 (2H, d, J = 8.4 Hz), 7.38-7.48 (2H, m), 7.55 (2H, d, J = 8.2 Hz), 8.01 (2H, d, J = 8.2 Hz).

Claims

WHAT IS CLAIMED IS:
1. A compound of the formula
Y1(R5)-C-Y3(R1)(R4)m-Z-Y2(R4)-A-B.
II X where X is O, S, C(R2) or NOR*, R* is H, C 6 alkyl or phenyl;
Rx is H, lower alkyl of 1 to 10 carbons, F, Cl, Br, I, CF3, OR2 SR2, OCH.OC^ alkyl or CF2CF3; ; R2 is independently H, lower alkyl of 1 to 10 carbons, R3Si, or
COR3 where R3 is independently H, lower alkyl of 1 to 6 carbons or phenyl;
R4 is lower alkyl of 1 to 6 carbons, F, Cl, Br, I, CF3, CF2CF3, N02, N(R6)2, CN, COR3, or N(R6)-COR3; m is an integer between 0 and 3;
Y, is phenyl, naphthyl or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl, naphthyl and heteroaryl groups being unsubstituted or substituted with one to three R5 groups, where R5 is alkyl of 1 to 10 carbons, fluoro-substituted alkyl of 1 to 10 carbons, alkenyl of 2 to 10 carbons and having 1 to 3 double bonds, alkynyl having 2 to 10 carbons and 1 to 3 triple bonds, F, Cl, Br, I, N02, CN, COOH, COOC^alkyl; N3; N(R6)2, OH, OR3; SR3; OCOR3, or SCOR3; Z is -CΓëíC-
-N=N-, -N(0)=N-, -N=N(0)-, -N=CR 6 >
-CR6=N,
-(CR6=CR6)ΓÇ₧- where n is an integer having the value 0 - 5,
-CO-NRΛ 6 > -CS-NR6-,
-NR6-CO, -NR6-CS, -COO-, -OCO-; -CSO-;
-OCS-;
-CO-CR6=CR6- R6 is independently H or lower alkyl of 1 to 6 carbons; Y2 is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and heteroaryl groups being unsubstituted or substituted with one or two R4 groups, or when Z is -(CR6=CR6)n and n is 3, 4 or 5 then Y2 represents a direct valence bond between said (CR6=CR6)n group and B;
Y3 is phenyl, pyridyl, thienyl or furyl unsubstituted or substituted with up to 3 Rt groups and unsubstituted or substituted with up to 3 R4 groups;
A is (CH2)q where q is 0-5, lower branched chain alkyl having 3-6 carbons, cycloalkyl having 3-6 carbons, alkenyl having 2-6 carbons and 1 or 2 double bonds, alkynyl having 2-6 carbons and 1 or 2 triple bonds;
B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, COOR8, CONR^, -CH2OH, CH2ORπ, CH2OCORπ, CHO, CH(OR12)2, CH(OR130), -COR,, CR7(OR12)2, CR7(OR130), or Si( . 6alkyl)3, where R, is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbons, R8 is an alkyl group of 1 to 10 carbons or (trimethylsilyl)alkyl where the alkyl group has 1 to 10 carbons, or a cycloalkyl group of 5 to 10 carbons, or R8 is phenyl or lower alkylphenyl, Rg and R10 independently are hydrogen, an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5-10 carbons, or phenyl, hydroxyphenyl or lower alkylphenyl, Rn is lower alkyl, phenyl or lower alkylphenyl, R12 is lower alkyl, and R13 is divalent alkyl radical of 2-5 carbons.
2. A compound in accordance with Claim 1 where X is S.
3. A compound in accordance with Claim 1 where Z is selected from the group consisting of -CΓëíC-, -CH=CH-, -CONH-, - COO-, -OCO-, -NHCO-, and -(CRΓé¼=CR6)n- where n is zero or 3.
4. A compound in accordance with Claim 1 where the A-B group is (CH2)qCOOH or (CH2)q-COOR8.
5. A compound in accordance with Claim 1 where Rj is OH, or OR2.
6. A compound of Claim 1 wherein X is O, or CH2;
Rt is H, lower alkyl of 1 to 10 carbons, OCH2OCH3, or OR2; R2 is H, lower alkyl of 1 to 10 carbons, tri-(C1.6alkyl)silyl, or
COR3;
R4 is lower alkyl of 1 to 6 carbons, F, Cl, Br, I, or CF3; m is an integer between 0 and 3;
Yx is phenyl, naphthyl or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, or thiazolyl, said phenyl, naphthyl and heteroaryl groups being unsubstituted or substituted with one to three Rs groups, where R5 is alkyl of 1 to 10 carbons, or fluoro-substituted alkyl of 1 to 10 carbons, F, Cl, Br, I, N02, CN, COOH, or COOC,.6alkyl;
Z is -CΓëíC-
-(CR6=CR6)n- where n is an integer having the value 0 - 5,
-CO-NR6-, -CS-NR6-,
-NR6-CO,
-NR6-CS,
-COO-,
-OCO-; Y2 is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, or furyl, said phenyl and heteroaryl groups being unsubstituted or substituted with one or two R4 groups, or when Z is -(CR6=CR6)n and n is 3, 4 or 5 then Y2 represents a direct valence bond between said (CR6=CR6)n group and B and Y3 is phenyl.
7. A compound in accordance with Claim 6 where Y2 is phenyl and Z is -CΓëíC-.
8. A compound of the formula
wherein X is O, or CH 2> Rl is H, OCH2OCH3, or OR2;
R2 is H, lower alkyl of 1 to 10 carbons, tri-(Cj.6alkyl)silyl, or COR3 where R3 is H, or lower alkyl;
R4 is H or lower alkyl of 1 to 6 carbons; R4* is H or F;
R5 is H, F or lower alkyl of 1 to 6 carbons, and
R8* is H, lower alkyl of 1 to 6 carbons, or a pharmaceutically acceptable salt thereof.
9. A compound in accordance with Claim 8 where X is CH2 and R5 is 4-methyl.
10. A compound in accordance with Claim 9 where R4 is H.
11. A compound in accordance with Claim 10 where Rt is H.
12. A compound in accordance with Claim 11 where R4* is H and R8* is H or ethyl.
13. A compound in accordance with Claim 10 where Rj is
CH3OCH20-.
14. A compound in accordance with Claim 13 where R4* is H and R8* is H or ethyl.
15. A compound in accordance with Claim 10 where Rt is OH.
16. A compound in accordance with Claim 15 where R4* is H and R8* is H or ethyl.
17. A compound in accordance with Claim 10 where Rt is OCH3.
18. A compound in accordance with Claim 17 where R4* is H and Rg* is H or ethyl.
19. A compound in accordance with Claim 10 where R, is OCH(CH3)2 .
20. A compound in accordance with Claim 19 where R4* is H and R8* is H or ethyl.
21. A compound in accordance with Claim 19 where R4* is F and R8* is H or ethyl.
22. A compound in accordance with Claim 8 where X is CH2 and R5 is 3-methyl.
23. A compound in accordance with Claim 22 where R4 is H, Rt is OCH(CH3)2 R4* is H and R8* is H or ethyl.
24. A compound in accordance with Claim 8 where X is O and Rs is 4-methyl.
25. A compound in accordance with Claim 24 where R4 is H.
26. A compound in accordance with Claim 25 where Rj is CH3OCH20-.
27. A compound in accordance with Claim 26 where R4* is H and R8* is H or ethyl.
28. A compound in accordance with Claim 25 where Rx is OH.
29. A compound in accordance with Claim 28 where R4* is H and R8* is H or ethyl.
30. A compound in accordance with Claim 25 where Rx is OCH3 .
31. A compound in accordance with Claim 24 where R4 is CH3 .
32. A compound in accordance with Claim 31 where Rj is OH.
33. A compound in accordance with Claim 32 where R4* is F. AMENDED CLAIMS
[received by the International Bureau on 28 September 1998 (28.09.98); original claims 1-14 amended: remaining claims unchanged (5 pages)]
1
2 1. (AMENDED) A compound of the formula
3 Y1(R5)-C-Y3(R1)(R4)m-Z-Y2(R4)-A-B.
4 ,╬╣
5 X
6 where X is O, S, C(R2) or NOR*,
7 R* is H, .6 alkyl or phenyl;
8 Rt is H, lower alkyl of 1 to 10 carbons, F, Cl, Br, I, CF3, OR2
9 SR2, OCT OC^ alkyl or CF2CF3; ; 0 Rj- is independently H, lower alkyl of 1 to 10 carbons, R3Si, or 1 COR3 where R3 is independently H, lower alkyl of 1 to 6 carbons or 2 phenyl; 3 R4 is lower alkyl of 1 to 6 carbons, F, Cl, Br, I, CF3, CF2CF3, 4 N02, N(R6)2, CN, COR3, or N(R6)-COR3; 5 m is an integer between 0 and 3; 6 Yj is phenyl, naphthyl or heteroaryl selected from a group 7 consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, 8 thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl, naphthyl and 9 heteroaryl groups being unsubstituted or substituted with one to three 0 R5 groups, where R5 is alkyl of 1 to 10 carbons, fluoro-substituted alkyl 1 of 1 to 10 carbons, alkenyl of 2 to 10 carbons and having 1 to 3 double 2 bonds, alkynyl having 2 to 10 carbons and 1 to 3 triple bonds, F, Cl, Br, 3 I, N02, CN, COOH, COOC^alkyl; N3; N(R6)2, OH, OR3; SR3; OCOR3, 4 or SCOR3; 5 Z is -CΓëíC- 6 -N=N-, 7 -N(0)=N-, 8 -N=N(0)-, -N=CR6-, -CR6=N, -(CR6=CR6)n- where n is an integer having the value 0 - 5, -CO-NR6-, -CS-NR6-, -NR6-CO, -NR6-CS, -COO-, -OCO-; -CSO-; -OCS-; -CO-CR6=CR6- R6 is independently H or lower alkyl of 1 to 6 carbons; Y2 is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and heteroaryl groups being unsubstituted or substituted with one or two R4 groups, or when Z is -(CR6=CR6)n and n is 3, 4 or 5 then Y2 represents a direct valence bond between said (CR6=CR6)n group and B; Y3 is phenyl, pyridyl, thienyl or furyl unsubstituted or substituted with up to 3 Rl groups and unsubstituted or substituted with up to 3 R4 groups; A is (CH2)q where q is 0-5, lower branched chain alkyl having 3-6 carbons, cycloalkyl having 3-6 carbons, alkenyl having 2-6 carbons and 1 or 2 double bonds, alkynyl having 2-6 carbons and 1 or 2 triple bonds; B is COOH or a pharmaceutically acceptable salt thereof, COOR8, CONR^o, -CH2OH, CH2ORu, CH2OCORn, CHO, CH(OR12)2, CH(OR130), -COR,, CR7(OR12)2, CR7(OR130), or Si(C,. 6alkyl)3, where R, is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbons, R8 is an alkyl group of 1 to 10 carbons or (trimethylsilyl)alkyl where the alkyl group has 1 to 10 carbons, or a cycloalkyl group of 5 to 10 carbons, or R8 is phenyl or lower alkylphenyl, R, and R10 independently are hydrogen, an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5-10 carbons, or phenyl, hydroxyphenyl or lower alkylphenyl, Ru is lower alkyl, phenyl or lower alkylphenyl, Ru is lower alkyl, and R13 is divalent alkyl radical of 2-5 carbons. 2. A compound in accordance with Claim 1 where Yt is phenyl, pyridyl, thienyl, furyl and thiazolyl, said phenyl and heteroaryl groups being unsubstituted or substituted with up to 3 Rs groups. 3. A compound in accordance with Claim 2 where Yx is phenyl unsubstituted or substituted with up to 3 R5 groups. 4. A compound in accordance with Claim 1 where X is O. 5. A compound in accordance with Claim 1 where X is CH2. 6. A compound in accordance with Claim 1 where X is S. 7. A compound in accordance with Claim 1 where Z is selected from the group consisting of -CΓëíC-, -CH=CH-, -CONH-, - COO-, -OCO-, -NHCO-, and -(CR^CR^- where n is zero or 3. 8. A compound in accordance with Claim 7 where Z is selected from the group consisting of -CΓëíC-, -C=C-, and -CONH-. 9. A compound in accordance with Claim 1 where Y2 is phenyl, naphthyl, pyridyl, thienyl or furyl said groups being unsubstituted or substituted with the R4 group. 10. A compound in accordance with Claim 1 where the A-B group is (CH2)qCOOH or (CH2)q-COOR8. 11. A compound in accordance with Claim 1 where Rt is OH, or ORj. 12. (AMENDED) A compound of the formula
wherein X is O, or CH2; Ri is H, lower alkyl of 1 to 10 carbons, OCH2OCH3, or OR^ R2 is H, lower alkyl of 1 to 10 carbons, tri-(C,.6alkyl)silyl, or COR3 where R3 is H, lower alkyl of 1 to 6 carbons or phenyl; R4 is lower alkyl of 1 to 6 carbons, F, Cl, Br, I, or CF3; m is an integer between 0 and 3; Yx is phenyl, naphthyl or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, or thiazolyl, said phenyl, naphthyl and heteroaryl groups being unsubstituted or substituted with one to three Rj groups, where R, is alkyl of 1 to 10 carbons, or fluoro-substituted alkyl of 1 to 10 carbons, F, Cl, Br, I, N02, CN, COOH, or COOC,.6alkyl; Z is -CΓëíC- -(CR6=CR6)n- where n is an integer having the value 0 - 5, -CS-NR6-, -NR6-CO, -NR6-CS, -COO-, -OCO-; R6 is H or lower alkyl of 1 to 6 carbons; Y2 is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, or furyl, said phenyl and heteroaryl groups being unsubstituted or substituted with one or two R4 groups, or when Z is -(CR6=CR6)n and n is 3, 4 or 5 then Y2 represents a direct valence bond between said group and B; A is (CH2)q where q is 0-5, lower branched chain alkyl having 3-6 carbons, cycloalkyl having 3-6 carbons, alkenyl having 2-6 carbons and 1 or 2 double bonds, alkynyl having 2-6 carbons and 1 or 2 triple bonds; B is COOH or a pharmaceutically acceptable salt thereof, COOR8, -CH2OH, CH2ORu, CH2OCORn, CHO, CH(OR12)2, CH(OR130), -COR,, CR7(OR12)2, CR7(OR130), or Si(C,. 6alkyl)3, where R, is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbons, R8 is an alkyl group of 1 to 10 carbons or (trimethylsilyl)alkyl where the alkyl group has 1 to 10 carbons, or a cycloalkyl group of 5 to 10 carbons, or Rg is phenyl or lower alkylphenyl, R, and R10 independently are hydrogen, an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5-10 carbons, or phenyl, hydroxyphenyl or lower alkylphenyl, Ru is lower alkyl, phenyl or lower alkylphenyl, R^ is lower alkyl, and R13 is divalent alkyl radical of 2-5 carbons, or a pharmaceutically acceptable salt thereof. 13. A compound in accordance with Claim 12 where Yx is phenyl. 14. A compound in accordance with Claim 12 where Y2 is phenyl.
EP98918157A 1997-04-19 1998-04-13 Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity Expired - Lifetime EP0975573B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/845,019 US6037488A (en) 1997-04-19 1997-04-19 Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity
US845019 1997-04-19
PCT/US1998/007394 WO1998047854A1 (en) 1997-04-19 1998-04-13 Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity

Publications (2)

Publication Number Publication Date
EP0975573A1 true EP0975573A1 (en) 2000-02-02
EP0975573B1 EP0975573B1 (en) 2002-09-18

Family

ID=25294215

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98918157A Expired - Lifetime EP0975573B1 (en) 1997-04-19 1998-04-13 Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity

Country Status (9)

Country Link
US (3) US6037488A (en)
EP (1) EP0975573B1 (en)
JP (2) JP4072208B2 (en)
AT (1) ATE224351T1 (en)
AU (1) AU734939B2 (en)
CA (1) CA2286681A1 (en)
DE (1) DE69808065T2 (en)
ES (1) ES2184252T3 (en)
WO (1) WO1998047854A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037488A (en) 1997-04-19 2000-03-14 Allergan Sales, Inc. Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity
ATE365158T1 (en) 1999-04-28 2007-07-15 Inst Med Molecular Design Inc PYRIMIDINE CARBOXYLIC ACID DERIVATIVES
US6713515B2 (en) 2000-09-13 2004-03-30 Bristol Myers Squibb Company Retinoic acid receptor antagonists as promoters of angiogenesis
US20020193403A1 (en) 2001-05-03 2002-12-19 Allergan Sales, Inc. Methods of treating hyperlipidemia
EP1260546A1 (en) * 2001-05-21 2002-11-27 Borealis Technology OY Polyolefin multilayer pipe
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
GB0207253D0 (en) * 2002-03-27 2002-05-08 Syngenta Participations Ag Chemical compounds
US6620963B1 (en) 2002-09-19 2003-09-16 Allergan, Inc. TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-PHENYL AND TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-HETEROARYL AND RELATED COMPOUNDS HAVING RARα RECEPTOR SELECTIVE BIOLOGICAL ACTIVITY
US7105566B2 (en) * 2002-10-22 2006-09-12 Allergan, Inc. Methods of treatment during vascular procedures
FR2848424B1 (en) * 2002-12-13 2006-06-23 Oreal MASCARA COMPRISING A FILMOGENIC POLYMER AND A FATTY PHASE
JP2007518719A (en) * 2003-12-26 2007-07-12 アラーガン　インコーポレイテッド Disubstituted chalcone oximes having RARγ retinoid receptor antagonist activity
US7476673B2 (en) * 2003-12-30 2009-01-13 Allergan, Inc. Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
CN101316583A (en) 2005-09-30 2008-12-03 生命医药公司 Treating cancer with specific RXR agonists
TR201819157T4 (en) * 2006-05-16 2019-01-21 Io Therapeutics Llc Rar Antagonist Or Inverse Agonist For Use In The Treatment Of Side Effects Of Chemotherapy And Radiation Therapy
WO2009137337A1 (en) * 2008-05-05 2009-11-12 The Scripps Research Institute STEREOSELECTIVE SYNTHESIS OF 17-α -AND 17-β -ARYL STEROIDAL COMPOUNDS
US8916250B2 (en) * 2008-10-01 2014-12-23 Borealis Ag Sewage pipe comprising beta nucleated polypropylene material with improved properties
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
WO2013090616A1 (en) 2011-12-13 2013-06-20 Io Therapeutics, Inc. Autoimmune disorder treatment using rxr agonists
CN116077626A (en) 2015-10-31 2023-05-09 Io治疗公司 Treatment of neurological disorders using a combination of RXR agonists and thyroid hormones
EP3380086B1 (en) 2015-11-25 2021-10-13 IO Therapeutics, Inc. Cyp26-resistant rar-alpha selective agonists in the treatment of cancer
US10835507B2 (en) 2016-03-10 2020-11-17 Io Therapeutics, Inc. Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones
KR102605349B1 (en) 2016-03-10 2023-11-22 아이오 테라퓨틱스, 인크. Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
WO2017214575A1 (en) 2016-06-10 2017-12-14 Io Therapeutics, Inc. Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
WO2019014468A1 (en) 2017-07-13 2019-01-17 Io Therapeutics, Inc. Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
US10363272B2 (en) 2017-08-31 2019-07-30 Io Therapeutics, Inc. RAR selective agonists in combination with immune modulators for cancer immunotherapy
CA3076373A1 (en) 2017-09-20 2019-03-28 Io Therapeutics, Inc. Treatment of disease with esters of selective rxr agonists
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
CA3242047A1 (en) 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist in treating drug resistant her2+ cancers
AU2022408160A1 (en) 2021-12-07 2024-06-06 Board Of Regents, The University Of Texas System Use of an rxr agonist and taxanes in treating her2+ cancers

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4085091A (en) * 1976-12-16 1978-04-18 E. I. Dupont De Nemours And Company Thermally stable, rigid polyesters from thermally stable, rigid dibasic acids and aromatic dihydroxy compounds
US4326055A (en) * 1977-12-22 1982-04-20 Hoffmann-La Roche Inc. Stilbene derivatives
EP0047817A3 (en) * 1980-08-14 1982-05-26 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Hydrogenated naphthalines, their preparation and application, and mixtures containing such naphthalines
CH651034A5 (en) 1982-05-12 1985-08-30 Hoffmann La Roche CHROMAN, THIOCHROMAN OR 1,2,3,4-TETRAHYDROCHINOLIN DERIVATIVES AND THEIR USE AS MEDICINAL ACTIVE SUBSTANCES.
DK158947C (en) * 1982-07-06 1991-01-21 Hoffmann La Roche TETRAHYDRONAPHTHALIN, BENZOFURAN AND BENZOTHIOPHENDER DERIVATIVES, PREPARATION AND USE THEREOF, AND RODENTICID CONTAINING SUCH DERIVATIVES
US4539154A (en) * 1983-06-15 1985-09-03 Hoffmann-La Roche Inc. Polyene compounds
ATE38835T1 (en) * 1983-07-05 1988-12-15 Pfizer CARBONIC ACID DERIVATIVES USEFUL IN PREVENTING DECOMPOSITION OF CARTILAGE.
US4826984A (en) * 1984-04-09 1989-05-02 The Board Of Regents For The Oklahoma Agricultural And Mechanical College Acting For And On Behalf Of Oklahoma State University Heteroarotinoid compounds as anticancer agents
JPS60222445A (en) * 1984-04-19 1985-11-07 Yoshitomi Pharmaceut Ind Ltd Phthalic acid compound
DE3580134D1 (en) * 1984-07-07 1990-11-22 Shudo Koichi Prof Dr Chem BENZOESAEUR DERIVATIVES.
JPS6122046A (en) * 1984-07-07 1986-01-30 Koichi Shiyudo Stilbene derivative
LU85544A1 (en) * 1984-09-19 1986-04-03 Cird AROMATIC HETEROCYCLIC DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN THE THERAPEUTIC AND COSMETIC FIELDS
DE3434947A1 (en) * 1984-09-22 1986-04-03 Basf Ag, 6700 Ludwigshafen ISOXAZOLIC CARBONIC ACID DERIVATIVES, THEIR PRODUCTION AND USE
DE3434942A1 (en) * 1984-09-22 1986-04-03 Basf Ag, 6700 Ludwigshafen TETRALINE DERIVATIVES, THEIR PRODUCTION AND USE
IL80270A0 (en) * 1985-10-11 1987-01-30 Cird Naphthalene derivatives,their preparation and pharmaceutical compositions containing them
DE3602473A1 (en) 1986-01-28 1987-07-30 Basf Ag VINYLPHENOL DERIVATIVES, THEIR PRODUCTION AND USE
LU86351A1 (en) 1986-03-12 1987-11-11 Oreal BENZOPYRANNYL AND BENZOTHIOPYRANNYL BENZOIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN COSMETICS AND HUMAN AND VETERINARY MEDICINE
DE3615157A1 (en) * 1986-05-05 1987-11-12 Schwabe Willmar Gmbh & Co 5-ARYLALKYL-4-ALKOXY-2 (5H) -FURANONE, INTERMEDIATE PRODUCTS AND METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS THERAPEUTIC ACTIVE SUBSTANCES
ZW6587A1 (en) 1986-05-13 1987-12-02 Hoffmann La Roche Tetrahydro naphthanline derivatives
ZW7487A1 (en) 1986-05-23 1987-12-16 Hoffmann La Roche Tetrahydronaphthaline and indane derivatives
ZW10287A1 (en) 1986-07-15 1988-01-13 Hoffmann La Roche Tetrahydronaphthaline and indane derivatives
US4739098A (en) * 1986-09-22 1988-04-19 Allergan, Inc. Ethynylphenyl-containing retinoic acid derivatives
US4923884A (en) * 1986-12-24 1990-05-08 Allergan, Inc. Ethynylheteroaromatic-acids having retinoic acid-like activity
NZ222968A (en) 1986-12-24 1990-05-28 Allergan Inc Ethynylheteroaromatic derivatives and medicaments
US4927947A (en) * 1986-12-24 1990-05-22 Allergan, Inc. Ethynylheteroaromatic-acids having retinoic acid-like activity
DE3707060A1 (en) 1987-03-05 1988-09-22 Hoelter Heinz Production of special coals from waste products of coal winning for the reduction of NOx, SO2/SO3, HCl and HF in coal-fired power stations or heating installations which are equipped with a fluidised bed, a moving grate or pulverised coal-firing
US5149705A (en) 1987-03-13 1992-09-22 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a tetralin group and having retinoid like activity
US5089509A (en) * 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5602130A (en) * 1987-03-20 1997-02-11 Allergan Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5234926A (en) * 1987-03-20 1993-08-10 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
CA1305480C (en) 1987-03-20 1992-07-21 Roshantha A.S. Chandraratna Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5264578A (en) * 1987-03-20 1993-11-23 Allergan, Inc. Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
US4810804A (en) * 1987-03-26 1989-03-07 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a heterobicyclic group having retinoid-like activity
IL85896A (en) 1987-04-06 1993-01-14 Riker Laboratories Inc Substituted di-tert.- butylphenols and pharmaceutical compositions containing them
DE3726806A1 (en) 1987-08-12 1989-02-23 Basf Ag ARYLPHOSPHOR DERIVATIVES, THEIR PRODUCTION AND USE
ZA885192B (en) 1987-08-19 1989-04-26 Hoffmann La Roche Pharmaceutical preparations
CA1298309C (en) 1987-11-06 1992-03-31 Michael Klaus Benzocycloheptene derivatives
KR0139216B1 (en) * 1988-04-11 1998-05-01 제임스 엠. 캐내지 Tetralin esters of phenols or benzoic acids having retinoic like activity
US5231113A (en) * 1988-04-11 1993-07-27 Allergan, Inc. Tetralin esters of phenols or benzoic acids having retinoid like activity
US5015658A (en) * 1988-06-29 1991-05-14 Allergan, Inc. Thiochroman esters of phenols and terephthallates having retinoid-like activity
US4895868A (en) * 1988-06-29 1990-01-23 Allergan, Inc. Thiochroman esters of phenols and terephthallates having retinoid-like activity
AU626881B2 (en) 1988-07-14 1992-08-13 F. Hoffmann-La Roche Ag Benzofused heterocyclics used as pharmaceuticals
US5217867A (en) 1988-11-30 1993-06-08 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
WO1990007517A1 (en) 1988-12-23 1990-07-12 The Salk Institute For Biological Studies Receptor transcription-repression activity compositions and methods
US5068252A (en) * 1989-07-26 1991-11-26 Allergan, Inc. Methods of using phenylethenyl compounds having retinoid-like activity
US4992468A (en) * 1989-07-26 1991-02-12 Allergan, Inc. Phenylethenyl compounds having retinoid-like activity
DE3926148A1 (en) 1989-08-08 1991-02-28 Basf Ag DIARYLACETYLENE, THEIR MANUFACTURE AND USE
US5248777A (en) * 1989-09-19 1993-09-28 Allergan, Inc. Process and intermediates for preparing compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity
US5053523A (en) * 1989-09-19 1991-10-01 Allergan, Inc. Ethynyl-chroman compounds
US5183827A (en) * 1989-09-19 1993-02-02 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5162546A (en) * 1989-09-19 1992-11-10 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5023341A (en) * 1989-09-19 1991-06-11 Allergan, Inc. Compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity
US5399561A (en) * 1989-09-19 1995-03-21 Allergan, Inc. Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-oxochromanyl, 2-oxothiochromanyl or 2-oxo-1,2,3,4-tetrahydro-quinolinyl group having retinoid-like biological activity
US4980369A (en) * 1989-09-19 1990-12-25 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl or thiochromanyl group having retinoid-like activity
US5045551A (en) * 1989-09-19 1991-09-03 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5272156A (en) * 1989-09-19 1993-12-21 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5006550A (en) * 1989-12-29 1991-04-09 Allergan, Inc. Chroman esters of phenols and benzoic acids having retinoid-like activity
US5175185A (en) * 1989-12-29 1992-12-29 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a substituted phenyl group having retinoid like activity
US5264456A (en) * 1989-12-29 1993-11-23 Allergan, Inc. Acetylenes disubstituted with a furyl group and a substituted phenyl group having retinoid like activity
US5013744B1 (en) * 1989-12-29 1994-09-20 Allegran Inc Acetylenes disubstituted with a pyridinyl group and a substituted phenyl group having retinoid like activity
US5202471A (en) * 1990-02-06 1993-04-13 Allergan, Inc. Alkyl, alkoxy and thioalkoxy substituted diphenyl acetylenes having retinoid like activity
KR960014911B1 (en) 1990-03-20 1996-10-21 시오노기세이야꾸 가부시끼가이샤 New preparation method of benzoic acid derivative
US5563292A (en) * 1990-10-17 1996-10-08 Schering Corporation Lipoxygenase inhibitors
EP0571546B1 (en) * 1991-02-13 1996-10-16 Allergan, Inc. Chroman and thiochromans with phenylethynyl substituents at the 7-position having retinoid-like biological activity
WO1992017471A1 (en) * 1991-03-26 1992-10-15 Allergan, Inc. Chromans and thiochromans with heteroarylethynyl substituents at the 7-position having retinoid-like biological activity
US5134159A (en) * 1991-03-26 1992-07-28 Allergan, Inc. 7-chromanyl esters of phenols and benzoic acids having retinoid-like activity
FR2676440B1 (en) 1991-05-15 1993-07-30 Cird Galderma NOVEL AROMATIC COMPOUNDS DERIVED FROM IMINE, THEIR PREPARATION PROCESS AND THEIR USE IN HUMAN AND VETERINARY MEDICINE AND IN COSMETICS.
CA2115452A1 (en) 1991-09-17 1993-04-01 Ronald M. Evans Receptor of the thyroid/steroid hormone receptor superfamily
AU3659293A (en) * 1992-02-11 1993-09-03 Allergan, Inc. Heteroaryl substituted phenylethenyl compounds having retinoid-like biological activity
US5326898A (en) * 1992-02-11 1994-07-05 Allergan, Inc. Substituted phenylethenyl compounds having retinoid-like biological activity
US5420145A (en) * 1993-03-22 1995-05-30 Koichi Shudo Carboxylic acid derivative
EP0617020A1 (en) 1992-04-02 1994-09-28 Shudo, Koichi, Prof. Dr. Carboxylic acid derivatives having retinoic acid-like activity
US5324840A (en) * 1992-06-11 1994-06-28 Allergan, Inc. Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects
US5466861A (en) * 1992-11-25 1995-11-14 Sri International Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
US5455265A (en) * 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
US5399586A (en) * 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
EP0619116A3 (en) 1993-04-05 1994-11-23 Hoechst Japan Use of synthetic retinoids for osteopathy.
US5344959A (en) * 1993-05-18 1994-09-06 Allergan, Inc. Tetrahydronaphthyl and cyclopropyl substituted 1,3-butadienes having retinoid-like activity
US5475022A (en) * 1993-10-18 1995-12-12 Allergan, Inc. Phenyl or heteroaryl and tetrahydronaphthyl substituted diene compounds having retinoid like biological activity
FR2713635B1 (en) 1993-12-15 1996-01-05 Cird Galderma New bi-aromatic propynyl compounds, pharmaceutical and cosmetic compositions containing them and uses.
US5451605A (en) * 1993-12-30 1995-09-19 Allergan, Inc. 1,2-epoxycyclohexanyl and bicyclic aromatic substituted ethyne compounds having retinoid-like biological activity
US5470999A (en) * 1993-12-30 1995-11-28 Allergan, Inc. Cyclohexene and bicyclic aromatic substituted ethyne compounds having retinoid-like biological activity
US5426118A (en) * 1993-12-30 1995-06-20 Allergan, Inc. [4-(1,2-epoxycyclohexanyl)but-3-en-1-ynyl]aromatic and heteroaromatic acids and derivatives having retinoid-like biological activity
CA2138000A1 (en) 1994-01-03 1995-07-04 John E. Starrett, Jr. Retinoid-like compounds
CA2137997A1 (en) 1994-01-03 1995-07-04 John E. Starrett, Jr. Retinoid-like compounds
US5498755A (en) * 1994-08-23 1996-03-12 Chandraratna; Roshantha A. Disubstituted aryl and heteroaryl imines having retinoid-like biological activity
IL116259A (en) 1994-12-19 2000-07-16 American Cyanamid Co Analogs of 9-cis retinoic acid and their use
US5498795A (en) * 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
US5556996A (en) * 1994-12-29 1996-09-17 Allergan Oxiranyls disubstituted with a phenyl group and a substituted chromanyl or tetrahydroquinolinyl group having retinoid like activity
US5648514A (en) * 1994-12-29 1997-07-15 Allergan Substituted acetylenes having retinoid-like biological activity
US5599967A (en) * 1994-12-29 1997-02-04 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl of heteroaryl group having retinoid-like biological activity
US5543534A (en) * 1994-12-29 1996-08-06 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity
US5514825A (en) * 1994-12-29 1996-05-07 Allergan, Inc. Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5489584A (en) * 1994-12-29 1996-02-06 Allergan, Inc. Acetylenes disubstituted with a 5-amino or substituted 5-amino substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5618943A (en) * 1994-12-29 1997-04-08 Allergan Acetylenes disubstituted with a 5 OXO substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5534641A (en) * 1994-12-29 1996-07-09 Allergan Acetylenes disubstituted with 2-tetrahydropyranoxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
US5618931A (en) * 1994-12-29 1997-04-08 Allergan Acetylenes disubstituted with a 5 substituted dihydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5559248A (en) * 1995-04-05 1996-09-24 Bristol-Myers Squibb Co. Retinoid-like heterocycles
US5616712A (en) * 1995-05-16 1997-04-01 Allergan Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-thio-1,2,3,4-tetrahdroquinolinyl, 2-alkylthio-3,4-dihydroquinolinyl or 2-alkoxy-3,4-dihydroquinolinyl group having retinoid-like biological activity
US5675033A (en) * 1995-06-06 1997-10-07 Allergan 2,4-pentadienoic acid derivatives having retinoid-like biological activity
US5663357A (en) * 1995-11-22 1997-09-02 Allergan Substituted heteroarylamides having retinoid-like biological activity
US6037488A (en) 1997-04-19 2000-03-14 Allergan Sales, Inc. Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9847854A1 *

Also Published As

Publication number Publication date
US6235923B1 (en) 2001-05-22
JP2001524099A (en) 2001-11-27
US6225494B1 (en) 2001-05-01
EP0975573B1 (en) 2002-09-18
WO1998047854A1 (en) 1998-10-29
DE69808065T2 (en) 2003-05-22
ES2184252T3 (en) 2003-04-01
DE69808065D1 (en) 2002-10-24
US6037488A (en) 2000-03-14
ATE224351T1 (en) 2002-10-15
AU734939B2 (en) 2001-06-28
CA2286681A1 (en) 1998-10-29
JP4072208B2 (en) 2008-04-09
AU7113298A (en) 1998-11-13
JP2008024719A (en) 2008-02-07

Similar Documents

Publication Publication Date Title
US6037488A (en) Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity
US6187950B1 (en) Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological
EP0948478B1 (en) ARYL OR HETEROARYL SUBSTITUTED 3,4-DIHYDROANTHRACENE AND ARYL OR HETEROARYL SUBSTITUTED BENZO[1,2-g]-CHROM-3-ENE, BENZO[1,2-g]-THIOCHROM-3-ENE AND BENZO[1,2-g]-1,2-DIHYDROQUINOLINE DERIVATIVES HAVING RETINOID ANTAGONIST OR RETINOID INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY
EP0937045B1 (en) N-aryl substituted tetrahydroquinolines ligands for retinoid receptors having agonist, antagonist or inverse agonist type activity
US6127382A (en) Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
US20030166932A1 (en) Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
US7026487B2 (en) Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, a pyridyl group and an alkyl group, having retinoid-like biological activity
AU720975B2 (en) Aryl- and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity
US6093838A (en) Amines substituted with a dihydro-benzofuranyl or with a dihydro-isobenzofuranyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991018

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20010424

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020918

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020918

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020918

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020918

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020918

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020918

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020918

REF Corresponds to:

Ref document number: 224351

Country of ref document: AT

Date of ref document: 20021015

Kind code of ref document: T

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69808065

Country of ref document: DE

Date of ref document: 20021024

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20021218

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20021218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20021219

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2184252

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030413

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030413

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030414

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030430

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20030619

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20080428

Year of fee payment: 11

Ref country code: DE

Payment date: 20080602

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20080428

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20080417

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20080429

Year of fee payment: 11

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20090413

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20091231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091103

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090413

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091222

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20090414

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090414

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090413